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Abstract 
Bacterial infections rendered almost untreatable by resistance to last-line antibiotics such as 
carbapenems are now a common occurrence worldwide. Genes conferring carbapenem resistance 
are commonly associated with structures called integrons, but little is known about their regulation, 
particularly in species of clinical importance. Integron gene expression is regulated by two 
divergently orientated promoters (Pc and Pint) that co-ordinate the expression of the resistance gene 
cassettes and the integron integrase, respectively. This PhD aimed to use a rational high-throughput 
approach to identify novel regulators of clinical integrons in the pathogenic species Pseudomonas 
aeruginosa. We hypothesised that the opposing physiological roles of integrase and cassette 
expression would result in mutually exclusive expression from the two promoters. 
 
To explore regulation of integron promoter activity, a carbapenemase-containing integron from a 
clinical source was identified, sourced, and modified to allow investigation of integron promoter 
activities in P. aeruginosa through transcriptional reporters of Pc and Pint activity. A functional 
analysis of carbapenem susceptibility was also performed through assessment of carbapenemase 
expression from Pc.  
 
From these examinations, we report the first evidence of carbon source dependent regulation of 
mobile integrons, via the Pseudomonas catabolite regulatory control system, crc and cbrAB, 
demonstrating that there is a clear need for further study before the full nature of integron 
regulation in response to pressures from the ambient environment is understood.  
 
Furthermore, we have validated the use of a compendium approach to simultaneously examine 
large numbers of potential regulatory targets, by identifying at least one further effector of 
regulatory control of integron promoters: PA14_31900, which encodes the MuxC component of the 
MuxABC-OpmB RND-type efflux pump. A PA14_31900 loss of function mutant exhibits decreased in 
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vitro transcription from Pint, increased in vitro transcription from Pc, and increased resistance to 
carbapenems in vitro and in vivo, in a murine model of gastrointestinal colonisation.   
 5 
Declaration of originality 
I declare that the work described in this thesis was carried out in accordance with the requirements 
of the University's Regulations and Code of Practice for Research Degree Programmes and that it has 
not been submitted for any other academic award. Except where indicated by specific reference in 
the text, the work described is my own work.  
 
SIGNED: Erin V. McAlister 
DATE: March 2016 
 
  
 6 
Copyright declaration 
The copyright of this thesis rests with the author and is made available under a Creative Commons 
Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, distribute or 
transmit the thesis on the condition that they attribute it, that they do not use it for commercial 
purposes and that they do not alter, transform or build upon it. For any reuse or redistribution, 
researchers must make clear to others the licence terms of this work. 
  
 7 
Acknowledgements 
I owe huge thanks to my supervisors Elaine Bignell and Andy Edwards for their help, patience and 
support over the past four years of my PhD, especially during periods where I found it particularly 
difficult and wanted to avoid the outside world. 
I would also like to thank all of the CMBI 5th floor, past and present. In particular, Kim and Sophie 
(CMBI 4 really, but close enough to count!) for being the most valuable source I can imagine of 
meltdown-support and reassuring coffee breaks. I also can’t thank Kylie Glasgow and Sophie Kemp 
enough for all their support, far in excess of their job. Thanks to Marghe for being such a supportive 
post-doc, role model and friend. I have learnt so much from her and am very grateful to have been 
introduced to (what I’m told is) the only Italian chain restaurant that Italians are prepared to eat at; 
it will come in handy for years to come. Thanks also to Vera for her unlimited belief in me despite 
the many times I have shown my flaws. Vera is one of the smartest people I have met and her 
unending faith, humour, dance steps, and interesting facts have helped me through some difficult 
times.  
There are also a plethora of people outside of Imperial that I need to thank, including: 
My friends in Cambridge from the Dowsing Sound Collective, who have provided me with much 
needed distractions, whether singing our hearts out at choir, wild nights of dancing and espresso 
martinis, or ‘quiet’ games nights. In particular, Esther, Eva, and Col: thank you for all of your little 
reassurances along the way – they’ve meant a lot!  
I’d also like to thank my oldest friend Leah, who I have known for longer than I haven’t. Despite 
spending most of her free time trainspotting she has still managed to find plenty of time to make 
sure I was still a vaguely functioning member of society. I can’t thank Kim and Leah enough for the 
amount of help they have given me, especially taking me away from it all on our holiday to Costa 
Rica when I was approaching meltdown. Those were some of the best times I can remember, and 
now that I’ll have considerably more time on my hands I hope it won’t be a one off! 
To my lovely fiancé Matthew, you have been such a crucial source of support through this writing 
period, and I can’t thank you enough for all the hugs, hot drinks and care you’ve provided. I’ve made 
the age-old joke to you about people only getting an acknowledgement if they’ve really earned it, 
but you couldn’t be more deserving!  
 8 
Friends like mine are hard to come by, and I consider myself very lucky. I wouldn’t have got nearly 
this far without you all! 
Finally I would love to thank my wonderful family. Mom (I’m a Brummie, not an American) and Dad, 
thank you for being my inspiration and the reason I was even able to begin this mammoth process. 
Dad: I can’t remember the stakes for that bet we placed when I was 17, but we can agree that 
victory is mine, yes? Thank you Lauren for being incredulous and angry at every wobble. And thanks 
Auntie Anna for having taught me to read in the first place. Of course, this wouldn't have been 
possible without the unending love and support I’ve received from you all, and for never doubting 
me (even when I do). 
To conclude, a summary courtesy of Neil Gaiman (Sandman 9: Kindly Ones, epilogue): “I don’t know 
how close I got or how far I came from what I set out to say. Still, in hardback at least, it could 
undoubtedly be used to stun a burglar; which has always been my definition of real art.”  
  
 9 
Contents 
Abstract ....................................................................................................................................... 3 
Declaration of originality .............................................................................................................. 5 
Copyright declaration ................................................................................................................... 6 
Acknowledgements...................................................................................................................... 7 
Contents ...................................................................................................................................... 9 
List of abbreviations and acronyms ............................................................................................ 15 
List of figures ............................................................................................................................. 17 
List of tables .............................................................................................................................. 21 
1 Introduction ....................................................................................................................... 22 
1.1 Antibiotic resistance ............................................................................................................. 22 
1.1.1 Dawn of antibiotic era and emergence of resistance ................................................... 22 
1.1.2 β-lactams and carbapenems ......................................................................................... 25 
1.1.3 Resistance to β-lactam antibiotics ................................................................................ 28 
1.2 Integrons ............................................................................................................................... 31 
1.2.1 Role, prevalence, and origins ........................................................................................ 31 
1.2.2 General structure of mobile integrons ......................................................................... 33 
1.2.3 Integrase mode of action .............................................................................................. 36 
1.2.4 Regulation as currently understood ............................................................................. 38 
1.3 P. aeruginosa ........................................................................................................................ 44 
1.3.1 Description, lifestyle, risk factors and epidemiology .................................................... 44 
1.3.2 Regulation and metabolism control.............................................................................. 46 
1.3.3 Role of P. aeruginosa as a model organism .................................................................. 47 
1.3.4 Murine models of P. aeruginosa infection.................................................................... 49 
1.4 Objectives of this study ......................................................................................................... 50 
2 Materials and Methods ....................................................................................................... 53 
 10 
2.1 Chemicals, reagents and enzymes ........................................................................................ 53 
2.2 Bacterial strains and growth conditions ............................................................................... 53 
2.3 Oligonucleotide primer synthesis ......................................................................................... 54 
2.4 Plasmids ................................................................................................................................ 55 
2.5 Molecular biology ................................................................................................................. 55 
2.5.1 Genomic DNA extraction .............................................................................................. 55 
2.5.2 Preparation of chemically competent E. coli cells ........................................................ 55 
2.5.3 Low-throughput plasmid mobilisation .......................................................................... 56 
2.5.4 Plasmid DNA extraction ................................................................................................ 59 
2.5.5 Separation of DNA fragments by electrophoresis ........................................................ 59 
2.5.6 Nucleic acid quantification ............................................................................................ 59 
2.5.7 Restriction enzyme digests ........................................................................................... 59 
2.5.8 Polymerase chain reaction (PCR) .................................................................................. 60 
2.5.9 GeneArt seamless cloning ............................................................................................. 60 
2.5.10 Ligation .......................................................................................................................... 60 
2.5.11 Sequencing .................................................................................................................... 60 
2.5.12 Quantitative PCR (qPCR) ............................................................................................... 61 
2.6 Low throughput protein techniques ..................................................................................... 61 
2.6.1 Protein extraction ......................................................................................................... 61 
2.6.2 Protein quantification ................................................................................................... 62 
2.6.3 Reporter assays ............................................................................................................. 62 
2.7 P. aeruginosa PA14 NR Library manipulation techniques .................................................... 63 
2.7.1 Library culture conditions ............................................................................................. 63 
2.7.2 Transfer to storage plates ............................................................................................. 64 
2.7.3 Conjugation in 96-well deepwell blocks ....................................................................... 64 
2.7.4 Protein techniques in 96-well high-throughput format................................................ 67 
 11 
2.8 In vivo virulence analysis ....................................................................................................... 69 
2.8.1 Murine Model of gastrointestinal tract colonization by P. aeruginosa ........................ 69 
2.8.2 In vivo 2D bioluminescent optical imaging of P. aeruginosa- gastrointestinally 
colonised mice .............................................................................................................................. 70 
3 Identification and characterisation of a clinically-relevant model integron ........................... 71 
3.1 Introduction .......................................................................................................................... 71 
3.2 Objectives.............................................................................................................................. 72 
3.3 Results ................................................................................................................................... 73 
3.3.1 Analysis of integron structure, location and content through INTEGRALL database 
mining ....................................................................................................................................... 73 
3.3.2 Identification of pKOX105 as a nosocomially relevant integron reservoir for the study 
of mobile integron regulation ....................................................................................................... 76 
3.3.3 pKOX105 integron B is active in conferring carbapenem resistance ............................ 81 
3.4 Discussion .............................................................................................................................. 84 
4 Construction of P. aeruginosa integron reporter isolates, and optimisation of low- and high 
throughput assays of integron promoter activities. ..................................................................... 88 
4.1 Introduction .......................................................................................................................... 88 
4.2 Objectives.............................................................................................................................. 90 
4.3 Results ................................................................................................................................... 91 
4.3.1 Construction of a dual reporter of pKOX105 integron promoter activities in pCB267 
for use in E. coli ............................................................................................................................. 91 
4.3.2 Establishment of reporter assays for low-throughput assessment of integron activities 
in E. coli ....................................................................................................................................... 93 
4.3.3 Construction of a dual reporter of integron promoter activity for examination in P. 
aeruginosa .................................................................................................................................... 97 
4.3.4 Differential Pint activity and comparable Pc activity in E. coli and P. aeruginosa ........ 100 
 12 
4.3.5 Validation of high-throughput reporter assays for use in library screen.................... 102 
4.4 Discussion ............................................................................................................................ 104 
5 Targeted analysis of integron promoter transcriptional regulation ..................................... 110 
5.1 Introduction ........................................................................................................................ 110 
5.2 Objectives............................................................................................................................ 111 
5.3 Results ................................................................................................................................. 111 
5.3.1 Influence of carbon source on integron promoter activities ...................................... 111 
5.3.2 Transcriptional screening of carbon catabolite control mutants ............................... 114 
5.3.3 Functional screening of crc::Tn, cbrA::Tn and cbrB::Tn .............................................. 115 
5.3.4 Effects of antibiotic stress on integron promoter transcription ................................. 116 
5.4 Discussion ............................................................................................................................ 119 
6 Screen for transcriptional regulators of integron promoters .............................................. 122 
6.1 Introduction ........................................................................................................................ 122 
6.2 Objectives............................................................................................................................ 122 
6.3 Results ................................................................................................................................. 123 
6.3.1 Establishment of in-broth protocol for conjugation in high-throughput format ....... 123 
6.3.2 P. aeruginosa mutant sub-library ............................................................................... 125 
6.3.3 Introduction of integron dual reporter construct pMP220-intA into P. aeruginosa 
transposon mutants .................................................................................................................... 125 
6.3.4 Transcriptional screening of sub-library ..................................................................... 127 
6.3.5 Confirmational transcriptional rescreen of selected significant mutants .................. 140 
6.3.6 Further examination of integron promoter activities in the putative glutamine 
synthetase homologue mutant, PA14_72690::Tn. ..................................................................... 145 
6.4 Discussion ............................................................................................................................ 146 
7 Screen for regulators of integron-mediated drug resistance ............................................... 150 
7.1 Introduction ........................................................................................................................ 150 
 13 
7.2 Objectives............................................................................................................................ 150 
7.3 Results ................................................................................................................................. 151 
7.3.1 High-throughput functional screen ............................................................................. 151 
7.4 Discussion ............................................................................................................................ 160 
8 Analysis of integron activities in a murine gut model of Pseudomonas aeruginosa infection 164 
8.1 Introduction ........................................................................................................................ 164 
8.2 Objectives............................................................................................................................ 164 
8.3 Results ................................................................................................................................. 165 
8.3.1 Establishment of in vivo murine gastrointestinal colonisation model ........................ 165 
8.3.2 In vivo parallel fitness assay ........................................................................................ 168 
8.4 Discussion ............................................................................................................................ 177 
9 Discussion and future work ............................................................................................... 180 
10 References .................................................................................................................... 189 
Appendix 2.1 - Bacterial strains ................................................................................................ 208 
Appendix 2.2 - Oligonucleotides ............................................................................................... 209 
Appendix 2.3 - Plasmids ........................................................................................................... 211 
Appendix 3.1 – pMP220 sequence ............................................................................................ 212 
Appendix 3.2 – pEVM2a sequence ............................................................................................ 212 
Appendix 3.1 – pMP220 sequence ............................................................................................ 213 
Appendix 3.2 – pEVM2a sequence ............................................................................................ 223 
Appendix 4.1 – pCB267-intSOSminus sequence ......................................................................... 232 
Appendix 4.2 – pCB267-intA sequence ...................................................................................... 241 
Appendix 4.3 – pCB267-intB sequence ...................................................................................... 249 
Appendix 4.4 – pCB267-Pint sequence ....................................................................................... 257 
Appendix 4.5 – pMP220-intA sequence..................................................................................... 264 
Appendix 4.6 – pMP220-Pint sequence ...................................................................................... 276 
 14 
Appendix 6.1 – Screened strains ............................................................................................... 288 
Appendix 6.2 – Transcriptional screen data ............................................................................... 295 
Alkaline phosphatase output calculations ...................................................................................... 295 
Β-galactosidase output calculations ............................................................................................... 300 
Appendix 6.3 - Quantile normalised transcriptional screen output for mutants showing significant 
results in either activity assay ................................................................................................... 305 
Appendix 6.4 – Rescreen output calculations ............................................................................ 310 
Alkaline phosphatase rescreen calculations ................................................................................... 310 
Β-galactosidase rescreen calculations ............................................................................................ 311 
Appendix 7.1 – Functional screen data ...................................................................................... 312 
Screen with pEVM2a-conjugated mutants, grown in LB containing 30 µg/ml tetracycline and 512 
µg/ml imipenem ............................................................................................................................. 312 
Screen with pMP220-intA-conjugated mutants grown in LB containing 30 µg/ml tetracycline and 1 
µg/ml imipenem ............................................................................................................................. 317 
Appendix 7.2 – Venn diagram sector contents (Figure 7.4) ........................................................ 322 
 
  
 15 
List of abbreviations and acronyms 
μg  Microgram  
μl  Microlitre  
μm  Micrometre  
μM  Micromolar  
A405 Absorbance at 405 nm 
A540 Absorbance at 540 nm 
ATP Adenosine triphosphate 
β beta 
BCA Bicinchoninic acid 
bla β-lactamase 
BLAST Basic Local Alignment Search Tool 
BLI Bioluminescence imaging 
bp Base pair(s) 
C carbon 
CA Catabolite Activity 
cAMP Cyclic AMP 
cfu colony forming units 
CRP cAMP receptor protein 
DHP-I dehydropeptidase-I  
dH2O  Distilled water  
DNA Deoxyribonucleic acid  
ds Double stranded 
ESBL extended spectrum β-lactamases 
ESKAPE Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. 
EU European Union 
FIS Factor for Inversion Stimulation 
gDNA genomic DNA 
GFP Green fluorescent protein 
HAI Healthcare-associated infection 
H-NS Histone-like Nucleoid Structuring protein 
IHF Integration Host Factor 
hr Hour  
Kb  Kilobase  
kg Kilogram 
kV  kilovolts  
L or l Litre  
LB Luria Bertani 
LT lytic transglycosylases 
M Molar 
MBL Metallo-β-lactamase 
Mbp Megabase pair(s) 
MDR Multidrug resistant 
mg  Milligram  
mg/l Milligram per litre  
ml  Millilitre  
mM  millimolar  
MM Minimal media 
mRNA Messenger RNA 
 16 
N nitrogen 
N number 
ng nanogram 
nm nanometre 
O oxygen 
OD600 Optical density at 600 nm 
ORF Open reading frame 
OXA oxacillinase 
p p-value 
P Promoter 
P2 Integron secondary cassette promoter 
PA14NR Set Nonredundant library of PA14 transposon mutants 
PBP penicillin-binding protein 
PBS Phosphate buffered saline 
Pc Integron cassette promoter 
PCR  Polymerase chain reaction  
p.i. Post infection 
PIA Pseudomonas isolation agar 
Pint Integron integrase promoter 
PQS Pseudomonas quinolone signal 
RNA Ribonucleic acid  
rpm  revolutions per minute  
s Seconds 
S sulphur 
spp species 
ss Single stranded 
TE Tris EDTA buffer 
Tm Melting temperature 
UK United Kingdom 
UV Ultraviolet 
V Volts 
VIM Verona integron-mediated MBL 
v/v Volume/volume 
wt Wild type 
w/v Weight/volume 
6-APA 6-aminopenicillanic acid 
7-ACA 7-aminocephalosporanic acid 
  
 17 
List of figures 
Fig. 1.1 General structures of β-lactam antibiotics. 
Fig. 1.2 General structure of class 1 integrons. 
Fig. 1.3 Regulatory region of the first discovered integron, In2 from transposon Tn21. 
Fig. 1.4 CRP consensus binding profile in Enterobacteriales. 
Fig. 1.5 Schematic diagram of dual reporter plasmid, pCB267. 
Fig. 1.6 Regulatory region of In2, as determined by Cagle et al.  
Fig. 1.7 Proposed model for co-ordinated regulation of integron promoters. 
Fig. 2.1 Selection strategy for quantification of conjugation frequency on solid media. 
Fig. 2.2 Experimental procedure for conjugation in liquid media. 
Fig. 2.3 Experimental procedure for 96-well conjugation in liquid media. 
Fig. 3.1 Frequency and species distribution of MBL-containing integrons reported in the INTEGRALL 
database in P. aeruginosa, E. coli, K. pneumoniae and A. baumannii.  
Fig. 3.2 Overview of pKOX105 integrons. 
Fig. 3.3 Regulatory region in pKOX105 carbapenemase-containing integron (integron B). 
Fig. 3.4 Characterisation of pMP220. 
Fig. 3.5 Construction of carbapenemase-containing integron plasmid pEVM2a. 
Fig. 3.6 Confirmation of functionality of pKOX105 integron B through expression of blaVIM-1 
cassette via Pc. 
Fig. 4.1. Schematic diagram of pCB267-intSOSminus and regions sequenced in this study. 
Fig. 4.2 Construction of dual transcriptional reporters of pKOX105 clinical integrons, pCB267-intA 
and pCB267-intB. 
Fig. 4.3 Schematic diagram of pCB267-intA and pCB267-intB regions sequenced. 
Fig. 4.4 Constructs used to establish functionality of pKOX105 clinical integron promoters.  
Fig. 4.5 Activity of the integrase promoter, Pint, and cassette promoter, Pc, in the narrow-host range 
vector pCB267 in E. coli DH5α.  
 18 
Fig. 4.6 Construction of Pseudomonas-compatible dual reporter plasmid pMP220-intA.  
Fig. 4.7 Schematic diagram of pMP220-intA and pMP220-Pint regions sequenced.  
Fig. 4.8 Comparative analysis of integron promoter activity in E. coli DH5α and P. aeruginosa PA14, in 
a modified broad host-range vector, pMP220.  
Fig. 4.9 Effect of culture vessel on growth dynamics of P. aeruginosa PA14 harbouring dual reporter 
plasmid pMP220-intA. 
Fig. 4.10 Comparative analysis protein concentration from P. aeruginosa PA14 grown in 15 ml 
culture in Erlenmeyer flasks and 1.5 ml culture in 96-well deepwell plate. 
Fig. 4.11 Comparative analysis of integron promoter activity in P. aeruginosa PA14 grown in 15 ml 
culture in Erlenmeyer flasks and 1.5 ml culture in 96-well deepwell plate.  
Fig. 5.1 Expression from integron promoters in wild type P. aeruginosa PA14 containing pMP220-
intA following growth in 85 mM succinate followed by 2 hour stimulation in alternative (less 
preferred) carbon sources.  
Fig. 5.2 Expression from integrase promoters in wild type containing pMP220-intA following growth 
in 55 mM glucose followed by 2 hour stimulation in alternative carbon sources. 
Fig. 5.3 Transcriptional screen of crc::Tn, cbrA::Tn and cbrB::Tn containing pMP220-intA in LB (A) and 
minimal medium with 85 mM succinate as the sole carbon source (B). 
Fig. 5.4 Mutations in CCR genes affects blaVIM-1 expression from Pc. 
Fig. 5.5 Expression from integron promoters in wild type P. aeruginosa PA14 containing pMP220-
intA, following growth in 5 mM glucose plus 2 hour antibiotic stimulation. 
Fig. 6.1 Transconjugants obtained following conjugation on solid and liquid media, with incubation 
times of 2 and 4 hours. 
Fig. 6.2 Example 96-well conjugation plates after 48 hours of incubation at 37 °C.  
Fig. 6.3 Growth (OD600) of transconjugants used for high-throughput transcriptional screen.  
Fig. 6.4 Histograms of concentration of total protein extracts compared with the replicate mean 
concentration (µg/ml). 
 19 
Fig. 6.5 Data analysis pipeline for library transcriptional screen. 
Fig. 6.6 Integron promoter activities from library parental strain, P. aeruginosa PA14.  
Fig. 6.7 β-galactosidase mean log2 of fold change for n = 532 mutants.  
Fig. 6.8 Alkaline phosphatase mean log2 of fold change for n = 532 mutants.  
Fig. 6.9 Transformation of data through quantile normalization. 
Fig. 6.10 Distribution of transcriptional screen significant hits within sub-library.  
Fig. 6.11 Mean quantile normalized fold change β-galactosidase output for n = 253 mutants 
exhibiting significantly altered β-galactosidase or alkaline phosphatase activity.  
Fig. 6.12 Mean quantile normalized fold change alkaline phosphatase output for n = 253 mutants 
exhibiting significantly altered β-galactosidase or alkaline phosphatase activity.  
Fig. 6.13 Data analysis pipeline for rescreen of mutants with significant phenotypes in the library 
transcriptional screen.  
Fig. 6.14 Effect of xs glutamate on expression from integron promoters in wild type and 
PA14_72690::Tn containing pMP220-intA, following growth in LB followed by 2 hour stimulation +/- 
xs glutamate. 
Fig. 6.15 Effect of xs L-glutamine on expression from integron promoters in wild type and 
PA14_72690::Tn containing pMP220-intA, following growth in LB followed by 2 hour stimulation +/- 
xs L-glutamine. 
Fig. 7.1 Data analysis pipeline for functional screen of mutant library. 
Fig. 7.2 Distribution of functional screen significant hits within sub-library. 
Fig. 7.3 Significant hits from functional screen of n = 532 mutants. 
Fig. 7.4 Venn diagram summarising the mutants highlighted in the functional screen of Pc-regulated 
β-lactamase expression (chapter 7), the transcriptional screen for differential Pint transcription 
(chapter 6 – β-galactosidase screen output), and the transcriptional screen for differential Pc 
transcription (chapter 6 – alkaline phosphatase screen output). 
Fig. 8.1 Murine gastrointestinal colonisation timeline. 
 20 
Fig. 8.2 Gastrointestinal colonisation levels in CD1 mice by P. aeruginosa strains PA01 (A) and PA14 
(B). 
Fig. 8.3 In vivo optical imaging of bioluminescent P. aeruginosa at day 4 p.i.  
Fig. 8.4 Localisation of bacteria with ex vivo 2DBLI.  
Fig. 8.5 In vivo parallel fitness assay timeline.  
Fig. 8.6 qPCR analysis of genomic DNA extracted from input pool in drinking water. 
Fig. 9.1 Proposed model of imipenem-induced integron gene induction in wild type and muxC 
mutant. 
Fig. 9.2 Scavenging plasmid schematic. 
  
 21 
List of tables 
Table 1.1 Cassette promoter variations, ranked according to strength of promoter activity. 
Table 2.1. Antibiotic concentrations for selection of bacterial strains. 
Table 2.2. Minimal medium of Davis and Mingioli. 
Table 2.3. β-galactosidase assay components. 
Table 3.1 Prevalence of β-lactamase variants documented in the INTEGRALL database, and Ambler 
classification. 
Table 6.1 Antibiotic selection panel used for conjugation of pIPCi214c_A into PA14NR Set mutants on 
solid media. 
Table 6.2 Mutants selected for rescreening in 96-well format.  
Table 6.3 Alkaline phosphatase assay output from mutants rescreened in 96 well high-throughput 
format. 
Table 6.4 β-galactosidase assay output from mutants rescreened in 96 well high-throughput format. 
Table 6.5 Average % change in expression compared with wild type across for the 8 mutants which 
were identified as significantly different in both the high throughput transcriptional screen and the 
confirmational rescreen. 
Table 7.1 Antibiotic selection panel used for conjugation of pEVM2a into PA14NR Set mutants. 
Table 7.2 PA14NR Set mutants into which pEVM2a was not successfully conjugated.  
Table 7.3. Identification of functional screen significant hits, sorted by sub-library location, alongside 
quantile normalised data output. 
Table 8.1 Mutants selected for in vivo parallel fitness study due to their significance in either the 
functional screen (FS) or the alkaline phosphatase assays in the regulatory screen (RS-AP). 
Table 8.2 qPCR output. 
  
 22 
1 Introduction 
1.1 Antibiotic resistance  
1.1.1 Dawn of antibiotic era and emergence of resistance 
Taking the definition of ‘antibiotic’ as any substance which is “injurious to, or destructive of, living 
matter, esp. micro-organisms” [1], the antibiotic era can be said to have begun in 1899 with the 
extraction and use of Pyocyanase from Bacillus pyocyaneus (now Pseudomonas aeruginosa) to kill 
Vibrio cholera, Salmonella typhi, and Bacillus anthracis, with varying success [2]. The next major 
development was in 1909 with Paul Ehrlich and Sahachiro Hata’s demonstration of the anti-syphilitic 
properties of arsphenamine (Salvarsan) [3]. Salvarsan was used to treat syphilis until the 1940s, 
when it was replaced by penicillin as a safer and more effective drug [4]. In the meantime however, 
sulphonamides had begun to be used systematically in the early 1930s to treat a range of bacterial 
infections [5]. Then followed the golden era of discovery of novel antibiotics, from the 1950s to 
1970s [6], and with the dangers of infectious disease now of little concern, the nature of medicine 
was transformed: invasive procedures and immune suppression therapies, which would previously 
have been unthinkable, became a possibility. However, by the early 1980s an antibiotic drought had 
become established, and no new classes of antibiotic have made it to clinic since that time, with 
modifications of existing antibiotics being the only new source of new drugs [6, 7]. The complacency 
that appeared to have settled over policymakers, politicians and the public in recent decades 
appears to finally be lifting, with acknowledgments now being made that antibiotic research must 
receive more funding and attention than previously [8], and entirely new antibiotics such as 
teixobactin [9] are again beginning to be discovered. 
 
However, the emergence of antibiotic resistance within bacterial populations has never been far 
behind the discovery of new drugs: resistance to sulphonamides was reported by 1939 [10], and in 
the same year that penicillin was first reported as a potential chemotherapeutic agent against 
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bacterial infections [11], a bacterial penicillinase was identified by members of the same group [12]. 
In fact, the identification of bacterial resistance factors, even before drugs have been used in clinic, 
can now be appreciated in the context of antibiotics naturally existing as ancient weapons in the 
arsenal of microorganisms themselves as part of their ongoing competition for survival [13]. In order 
to establish and defend their ecological niches, microorganisms produce a range of compounds that 
are toxic to microbial competitors [14]. These competitors have therefore developed a range of 
mechanisms to withstand [15], avert [16], eject [17], negate [18], or destroy [19] these compounds 
and ensure their own continued survival. Resistance against antibacterial agents is therefore an 
ancient evolutionary mechanism which has only been compounded by the increased selection of 
antibiotic resistance by their use in clinical settings.  
 
Resistance emerges either endogenously, through chromosomal mutations, or exogenously, through 
horizontal gene transfer via conjugative plasmids, transposons and insertion sequences [20]. The 
ability of genes to spread from cell-to-cell is of particular concern in the context of antibiotic 
resistance, since a resistance determinant arising in one species can be distributed to others. The 
use of antimicrobial agents creates a selective pressure for resistant organisms to thrive, even when 
used appropriately, as in critically ill patients receiving long term antibiotics [21]. However, misuse of 
antibiotics has added additional societal pressures which have been shown to accelerate the 
increase of antimicrobial resistance [22]. Inappropriate clinical use of antibiotics can direct the 
resistance profiles of bacteria through Darwinian selection, resulting in the propagation of resistant 
organisms, for example through inaccurate diagnostics leading to inappropriate drug prescription 
[23, 24], inaccurate or inadequate diagnostics preceding prescription [24-26], and patient failure to 
complete the course [21, 27]. Additionally, there is great concern about environmental and zoonotic 
reservoirs of antibiotics and antibiotic resistance. Antibiotic contaminated water and soil, as a result 
of excreted antibiotics in sewage/manure from humans or animals [28], hospital effluent or as a 
result of release from antibiotic manufacturing facilities [29, 30] or water treatment [31], presents 
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an ideal forum for horizontal gene transfer and is a major source of resistant organisms [32]. Such 
organisms are then easily transmitted via food chains [33, 34] and water supplies [32, 35, 36]. The 
intestinal tracts of animals raised for meat consumption are also thought to be an important source 
of drug-resistant bacteria such as E. coli [37], since drug-resistant Enterobacteriaceae are routinely 
detected in such animals [38, 39] and in meat products [40]. Similar multiple-resistance plasmids 
have also been identified in bacteria from meat used as a food source and from human clinical 
samples in the same region [41]. Significantly, plasmid-mediated resistance has recently been 
identified towards colistin in both humans and pigs, meaning that horizontally acquired resistance to 
all known antibiotic groups now exists [42]. Drug resistant pathogens have also been recovered from 
aquatic food sources, for example the recovery of carbapenem resistant Pseudomonas fluorescens 
from shop-bought squid [43]. Since 70 billion animals are bred for meat annually worldwide [44], the 
use of antibiotics in industrial farming in the absence of infectious disease (i.e. prophylactically and 
as growth enhancers), is of huge concern in a potential resistance reservoir of such size.  
 
A group of bacterial pathogens has been identified, acronymically termed the ESKAPE pathogens, 
which together account for at least 60 % of UK healthcare-associated infections (HAIs) [45] and are 
the most common source of new antibiotic resistance genes [46]: Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, P. aeruginosa, and 
Enterobacter species [47]. Throughout Europe, large variations are observed in the resistance 
situation for these bacteria, most likely related to differences in antimicrobial use, infection control 
and healthcare provision in the different countries, with lower resistance generally observed in 
northern European countries and higher prevalence in the south [48]. However, despite the high 
prevalence of these species in the nosocomial environment, the level of drug resistance with which 
they are associated and the high priority of antimicrobial resistance outlined by the UK Chief Medical 
Officer [49], UK funding for antimicrobial resistance research has decreased from 10.4 % between 
1997 - 2010 to 0.01 % from 2011 – 2013 [50]. 
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1.1.2 β-lactams and carbapenems  
β-lactams were the first naturally derived class of antibiotics to have been widely therapeutically 
used and still dominate the antimicrobial market to this day, including 60 % of EU antibiotic 
consumption [51]. This broad group of drugs includes the penams (penicillin and derivatives) [52], 
cephalosporins [53], oxapenams [54], monobactams [55], and carbapenems [56] (Figure 1.1A), and is 
defined as all antibiotic agents containing a four-membered β-lactam ring, as shown in red in Figure 
1.1 [57]. This β-lactam ring is generally fused to either a five-membered heterocyclic ring (as in 
penams and carbapenems) or a six-membered ring (as in cephems) [58], with this fused ring either 
saturated, or unsaturated between C-2 and C-3 in five-member rings or C-3 and C-4 in six-member 
rings [57] (Figure 1.1).  
 
 
Figure 1.1 General structures of β-lactam antibiotics [57]. Structures grouped according to whether the core structure is 
naturally occurring (A) or synthetic (B). β-lactam ring shown in red.  
 
The early β-lactams primarily targeted Gram-positive bacteria, but subsequent classes and variants 
have extended the range of targets; since antibacterial activity is largely based on the chemical 
reactivity of the β-lactam ring, the nature of the side chains and heterocyclic ring to which it is fused 
are significant, causing substantial alterations in bioavailability, spectrum, stability and tolerance 
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[57]. Benzylpenicillin (penicillin G) [52] and phenoxymethylpenicillin (penicillin V) [59], were amongst 
the first naturally derived and clinically used penicillins, and are narrow spectrum drugs used 
primarily to treat Gram-positive bacteria, plus a few Gram-negatives including Neisseria gonorrhoeae 
and Neisseria meningitides [60]. Semi-synthetic penicillin derivatives have since been developed 
through modification of the side chains of the penicillin nucleus, 6-aminopenicillanic acid (6-APA) 
[61], to create variants such as the aminopenicillins (ampicillin and amoxicillin) [62, 63] and the 
carboxypenicillins (e.g. carbenicillin) [64]. Monobactams are only active against Gram-negative 
aerobic bacteria, with the only bioactive and commercially available monobactam antibiotic, 
aztreonam [55], being a semisynthetic construction with an antibacterial spectrum limited to P. 
aeruginosa, N. meningitidis, N. gonorrhoeae, and Haemophilus influenza [65]. Cephalosporins are 
broad-spectrum antibiotics which are used for the treatment of both Gram-positive and –negative 
bacterial infections: first-generation cephalosporins are primarily active against Gram-positives, 
while later generations display increased activity against Gram-negatives and simultaneously 
decreased Gram-positive activity [66]. The naturally occurring cephalosporin-C was discovered in 
1955 as a more stable, but less active, penicillin-like drug [53, 67], from which the 7-
aminocephalosporanic acid (7-ACA) core was isolated [58] and modified over subsequent 
generations to expand the spectrum of the group [66]. In addition, entirely synthetic drugs have 
been created by altering the basic 6-APA and 7-ACA cores, such as the penems [68], oxacephems 
[69], and carbacephems [70] (Figure 1.1B).  
 
The β-lactams also contain a group of important last-line antibiotics that are often the final 
opportunity to treat bacterial infections caused by multidrug resistant organisms: the carbapenems. 
Carbapenems possess an exceptionally broad spectrum of activity, including towards many Gram-
positive and Gram-negative bacteria (except meticillin-resistant S. aureus and E. faecium [56, 71-73]) 
and are highly stable against the majority of β-lactam-inactivating enzymes [74], as discussed in 
Chapter 1.1.3. The first clinically useful carbapenem was imipenem, discovered by Merck in 1980 
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[75], as the stable N-formimidoyl derivative of the naturally occurring compound thienamycin. 
Thienamycin is a potent β-lactam antibiotic, with excellent activity against both Gram-positives, and 
the full range of Gram-negative bacteria, including P. aeruginosa [76]. It was discovered in 1976 in a 
previously unidentified Streptomyces species, Streptomyces cattleya [76]. Imipenem is highly active 
against Gram-positive organisms, as well as Gram-negative species including Enterobacteriaceae, P. 
aeruginosa, Bacteroides fragilis, and numerous other multidrug resistant bacteria [77]. However, 
since imipenem is rapidly hydrolysed by the renal enzyme dehydropeptidase-I (DHP-I) [78], resulting 
in the release of toxic degradation products and low urinary concentrations of antibiotic, it is 
administered in a 1 : 1 ratio with a specific DHP-I inhibitor, cilastatin [77]. Meropenem, discovered in 
1989, is stable to DHP-I so does not require co-administration with cilastatin [74], and induces fewer 
side effects than imipenem-cilastatin [79]. Meropenem has similar activity to imipenem, but is more 
effective against Enterobacteriaceae and P. aeruginosa, and less effective against staphylococci and 
enterococci [80]. Ertapenem, the only other carbapenem licensed for use in the UK [81], has a 
marginally reduced spectrum of activity compared to imipenem-cilistatin and meropenem, but is 
recommended for the management of serious infections acquired and treated in the community due 
to the once-a-day dosing regimen [71]. 
 
β-lactams function through inhibition of cell wall biosynthesis, by preventing peptidoglycan cross-
linking via irreversible inactivation of a group of transpeptidase and transglycosylase enzymes known 
as penicillin-binding proteins (PBPs) [82]. Since PBPs have varying affinities for different β-lactam 
antibiotics, the activity spectrum of each drug depends upon the range of PBPs present in each 
species and the essentiality of each for bacterial survival [83]; imipenem and meropenem have 
particularly high affinities for PBPs in both E. coli and P. aeruginosa in comparison with penicillin G 
[84]. As an analogue of the terminal D-alanyl-D-alanine group within the peptidoglycan precursor, 
the β-lactam ring acts as a suicide substrate for the PBP: the β-lactam ring competes to bind in the 
active site of the PBP, where the PBP catalyses the degradation of the β-lactam amide bond and 
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covalent acylation to the active serine residue, inactivating the enzyme [85, 86]. At the same time, 
non-cross-linked peptidoglycan is degraded by lytic transglycosylases (LTs) and recycled within the 
cell [87]. This disruption of the balance between peptidoglycan synthesis and degradation induces a 
cycle of incomplete cell wall synthesis and depletion of cellular peptidoglycan precursors, including 
those not consumed by the targeted PBP, resulting in systemic toxicity [88]. Cell death is therefore 
due to a combination of disrupted cell integrity resulting in an inability to grow or divide without cell 
lysis occurring [89], and a toxic depletion of cell resources [88]. 
 
1.1.3 Resistance to β-lactam antibiotics 
The development of resistance to β-lactam antibiotics occurs through: (a) the alteration of PBP 
targets to reduce affinity [86], for example the expression of PBP2a in S. aureus results in resistance 
to methicillin and other β-lactams [73, 90]; (b) altered trafficking into and out of the cell, through 
modified [91] or absent [92] porins preventing drug diffusion into cell, or active drug efflux from cells 
as in P. aeruginosa [93]; or (c) drug degradation through production of β-lactamase enzymes that 
hydrolyse and inactivate the β-lactam ring [94]. In Gram-negative bacteria, the production of β-
lactamases represents the greatest threat to β-lactams, as these enzymes are generally encoded by 
genes located in mobile elements such as plasmids and transposons, which are readily disseminated 
amongst different strains and species [95, 96]. Of particular concern are the β-lactamases that are 
capable of hydrolysing almost all β-lactam drugs, including carbapenems, which are termed the 
carbapenemases [97]. 
 
The widespread use of penicillins, often in combination with β-lactamase inhibitors such as 
clavulanic acid [98], provided a therapeutic advantage over Gram-negative bacteria late into the 
1970s. However, the widespread emergence of plasmid-encoded β-lactamases led to the increased 
use of alternative antibiotic classes and third-generation cephalosporins, which have a broader 
spectrum of activity and are less susceptible to enzyme-mediated hydrolysis [99]. This resulted in the 
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proliferation of extended spectrum β-lactamases (ESBLs), particularly blaTEM, blaSHV and blaCTX 
gene variants [100, 101], leaving carbapenems as the only group of β-lactams to which resistance 
remained rare. Carbapenems are less susceptible to β-lactamase activity since the hydrogen atoms 
attached to the β-lactam ring are arranged in cis rather than trans and are therefore less accessible 
to enzymatic degradation [56]. However, resistance to carbapenems among serious bacterial 
pathogens is increasingly being acknowledged as an urgent international concern; for example, 
resistance to carbapenems was reported in 62.3 % of Klebsiella pneumoniae isolates in Greece in 
2014 [48] and 16 % of P. aeruginosa blood isolates in the UK in 2014 [102]. Until 2007, 
carbapenemases were rarely found outside of Acinetobacter spp., but a diverse range of genes are 
now being observed in a variety of common human pathogens [103-105]. Additionally, because of 
the mobile nature of carbapenem resistance determinants, they are often accompanied by genes 
conferring resistance to other classes of antibiotics: in 2014, 81.4 % of European K. pneumoniae 
isolates that displayed resistance to carbapenems were also resistant to third-generation 
cephalosporins, fluoroquinolones, and aminoglycosides, with these quad-resistant isolates 
accounting for 5.7 % of the tested isolates [48]. 
 
β-lactamases are most commonly categorised according to their amino acid sequences, using the 
revised Ambler classification system [106, 107], with carbapenemase activity having been identified 
in all groups. Class A, C and D enzymes all contain an active serine residue within the active site of β-
lactam hydrolysis, and although there is no detectable sequence similarity between the three classes 
of serine β-lactamases, the level of structural similarity clearly indicates that they are descended 
from a common ancestor [107]. Class B β-lactamases are metalloenzymes that require a divalent 
active-site zinc to facilitate substrate hydrolysis [108]. 
 
Class A β-lactamases were the first identified serine-based enzymes [106], and are the group in 
which the BlaTEM, BlaSHV and BlaCTX ESBL variants belong [109, 110]. Class A carbapenemases have 
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been identified sporadically since the mid-1980s, but have not become widely disseminated, 
potentially due to being primarily chromosomally located and all inhibited by inhibitors such as 
clavulanic acid [97]. The most successful plasmid located class A β-lactamase, BlaKPC (Klebsiella 
pneumoniae carbapenemase), was identified in 2001 [111] and has since spread globally, but 
remains primarily restricted to K. pneumoniae hosts [112]. Class C β-lactamases are based on the 
AmpC cephalosporinase [113], but are not generally considered to be carbapenemases despite 
certain class C enzymes such as BlaCMY being able to degrade carbapenems when overexpressed in 
conjunction with reduced outer membrane permeability [114]. Class D are the oxacillinase (OXA) 
group of β-lactamases, which are a heterogeneous group of enzymes that are usually resistant to 
inhibitors such as clavulanic acid [115]. They have varying affinities for carbapenems, with at least 
191 distinct OXA- enzymes currently considered to be carbapenemases [115].  
 
However, the majority of epidemiologically significant carbapenemases are class B, zinc-based 
metallo-β-lactamases (MBLs) [116, 117]. The first reports of all acquired (non-chromosomal) MBLs 
have been in Pseudomonas spp, Enterobacteriaceae (e.g. Klebsiella spp.) or Acinetobacter spp [118], 
highlighting the importance of these species in the transmission of last line antibiotic resistance and 
the generation of new variants. Currently, the three most noteworthy MBL variants are BlaVIM, 
BlaIMP, and BlaNDM [118]. BlaIMP was the first identified plasmid-mediated MBL, first noted in a P. 
aeruginosa isolate in Japan in 1991 [119], then characterised from a Serratia marcescens isolate in 
1994 [120]. The current most broadly distributed MBL variant, BlaVIM (Verona integron-mediated 
MBL), has a remarkably high affinity for carbapenems [121], and was first identified in 1999 in a P. 
aeruginosa isolate in Italy [122], followed by the VIM-2 variant in P. aeruginosa in France in 2000 
[123]. Having arisen and spread initially in P. aeruginosa, VIM-type enzymes have become 
successfully dispersed both geographically and across species boundaries: these genes are now 
widespread in many Gram-negative species including a range of Enterobacteriaceae, and have been 
reported worldwide [118]. To date, VIM- and IMP- type MBLs (plus the rarer AIM, DIM, GIM and 
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SIM-types), have been found exclusively encoded within structures called integrons [118], and are 
now globally distributed across many Gram-negative species, regardless of the species in which they 
were discovered, indicating horizontal transfer of these genes between unrelated Gram-negative 
species [97]. These integron-associated genes are increasingly being identified as the cause of 
carbapenem resistance in Gram-negative bacteria, causing serious hospital outbreaks associated 
with high mortality rates [124-129]. 
 
1.2 Integrons  
1.2.1 Role, prevalence, and origins 
Integrons are naturally occurring gene traps that recruit and excise gene cassettes in accordance 
with selective pressures from the environment [130-133]. They are well established as reservoirs for 
antibacterial resistance genes, with their successful association with transposons and conjugative 
plasmids providing an ideal platform for cassette dissemination [41, 134]. Despite initially having 
been studied in the context of clinical resistance, integron-associated resistance genes are now 
known to be widely distributed in the environment [135], including in bacteria isolated from waste 
water [134], and hospital effluent [136]. 
 
The geographical distribution of integron-associated carbapenemase variants is variable, with the 
VIM- and IMP- types having spread particularly well [118]. The 48 currently identified BlaIMP 
variants are found most frequently in Asia, particularly in P. aeruginosa isolates, but are distributed 
worldwide [137, 138]. However, the most commonly identified carbapenemases worldwide are the 
41 VIM-type enzymes [137, 138], recently causing outbreaks in Brazil [139], Colombia [140], Ivory 
Coast [141], Croatia [142], and the USA [143, 144], and in food-producing animals as well as human 
populations [145]. They are currently endemic in Southern Europe [137, 146, 147], providing an 
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epicentre for European carbapenemase distribution and an explanation for its distinct North-South 
divide [48]. 
 
Integrons were first identified as a mechanism for antibiotic resistance gene capture and 
dissemination among Gram-negative bacteria [130, 148-150], responsible for distributing genes 
conferring resistance to β-lactams, aminoglycosides, trimethoprim and chloramphenicol under the 
control of the integron integrase [150-152]. These structures were discovered through closer 
inspection of the observation that transposons with different resistance determinants often differed 
only in the resistance genes they harboured [130, 152-154]. These genes are distributed in the form 
of covalently closed promoterless gene cassettes, consisting of the gene and an attC recombination 
site [155], which are scavenged and integrated by the integron integrase [156], and expressed by a 
dedicated cassette promoter [157]. The integron platform is itself non-mobilisable, but contains the 
machinery for resistance cassette dispersal and is often associated with mobile genetic elements, 
often on transposons or conjugative plasmids, allowing distribution of the full entity to other 
bacteria [158].  
 
While mobile integrons were originally identified as defective transposon derivatives [151], they are 
now known to be ancient structures whose origins are in the chromosomal integrons found in a 
range of bacterial families, including the Vibrionaceae, Pseudomonadaceae, and Xanthomonadaceae 
[159]. These chromosomal integrons (sometimes referred to as super-integrons [160]) are often 
huge, with more than 200 cassettes [161, 162]. The function of the majority of cassettes in these 
structures is currently unknown, but many of the cassettes do appear to perform important bacterial 
roles in either survival or virulence, including drug resistance (chloramphenicol acetyltransferases, 
fosfomycin resistance proteins and glutathione transferases), DNA metabolism, and potential 
virulence genes including haemagglutinin and lipoproteins [163]. 
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1.2.2 General structure of mobile integrons 
In addition to the chromosomal integrons from which they originated, three classes of mobile 
integron have been identified to date, located within functional and non-functional transposons 
[151, 164-166]. These integrons are distinguished according to the sequences of the conserved 
region containing the integrase gene and attI insertion site: despite all three classes of mobile 
integron catalysing the same attC x attC reaction to utilise a common pool of cassettes [167], the 
conserved regions themselves are not closely related, with IntI2 and IntI3 sharing only 45% and 60% 
amino acid identity with IntI1 respectively [166, 168-170].  
 
The first integron identified was a class 1 integron: In2, located within transposon Tn21, which 
contained an aadA1 aminoglycoside-resistance gene cassette [130]. This transposon was itself 
carried on a plasmid, NR1, that was isolated from Shigella flexneri in the late 1950s [171]. Class 1 
integrons have subsequently been established as significantly the most common in clinical isolates, 
with recent hospital samples having demonstrated 81 %, 89.7 % and 94.7 % of identified multi-drug 
resistant (MDR) integrons as Class 1 in E. coli [172], K. pneumoniae [173] and P. aeruginosa [174] 
respectively. 
 
The minimal integron platform comprises a gene encoding a site-specific tyrosine recombinase, intI, 
with its own dedicated promoter, Pint, a divergently orientated cassette promoter, Pc, and attI 
recombination site (Figure 1.2 – 5’ conserved region) [130, 149]. Class 1 integrons also often contain 
a conserved 3’ region comprising an independently expressed ethidium bromide resistance gene 
(qacEΔ1), sulphonamide resistance gene (sul1), and a putative conserved gene of unknown function 
which bears 47 – 50 % similarity to a puromycin-modifying enzyme from Streptomyces spp. (Figure 
1.2 – 3’ conserved region) [130, 175, 176]. Although the 3’ conserved region is no longer considered 
to be as highly conserved as in early studies [177, 178], the sul1 gene within this region is likely to 
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have contributed extensively to the widespread distribution of integrons, since sulphonamides were 
the first widely used antimicrobial agents that paved the way for the antibiotic revolution [179]. 
 
 
Figure 1.2 General structure of class 1 integrons. The conserved sections are shown in grey, with direction and location of 
promoter regions indicated by black arrows. The 5’ conserved region is comprised of an intI1 gene encoding an integrase 
with its own promoter (Pint), a cassette promoter, Pc, located within the coding region of intI1, and an attI recombination 
site (green triangle). The 3’ conserved region is usually (although not strictly) conserved, and consists of an independently 
regulated group of three genes: qacEΔ1 (encoding resistance to ethidium bromide and quaternary ammonium 
compounds), sul1 (encoding resistance to sulphonamides) and an open reading frame of unknown function. The variable 
region contains an array of promoterless gene cassettes (blue arrows) flanked by attC recombination sites (blue triangles). 
The integrase, IntI1, mediates both excision of cassettes into free, circular intermediates (blue circular arrow) with 
reconstituted attC sites (blue triangle) via attC x attC or attC x attI recombination, and integration of free cassettes (of both 
exogenous and endogenous origin) into the array at the attI site (green triangle).  
 
The DNA sequence of the 5’ conserved region of class 1 integrons (Figure 1.2) is highly conserved, 
with minor variations most commonly occurring in the region of the cassette promoter, Pc (Figure 
1.3, yellow boxed nucleotides) [180]. These variations are largely within the σ70 promoter -35 and -
10 hexamers, with Pc variants named according to their strength in relation to the derepressed tac 
promoter and to each other (Table 1.1): the ‘strong’ PcS variant is six times more efficient than the 
derepressed tac promoter [181] and 20 – 30 times more efficient than the ‘weak’ PcW variant [180, 
181]. Two hybrid promoters, PcH1 for Hybrid 1 and PcH2 for Hybrid 2, contain the -35 and -10 
hexamers of the PcW and PcS promoters in opposite combinations (Table 1.1), and confer 
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intermediate strengths of approximately 20 % and 68 % respectively, relative to PcS [180, 182]. 
Another variant, PcSS for ‘super strong’, was initially reported to be significantly stronger than PcS 
when it was discovered in a P. aeruginosa clinical isolate [183], but was found to be only about 10 % 
as efficient as PcS when subsequently tested using transcriptional fusions in E. coli [180]. Three other 
weak Pc variants have been described, named after the integrons/plasmids they are carried by: 
PcIn42 from integron In42 [184], PcIn116 from integron In116 [185], and PcPUO from plasmid 
pUO901 [186], and conferring strengths of approximately 5 %, 1 % and 6.5 % respectively, relative to 
PcS [180]. The other common point of variation for Pc promoters is a C to G mutation 2 bp upstream 
of the -10 hexamer, which creates a ‘TGN-10’ extended -10 motif that increases the transcription 
efficiency of σ70 promoters in E. coli by a factor of approximately 10 compared with the normal TCN 
motif [187]. However, the effect on cassette expression of this extended TGN-10 motif is dependent 
on the Pc variant preceding it: in integrons containing the weak cassette promoter variant, PcW, the 
TGN-10 motif increases cassette expression by a factor of 12, while reducing expression by 
approximately 6.5 % in integrons containing the ‘strong’ PcS variant, and conferring little effect on 
the intermediate promoter PcH2 [180]. 
 
Figure 1.3 Regulatory region of the first discovered integron, In2 from transposon Tn21 [130]. Blue highlighted sequences 
are the 5’ terminii of the divergently orientated intI1 and aadA1 genes respectively. Promoters Pc (PcW variant), P2, and Pint, 
and their internal -35 and -10 sites are indicated by white arrows. Yellow boxed nucleotides indicate the most common 
single nucleotide polymorphisms affecting integron promoter sequences in integron regulatory regions [180]. Orange 
boxed nucleotides indicate the 3 bp insertion which creates the secondary cassette promoter, P2, in a small subset of 
integrons [150].  
 36 
 
Table 1.1 Cassette promoter variations, ranked according to strength of promoter activity [180]. Nucleotides that differ 
from those of PcS are shown in red bold font. 
 
a Average β-galactosidase activities of Pc-lacZ transcriptional fusions analysed by Jové et al. [180] 
b Frequency of promoter variant amongst the 321 unique Class 1 integrons in NCBI analysed by Jové et al. [180] 
 
In addition, a small sub-set of class 1 integrons, including In2, contain a 3 base insertion in the region 
between the intI1 gene and the attI recombination site (Figure 1.3, orange boxed nucleotides), 
which results in the formation of an additional cassette promoter, P2 [150, 180]. Similarly to the 
TGN-10 motif, the effect of this additional promoter on cassette expression is dependent on the Pc 
variant preceding it, since strong promoters are weakened and weak ones are strengthened; in 
integrons containing the strong cassette promoter variants PcS and PcWTGN-10, the addition of a P2 
promoter reduces cassette expression by approximately 20 % and 11 % respectively, while in 
integrons containing the weak PcH1 and PcW variants, expression is increased to approximately 150 
% and 560 % respectively [180]. However, as this insertion is present in less than 10 % of integrons, it 
is considered atypical amongst those integrons recently dominating the nosocomial environment 
[176, 180]. 
1.2.3 Integrase mode of action 
The integron integrase, IntI, is a member of the integrase family of site-specific recombinases, and 
includes the four conserved amino acids that are characteristic of members of the integrase family 
[188]. IntI1 drives integration of exogenous promoterless cassettes (Figure 1.2, blue circular arrow) 
Designation
Promoter 
strength (Miller 
units)a 
-35 motif Spacer -10 motif
Integrase 
variant encoded Frequency (%)
b
PcS 1240 TTGACA TAAGCCTGTTCGGTTCG TAAACT IntI1R32_N39 23.7
PcSTGN-10 1160 TTGACA TAAGCCTGTTCGGTTGG TAAACT IntI1P32_N39 0.3
PcH2TGN-10 860 TTGACA TAAGCCTGTTCGGTTGG TAAGCT IntI1P32_N39 1.6
PcH2 840 TTGACA TAAGCCTGTTCGGTTCG TAAGCT IntI1R32_N39 2.8
PcWTGN-10 720 TGGACA TAAGCCTGTTCGGTTGG TAAGCT IntI1P32_H39 16.8
PcH1 240 TGGACA TAAGCCTGTTCGGTTCG TAAACT IntI1R32_H39 26.2
PcSS 120 TTGATA TAAGCCTGTTCGGTTCG TAAACT IntI1R32_I38_N39 0.3
PcPUO 80 TCGACA TAAGCCTGTTCGGTTCG TAAACT IntI1R32_D38_N39 0.6
PcIn42 60 TTGGCA TAAGCCTGTTCGGTTCG TAAACT IntI1R32_A38_N39 0.3
PcW 60 TGGACA TAAGCCTGTTCGGTTCG TAAGCT IntI1R32_H39 16.5
PcIn116 10 TTGACA TAAGCCTGTTCGGTTCG TGAACT IntI1S31_R32_N39 0.3
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through recombination between the cassette attC site and, preferentially, the attI site that marks 
the end of the 5’ conserved region (Figure 1.2, green triangle), to allow the incorporation and 
expression of free circular cassettes [155]. 
 
The attC recombination sites, previously known as 59-base elements [153], are imperfect 
palindromic sequences that can vary in length from 40 – 160 bp, with the recombination crossover 
point having been localised to between the adjacent G and T residues of the GTT triplet in the 
GTTRRRY (R = purine, Y = pyrimidine) terminal consensus region [189, 190]. The attI sites are 65 bp 
sequences with a pair of inversely orientated IntI1 binding domains, a pair of directly orientated IntI1 
binding domains, and a terminal RYYYAAC consensus sequence [191]. During cassette integration, 
the attC bottom strand adopts a folded stem and loop structure [156] which IntI1 binds to and 
stabilises [192]. In combination with the double stranded attI site, an atypical Holliday junction is 
thus created and resolved through IntI1-mediated cassette integration [193]. IntI1-mediated 
integrative recombination events have been documented between two attC sites [189, 190], but are 
far less frequent than integration into the attI site in the context of cassettes being integrated into 
integrons [194]. 
 
IntI also drives excision of resident cassettes into their free form, primarily through attC x attC 
recombination [155] (Figure 1.2), although not necessarily via the same mechanism as integration, 
since integration and excision efficiencies are not strictly linked [180]: the three integrase variants 
which account for almost 96 % of class 1 integrases, IntI1R32_H39, IntI1R32_N39 and IntI1P32_H39, display 
similar integration activities (recombination frequencies with all three variants were within 0.5 x 
log10) but very different excision efficiencies (recombination frequencies of approximately 2 x 10-2, 3 
x 10-4 and 5 x 10-5 respectively) [180]. It appears too, that different regions of the integrase are 
involved in the attI x attC and attC x attC recombination reactions, given that variations in intI1 
sequence can result in differences between the efficiency of these reactions [180]. 
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1.2.4 Regulation as currently understood 
The integron literature contains evidence of environmental stimuli directly influencing the 
transcriptional regulation of integron promoters. A regulatory sequence known as a LexA, or SOS, 
box was identified within the integrase promoter region (Pint), leading to the discovery that the 
bacterial SOS response, a coordinated cellular reaction to DNA damage, also induces expression of 
the integron integrase in the V. cholerae chromosomal integron and in mobile integrons in E. coli 
[131]. The SOS response is induced by accumulation of single stranded DNA within cells, and results 
in cell cycle arrest and induction of DNA repair and mutagenesis genes [195]. Two of the key 
regulatory components of this system are LexA, which binds to consensus sequences in promoter 
regions with varying affinities determined by the stage of the SOS cascade at which genes are 
induced, and RecA, which recognises single stranded DNA and polymerises around it to form an 
active multi-functional complex [196]. A major function of the active RecA complex is to catalyse the 
autodigestion of LexA to allow expression of SOS genes [197, 198]. In addition, it was established 
that upregulation of integron integrase is induced by introduction of foreign DNA via conjugative 
plasmid transfer (direct transfer of circular plasmids via cell-to-cell contact) [132] and transformation 
(uptake of extracellular DNA from environment) [133] in E. coli and V. cholerae, and that this 
response can be strongly alleviated in E. coli by the plasmid-mediated expression of a narrow host 
range anti-SOS factor, psiB [132]. It has also been demonstrated that conjugation induces integrase-
dependent recombination in both artificial and natural systems [132]: conjugation of plasmids into 
an E. coli DAP (2,6-diaminopimelic acid) auxotroph with an attI/attC flanked insertion in the dapA 
gene, induces expression of resident intI1 and subsequent integrase-dependant excision of the 
insert. Conjugation of V. cholerae also induces intI expression and triggers cassette rearrangement as 
a result of SOS induction in the naturally occurring V. cholerae chromosomal integron, at a 100-1000 
fold higher rate than under non stressed conditions [132].  
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It has also been demonstrated that carbon source, independently of SOS, controls intIA expression in 
the V. cholerae chromosomal integron via a cyclic AMP (cAMP) receptor protein (CRP)-dependent 
mechanism [133]. A CRP binding site was identified (5’ TGGTGTGATGCTCAACATACTG 3’), and 
confirmed to be responsible for PintIA induction by arabinose and succinate, and repression by 
glucose, both in situ in V. cholera, and in an E. coli host containing a PintIA-gfp transcriptional fusion. 
In E. coli, cAMP is produced in response to glucose starvation, and induces a conformational change 
upon binding to the CRP [199]. The cAMP-CRP complex is then able to activate transcription of 
regulated genes by binding tightly to specific DNA sites located upstream of the target gene 
promoter (Figure 1.4), and forming protein-protein interactions with the RNA polymerase to 
facilitate binding of the RNA polymerase to promoter DNA [199]. Glucose is therefore a known 
repressor of CRP-regulated genes in Enterobacteriaceae, while arabinose and succinate, as less 
preferred carbon sources, are inducers, in keeping with the effects seen on the Vibrio chromosomal 
integron promoter [133]. While the primary role of CRP in E. coli and other Enterobacteriaceae is in 
activating the expression of genes involved in the metabolism of alternative carbon sources, in 
several other groups of bacteria (including some in which chromosomal integrons are also present), 
it has roles in other cellular functions than catabolite repression [200]: roles in anaerobic respiration, 
amino acid metabolism, virulence and pathogenicity have been demonstrated in CRP-family 
regulators in Yersiniae, pseudomonads, and Xanthomonas campestris, appearing to be largely 
dependent on the availability/presence of adenylyl cyclases [200-204]. Despite no investigations into 
the effects of carbon source on mobile integrons having yet been performed, and no suggestion 
having been made of a similar CRP binding site in their regulatory region, the regulation of intIA 
expression through carbon catabolite control further serves to illustrate the importance of the 
extracellular environment in determining the gene content of integron cassette arrays. 
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Figure 1.4 CRP consensus binding profile in Enterobacteriales [205]. Built upon 2301 confirmed sites across 12 bacterial 
species. 
 
However, apart from characterisation of SOS-dependent regulation of Pint in chromosomal and 
mobile integrons in (non-pathogenic) E. coli and V. cholerae [131-133, 206], there is a general lack of 
research into the co-ordinated regulation of both mobile integron promoters, Pint and Pc, particularly 
in the context of clinical isolates. The first examination of the convergent expression from the 
integron promoters, Pint and Pc, was performed by Cagle et al. in 2011 [207]. Although atypical of the 
integrons dominating the nosocomial environment, this analysis was performed on the prototypical 
RecA-independent integron In2 [130]. This study used a range of constructs containing portions of 
the regulatory region of In2, fused to divergent lacZ and phoA reporter genes in the narrow host 
range vector, pCB267 (Figure 1.5), and identified consensus DNA binding sites for FIS (Factor for 
Inversion Stimulation), IHF (Integration Host Factor) and H-NS (Histone-like Nucleoid Structuring 
protein) (Figure 1.6) [207]. This study also confirmed experimentally that In2 is not subject to LexA-
mediated regulation due to the 3 bp insertion which eliminates the LexA binding site that was 
identified in previous studies of mobile integrons (Figure 1.3, orange boxed nucleotides), and results 
in the formation of the secondary cassette promoter, P2 [207].  
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FIS, IHF and H-NS are all DNA structuring proteins, with an analogous role to that of histones in 
eukaryotes: they are DNA-binding proteins responsible for compacting and structuring bacterial DNA 
[209]. They have additional roles as versatile global regulators, able to both activate (IHF and FIS) 
and repress (all three) genes according to the position and strength of their binding sites relative to 
the target gene promoter, by modulating DNA topology [210]. Cagle et al. revealed FIS and LexA as 
combinatorial repressors of both Pint and Pc, and IHF as an indirect activator of both promoters, 
acting independently of both FIS and LexA [207]. They also revealed repression of Pint by H-NS, and 
activation of cassette promoters in the absence of LexA [207]. 
 
However, despite having developed suitable molecular tools in the form of their dual reporter 
constructs, Cagle et al. did not simultaneously examine expression levels from both promoters in the 
same samples, choosing instead to measure individual promoter expressions from distinct samples 
[207]. Given the apparent sensitivity of integrons to their environment, this could have resulted in a 
loss of sensitivity in their assays, introducing extra variability to the comparison of Pc and Pint 
 
Figure 1.5 Schematic diagram of dual reporter plasmid, pCB267 [208]. adrA’, truncated diguanylate cyclase (from E. coli 
phoA operon); ampR, ampicillin resistance gene; PampR, ampR promoter; lacZ, β-galactosidase (from E. coli); phoA, alkaline 
phosphatase (from E. coli phoA operon); psiF, phosphate starvation-induced protein (from E. coli phoA operon). 
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expression that may have rendered small changes invisible. Additionally, despite the highly 
promiscuous nature of integrons amongst Gram-negative pathogens, at the outset of this PhD, 
specific examinations of mobile integron promoter regulation had been limited to non-pathogenic E. 
coli strains.  
 
However, during the course of this PhD, an example of integron-mediated antibiotic resistance 
occurring in a clinical P. aeruginosa isolate was published [211]. In this study, treatment of a non-
Pseudomonal infection with metronidazole was posited to have stimulated the SOS response in a 
concurrently infecting, integron-carrying, P. aeruginosa strain. This resulted in integron-mediated 
excision of a gcuF1 cassette from the 2nd position in the P. aeruginosa integron cassette array, 
moving the downstream blaOXA-28 extended spectrum β-lactamase cassette to 2nd position. 
Integrase-mediated excision of this gcuF1 cassette was demonstrated to have resulted in up-
regulation of the transcription, the translation, and the secretion of the OXA-28 extended spectrum 
β-lactamase, resulting in a β-lactam resistant strain that subsequently caused an outbreak in the 
hospital. This study, therefore represented the first published account of integron-based antibiotic 
resistance developing during therapeutic use of antibiotics, which was demonstrated to be due to 
induction of the SOS response by antibiotic treatment. However, to the best of our knowledge, this 
remains the only examination of mobile integron promoter regulation in a species other than non-
pathogenic E. coli, and it did not address the growing issue of integron-associated carbapenem 
resistance.   
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Figure 1.6 Regulatory region of In2, as determined by Cagle et al. [207]. Blue highlighted sequences are the 5’ terminii of the divergently orientated intI1 and aadA1 genes respectively. 
Promoters Pc (PcW variant), P2, and Pint and their internal -35 and -10 sites are indicated by white arrows. Predicted regulatory binding sites for FIS (olive), H-NS (blue), and IHF (red). 3 bp 
insertion which simultaneously creates P2 and eliminates LexA binding site indicated by purple highlighted nucleotides, with position of interrupted LexA binding sites indicated by purple 
dashed lines. 
 
  44 
 
1.3 P. aeruginosa  
1.3.1 Description, lifestyle, risk factors and epidemiology 
Pseudomonas spp. are a metabolically diverse genus of bacteria, and are therefore able to colonise a 
large range of niches, including acting as opportunistic pathogens of both plants and animals. The 
prototypical member of the genus, P. aeruginosa [212], is named after the greenish-blue colour 
(Latin: “aerugo”) it takes on in culture and in the pus of infected individuals due to its ability to 
produce and secrete the blue pigment pyocyanin, and the fluorescent green pigment pyoverdin 
[213]. 
 
P. aeruginosa is a Gram-negative facultative anaerobe which can exist with enormous environmental 
versatility as planktonic, unicellular organisms, or as sessile cells attached to surfaces in multicellular 
aggregates known as biofilms [214]. It can be isolated from terrestrial, freshwater and marine 
environments [215], artificial environments such as ventilators, catheters, and plumbing fixtures 
[216-220], and is considered to be part of the normal human microflora [221]. It is also able to 
pathogenise a large range of plant and animal hosts, often using many of the same virulence factors 
[222]. Since this range of hosts includes a large range of species that are commonly used as infection 
models, including Arabidopsis thaliana [223], Galleria mellonella [224], Drosophila melanogaster 
[225], Caenorhabditis elegans [226] and mice (Mus musculus) in both acute and chronic forms [227, 
228], the pathophysiology of P. aeruginosa infection and methods of virulence have been widely 
studied.  
 
P. aeruginosa does not generally cause infection in healthy individuals [229], however opportunistic 
infections can occur via both exogenous and endogenous routes, primarily in immunocompromised 
patients [230]. P. aeruginosa is therefore a common cause of nosocomial infections, including 
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approximately 3 % of monomicrobial bloodstream infections in the UK in 2014 [102], and is the most 
common source of healthcare-associated pneumonia and ventilator associated pneumonia in 
intensive care units [231-235]. A major risk factor for P. aeruginosa infection is cystic fibrosis (CF); P. 
aeruginosa colonisation is frequently associated with greater morbidity and mortality in these 
patients [236], with up to 97.5 % of CF patients already showing culture or serologic evidence of 
intermittent P. aeruginosa infection by 3 years of age [237]. Chronic colonisation of CF patients with 
P. aeruginosa commonly involves conversion of strains to an alginate overproducing, ‘mucoid’, 
phenotype, which is believed to result in production of biofilm-protected colonies that are sheltered 
from the host immune system [220], and which are associated with a significant increase in 
morbidity and mortality [238]. 
 
P. aeruginosa is intrinsically resistant to many antibiotic classes due to the low permeability of its cell 
membrane to hydrophilic molecules such as antibiotics [239], the presence of periplasmic β-
lactamases [240], a range of multidrug efflux pumps [241], and multiple chromosomally encoded 
resistance genes [241]. It is also a major source of novel mobile (plasmid- or transposon-located) 
resistance genes [123, 242-245]. As a result, when P. aeruginosa infections do occur, they are often 
persistent and difficult to treat: even following treatment, crude mortality rates can be as high as 72 
% in patients with ventilator associated pneumonia [246], although directly attributable P. 
aeruginosa mortality is estimated to be 24-50% in such groups [234, 247].  
 
The gastrointestinal tract is considered to be the most significant endogenous source of 
microorganisms reaching the respiratory tract [248, 249]. However, evidence suggests that despite 
colonization of the upper respiratory tract almost always preceding lung infection [250], 
transmission is generally via the transiently colonised hands of healthcare workers [251-253] rather 
than through aspiration of gastric colonising bacteria [254]. The significance of exogenous sources of 
P. aeruginosa has been repeatedly demonstrated during outbreaks of infections with this organism, 
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with almost any type of hospital equipment or utensil able to serve as a bacterial reservoir and 
potential source of contamination [255-258]. Water systems are a particularly common source of 
nosocomial infections [256, 259, 260], as P. aeruginosa is able to survive for long periods even in 
distilled water [261] and readily colonises water systems [258, 262, 263]. Colonized patients 
themselves can also serve as continuous exogenous sources of microorganisms from which other 
patients can be colonized via cross-acquisition [264, 265].  
 
1.3.2 Regulation and metabolism control 
P. aeruginosa strains have large and variable genomes, varying from 5.2 to 7 Mbp in size (without 
considering extrachromosomal genetic material) [266], with the sequenced reference strains PA01 
and PA14 having genomes of 6.3 Mbp (encoding 5688 annotated genes) and 6.5 Mbp (encoding 
5977 annotated genes) respectively [230, 267]. Consistent with the association between bacterial 
genome size and environmental versatility, approximately 9.4% of P. aeruginosa genes are predicted 
to be either transcriptional regulators or two-component regulatory system proteins, many of which 
are involved in the regulation of virulence [230]. P. aeruginosa encodes many complex regulatory 
networks, which allow it to thrive in diverse conditions by responding rapidly to changes in its 
environment through appropriate deployment of global regulatory systems. 
 
P. aeruginosa possesses approximately 200 cytoplasmic membrane transport systems that appear to 
be involved in the import of nutrients and other molecules, most of which display similar substrate 
specificities to those of E. coli and B. subtilis [230]. However, fewer than 10 of these are involved in 
sugar transport, compared with ~ 60 in E. coli and 40 in B.subtilis [230]. The vast microbial metabolic 
networks present in P. aeruginosa allow for a remarkable range of substrates to be utilised as carbon 
and nitrogen sources, including 146 different organic compounds [268], requiring wholesale 
metabolic reorganisation in response to the hierarchical level of the substrates they encounter 
[204]. P. aeruginosa preferentially utilises organic acids or amino acids as carbon sources, rather 
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than glucose, in stark contrast to Enterobacteriaceae [204], and lacks an intact glycolytic pathway 
[230].  
 
P. aeruginosa employs hierarchical control of growth substrate uptake and metabolism via the 
translational repressor ‘catabolite repression control’ (crc) [269], alongside the two-component 
systems CbrAB and NtrBC, involved in carbon and nitrogen utilisation respectively [270]. Crc plays a 
similar role to CRP in other species, by participating in the repression of genes responsible for 
metabolising non-preferred metabolites; however, Crc-mediated control is directly repressive in 
action rather than activating in the presence of a second messenger as is the case for CRP [204]. In 
the presence of preferred carbon sources, genes in the Crc regulon are repressed via binding of the 
Crc protein to Catabolite Activity (CA) motifs (AAnAAnAA) near the ribosome binding sites in the 
target mRNAs [204, 271, 272]. However, non-preferred carbon sources, including glucose, result in 
the induction of the CbrAB two component system, which in turn induces the siRNA, CrcZ [269, 271]. 
CrcZ sequesters Crc, resulting in the alleviation of Crc-mediated repression of genes responsible for 
metabolising non-preferred energy sources [269, 271]. 
 
1.3.3 Role of P. aeruginosa as a model organism 
P. aeruginosa serves as a useful model organism for investigation of behaviours such as chemotaxis 
[273], biofilm production [274], and opportunistic pathogenicity [275]. Due to the metabolic 
versatility discussed in Chapter 1.3.2, it is easy to manipulate under laboratory conditions and 
techniques now exist for ready genetic manipulation of the species, including horizontal gene 
transfer which can be easily induced through three partner conjugation [276]. Conjugation is a 
unidirectional process that occurs when DNA is transferred from one cell to another during direct 
cell-to-cell contact, with one cell acting as donor and the other as recipient. Mobilisation-deficient 
plasmids can be transferred in triparental matings with mobilisation occurring via the conjugative 
properties of pRK2013 within a donor strain such as E. coli 1047 [277]. 
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Several P. aeruginosa transposon mutant libraries are now available for genome-wide phenotypic 
analyses of commonly used strains of clinical origin. The P. aeruginosa PA01 mini-Tn5-luxCDABE 
mutant library utilises transcriptional lux fusions as real-time bioluminescent reporters of 
differentially regulated genes, and contains 2519 mapped insertion mutants, corresponding to 1284 
unique predicted ORFs [278]. This library presents a very useful tool for real-time phenotypic 
screening, but has coverage of only 23 % of predicted ORFs, meaning that a significant portion of 
potentially interesting targets are excluded from consideration. The P. aeruginosa PA01 library 
created by Jacobs et al. using a combination of mini-Tn5-phoA and –lacZ transposons, provides far 
more saturated coverage, with 4892 unique ORFs inactivated [279]. The comprehensive level of 
coverage in this library, with an average of 5.05 hits per ORF, was sufficient to designate the 678 
ORFs that were never hit as candidate-essential genes, without which the bacterium is unable to 
survive [279]. The Jacobs PA01 library has since been refined to include two sequence-verified 
mutants for most ORFs targeted in the primary library, which should help to provide even more 
confidence in any phenotypes observed from it [280]. The most widely utilised library currently 
appears to be the ordered, nonredundant library of P. aeruginosa PA14 transposon mutants 
(PA14NR Set), created by Liberati et al. primarily using the MAR2xT7 transposon, plus a small subset 
that were created using the Tn5-based transposon, TnPhoA [281]. This is a comprehensive 
secondary library of 5459 ordered mutants, representing 4469 unique inactivated ORFs, in which the 
majority of nonessential genes are represented by a single optimal mutant [281]. Since PA14 [282]is 
a more virulent and more recent clinical isolate than PA01 [230], the PA14NR Set is a valuable 
complementary resource to the refined PA01 library: for example, comparison of the ‘candidate-
essential’ genes from both libraries revealed a core list of 335 genes not disrupted in either library, 
providing more evidence to suggest that these are truly essential genes rather than missed by 
chance [281]. 
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1.3.4 Murine models of P. aeruginosa infection 
As an opportunistic human pathogen, P. aeruginosa causes both chronic and acute infections. Acute 
infections are generally the result of dissemination from previously colonised tissue, such as ulcers 
or burns injuries, followed by a dramatic failure in immune defences: such acute infections are 
associated with rapid tissue damage, sepsis and high mortality [283].  
 
However, since P. aeruginosa is most frequently investigated in the context of chronically colonised 
CF patients, the most common chronic colonisation models are of the lung, and generally involve 
surgical introduction of Pseudomonas-infused agarose beads [284], which is challenging and difficult 
to reproduce in small rodents [285]. Alternatively, mutant P. aeruginosa strains exhibiting the 
mucoid phenotypes that so readily colonise the CF lung can be used to study in vivo P. aeruginosa 
infection in relation to CF patients [227].  
 
However, despite the occasional identification of mucoidal carbapenem resistant P. aeruginosa from 
CF patients [286], integron-associated variants are more commonly isolated from bacteraemia and 
pneumonia patients [123, 242, 287]. Therefore non-CF mouse models of chronic P. aeruginosa 
colonisation are more appropriate to study integron-associated MDR P. aeruginosa infections. Since 
human infections with P. aeruginosa are commonly caused by colonisation of mucosal surfaces such 
as the lung, urinary tract and gut [216, 288], and are key sites for the isolation of strains carrying 
carbapenemase-containing integrons [124, 289, 290], simple colonisation models in these sites are 
likely to be appropriate for observing integron activity. The gut mucosa in particular is an ideal 
surface for colonisation and is a highly relevant site to study: gastrointestinal flora are major 
reservoirs of carbapenem resistant P. aeruginosa, particularly in intensive care populations [291, 
292], and endogenous P. aeruginosa strains in the GI flora have been shown to be the source of lung 
infections in both CF and intensive-care populations [216, 293, 294]. Gastrointestinal colonisation 
can easily be achieved without requiring the use of an immobilising agent, as in wild type lung 
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models [285, 295]: the model developed by Koh et al. [296], which achieved colonisation levels of 
105 and 108 cfu/g stool at days 1 and 5 post-infection respectively [293], involves introducing 
bacteria to the gut of mice in drinking water, along with prophylactic antibiotics to clear the 
indigenous gut flora. Such depletion of the murine GI microbiota is analogous to that in the human 
patient population, where mucosal surfaces are routinely conditioned for colonisation by the use of 
broad-spectrum antibiotics [293]. This model can also be used to produce an acute systemic 
infection by disseminating the stably colonised bacteria through induction of neutropenia [293, 296], 
and has been successfully used in combination with PA14 NR Set mutants to examine the genes 
needed for gastrointestinal colonisation and dissemination [297]. 
 
1.4 Objectives of this study  
The major aim of this study is to characterise the regulation of integron-mediated gene capture and 
gene expression during in vitro and in vivo culture of clinically relevant bacteria. 
 
We hypothesise that, given the opposing physiological roles of integrase and cassette expression (i.e. 
stable maintenance of antibiotic resistance cassettes versus plasticity of integron architecture 
through mobilisation of these same cassettes), mutually exclusive expression from the two 
promoters would have physiological relevance. According to this hypothesis a model for integron 
functionality is proposed which considers that, under non-stressed conditions, the transcriptional 
activity of Pint is limited by repressors including LexA and Pc activity (Figure 1.7A, pink/green ovals 
and red line from Pc), but that under conditions of stress such as exposure to antibiotics, this 
repression is lifted (Figure 1.7B). This leads to Pint activation with integrase expression dominant, 
resulting in reorganisation of the cassette repertoire (Figure 1.7B). However upon recruitment of a 
novel cassette, Pint repression is re-established (Figure 1.7C). This allows dominant expression of the 
cassette and results in cell survival.  
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Additionally, we hypothesise that environmental cues (including SOS-inducing cues), detected by the 
bacterial host, are utilised for the governance of such a balanced regulation. 
 
 
Figure 1.7 Proposed model for co-ordinated regulation of integron promoters. A: In normal growth conditions, 
transcription of gene cassettes (blue arrow) from Pc predominates, with the transcriptional activity of Pint limited by 
repressors including LexA (pink/green ovals) and Pc activity (red line). B: Under conditions of stress such as exposure to 
antibiotics (red stars), this repression is lifted, leading to Pint activation and dominant intI1 expression (grey arrow = intI1. 
Grey blob = IntI1). This results in integrase-mediated reorganisation of the cassette repertoire and integrase-mediated 
induction of Pc. C: Pc is activated, resulting in expression of the cassette (blue blob) and re-establishment of Pint repression. 
Ineffective products of the gene cassette do not affect levels of stressor, returning cells to a state of dominant Pint activity 
(B), while effective removal of the stressor results in cell survival and a return of the cell to normal growth conditions (A).  
 
Examination of these hypotheses was conducted according to these specific objectives: 
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1. To identify, clone and modify a clinically-derived, carbapenamase-expressing integron for 
studies in a bacterial pathogen of clinical relevance, P. aeruginosa. 
 
2. To construct transcriptional reporters of cassette and integrase expression for studies in P. 
aeruginosa and to establish reporter assays suited to both low and high throughout assays of 
integron activities. 
 
3. To use transcriptional reporters of integron promoters to perform a targeted analysis of 
integron promoter activities and examine the relevance of environmental cues to integron 
responsiveness in P. aeruginosa. 
 
4. To establish a high-throughput transcriptional screen for identification of novel Pint and Pc 
transcriptional regulators in P. aeruginosa. 
 
5. To perform a high-throughput functional screen for identification of novel regulators of 
integron-mediated carbapenem resistance in P. aeruginosa. 
 
6. To establish a suitable model of P. aeruginosa in vivo colonisation in which to examine novel 
regulators of integron-mediated carbapenem resistance in P. aeruginosa in vivo. 
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2 Materials and Methods 
2.1 Chemicals, reagents and enzymes 
Chemicals and reagents were purchased from Sigma-Aldrich; Merck Millipore (Darmstadt, Germany) 
or Thermo Fisher Scientific, Inc. (Waltham, MA, USA) unless otherwise stated. Enzymes for cloning, 
including restriction enzymes, ligases, kinases and phosphatases were purchased from New England 
Biolabs (UK). DNA polymerases were purchased from KAPA Biosystems, Inc. (Wilmington, MA, USA), 
Clontech Laboratories, Inc. (Mountainview, CA, USA) and Sigma-Aldrich; Merck Millipore. All 
protocols were conducted using manufacturer‘s guidelines, unless otherwise stated 
2.2 Bacterial strains and growth conditions 
All bacterial strains used in this study are listed in Appendix 2.1 and in the following chapters as 
appropriate. 
 
Unless otherwise stated, all ingredients were purchased from Oxoid; Thermo Fisher Scientific, Inc., 
Merck Millipore, Thermo Fisher Scientific, Inc., or Sigma-Aldrich; Merck Millipore. All media were 
sterilised by autoclaving at 121 °C for 15 minutes. Following autoclaving, media was supplemented 
with antibiotics as required, according to Table 2.1. 
 
Table 2.1. Antibiotic concentrations for selection of bacterial strains. 
Antibiotic Concentration for liquid 
culture (μg/ml) 
Concentration for solid culture 
(μg/ml) 
Ampicillin 50 50 
Imipenem 50 100 
Kanamycin 50 50 
Tetracycline 30 90 (not suitable for PIA) 
Trimethoprim 100 500 
 
Unless otherwise stated, bacterial strains were grown in LB-Miller broth (1 % peptone from casein 
(w/v); 0.5% yeast extract (w/v); 1 % sodium chloride (w/v)) at 37 °C with shaking at 180 rpm.  
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Solid LB was made by addition of 1.25 % (w/v) agar to LB-Lennox broth (1 % tryptone (w/v); 0.5 % 
yeast extract (w/v); 0.5 % sodium chloride (w/v)) prior to autoclaving. Pseudomonas strains were 
selected on Pseudomonas isolation agar (1.36 % agar (w/v); 0.14 % magnesium chloride (w/v); 2 % 
peptic digest of animal tissue (w/v); 1 % potassium sulfate (w/v); 0.0025 % triclosan (Irgasan) (w/v)). 
Strains were stored on plates for up to 1 week at 4°C. For longer term storage, strains were stored in 
15-25% (w/v) glycerol at -80 °C. 
 
Minimal media was prepared according to Table 2.2, with carbon source added after the remainder 
of the medium was autoclaved, then the final media filter sterilised through a 0.2 μm cellulose 
acetate syringe filter (VWR International, Radnor, PA, USA). 
 
Growth curves were performed in clear, flat-bottomed 96-well microtitre plates (Nalge Nunc 
International, Penfield, NY, USA) in a POLARStar Omega multiwall plate reader (BMG Labtech Ltd., 
Aylesbury, UK). Seed cultures of each strain were diluted 1 : 10 in a final volume of 200 µl of fresh 
medium (with appropriate antibiotics) and incubated in the plate reader at 37 °C, shaking at 500 
rpm, for 18.5 hours, with OD600 readings taken every 30 minutes. 
2.3 Oligonucleotide primer synthesis  
All oligonucleotides used in this study were purchased from Sigma-Aldrich; Merck Millipore and are 
listed in Appendix 2.2 and within the following chapters as appropriate.  
 
Table 2.2. Minimal medium of Davis and Mingioli [298]. 
Basal medium 
Carbon source 1 % w/v 
Dipotassium hydrogen phosphate (K2HPO4) 7 g 
Potassium dihydrogen phosphate (KH2PO4) 3 g 
Sodium citrate (Na3C6H5O7.2H20) 0.5 g 
Magnesium sulphate (MgSO4.7H2O) 0.1 g 
Ammonium sulphate ((NH4)2SO4) 1 g 
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Trace element solution 5 ml 
Distilled water To 1 L 
  
Trace element solution  
Ferrous sulphate (FeSO4.7H2O) 0.5 g 
Zinc sulphate (ZnSO4.7H2O) 0.5 g 
Manganese sulphate (MnSO4.3H2O) 0.5 g 
Sulphuric acid (H2SO4, 0.1 N) 10 ml 
Distilled water To 1 L 
 
2.4 Plasmids 
All plasmids used in this study are listed in Appendix 2.3 and in the following chapters as 
appropriate.  
2.5 Molecular biology  
2.5.1 Genomic DNA extraction 
Genomic DNA was extracted from overnight bacterial cultures using the PureLink Genomic DNA kit 
(Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer’s instructions. 
2.5.2 Preparation of chemically competent E. coli cells 
100 ml of fresh media (with antibiotic where appropriate) was inoculated with an overnight culture 
of the appropriate bacterial strain to OD600 of 0.1. The cells were grown at 37 °C with shaking at 180 
rpm until the OD600 of the culture reached 0.48. The culture was then split into 50 ml volumes and 
cooled on ice for 5 min, before cells were harvested by centrifugation at 3200 x g for 10 min at 4 °C. 
Pellets were resuspended in 40 ml ice-cold TfbI (30 mM KAc, 100 mM KCl, 10 mM CaCl2, 50 mM 
MnCl2, Glycerol 15%, pH 5.8 with 0.2 M acetic acid), chilled on ice for 5 min, then centrifuged again 
at 3200 x g for 10 min at 4 °C. Pellets were then resuspended in 4 ml ice-cold TfbII (10 mM MOPs or 
PIPES, 10 mM CaCl2, 10 mM KCl, Glycerol 15%, pH to 6.5 with 3 M KOH), chilled on ice for 15 min, 
then split into 100 μl aliquots for immediate transformation or storage at -80 °C.  
  56 
2.5.3 Low-throughput plasmid mobilisation 
2.5.3.1 Heat-shock transformation  
Plasmid DNA (10 – 300 ng) was added to 50 μl chemically competent E. coli cells and incubated on 
ice for 30 min. The mixture was then heat-shocked by incubation for 30 seconds in a 42 °C water 
bath, before being returned to ice for 2 min. 250 ul SOC or LB (without drug) was then added and 
the suspension was left to recover at 37 °C for 1 hour, shaking at 180 rpm. Cells were then plated 
onto selective solid media and incubated at 37 °C overnight. 
2.5.3.2 Conjugation 
Plasmids were mobilised from E. coli strains to P. aeruginosa by triparental mating [17]. E. coli TOP10 
or DH5α were used in triparental matings as the plasmid donor strain with mobilisation occurring via 
the conjugative properties of pRK2013 within E. coli 1047.  
2.5.3.2.1 Conjugation on solid media 
Equal volumes of donor and helper strains were combined on LB plates (without antibiotic) at 37 °C 
for 2 hours while simultaneously incubating the recipient strain at 43 °C for 2 hours to inactivate the 
Pseudomonas restriction modification system [299]. The recipient strain was then added at twice the 
volume of the donor strain to the donor/helper spot, and plates incubated at 37 °C for 2 and 4 
hours. After 2 and 4 hours, the conjugation patch and control patches were resuspended in LB, and 
serial dilutions plated onto selective LB agar (Figure 2.1). Plates were incubated at 37 °C for up to 48 
hours, before colony counts were made.  
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Figure 2.1 Selection strategy for quantification of conjugation frequency on solid media. Helper strain = E. coli 
1047/pRK2013. Donor strain = E. coli/pMP220. Recipient strain = P. aeruginosa PA14. Transconjugants = P. aeruginosa 
PA14/pMP220. Expected presence or absence of growth of each strain on each media type is indicated by tick or cross, 
respectively. Colony counts were made from plating serial dilutions of the conjugation mixture. 
 
At each time point, spots of donor, helper and recipient were also individually resuspended in LB and 
each plated onto all three types of selective LB to confirm the reliability of selection media (Figure 
2.1). 
P. aeruginosa transconjugants were confirmed by replating onto Pseudomonas isolation agar (PIA) 
supplemented with 90 μg/ml tetracycline, but colony counts were not performed on these plates. 
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2.5.3.2.2 Conjugation in liquid media 
Solid conjugation protocol was adapted for use in liquid media as outlined in Figure 2.2. Helper, 
donor and recipient controls were plated as previously (Figure 2.1), with the addition of PIA control 
plates to confirm purity of Pseudomonas cultures. To confirm reliability of the transconjugant 
selection method, at least 50 potential transconjugants (colonies on LB + 50 μg/ml ampicillin and 90 
μg/ml tetracycline) from each experiment were restreaked onto PIA + 90 μg/ml tetracycline and 
incubated at 37 °C for 24 hours.  
 
Figure 2.2 Experimental procedure for conjugation in liquid media. A: Schematic for low-throughput conjugation in liquid 
media. Helper strain = E. coli 1047/pRK2013. Donor strain = E. coli/pMP220. Recipient strain = P. aeruginosa PA14. 
Transconjugants = P. aeruginosa PA14/pMP220. 
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2.5.4 Plasmid DNA extraction 
Plasmids were extracted from overnight bacterial cultures using the QIAprep Spin Miniprep Kit 
(Qiagen GmbH, Hilden Germany) or the NucleoSpin Plasmid kit (Macherey-Negel GmbH, Wetzlar, 
Germany), according to the manufacturer’s instructions. 
2.5.5 Separation of DNA fragments by electrophoresis  
DNA fragments were separated alongside 100 bp or 1 kb DNA ladder (New England BioLabs, Inc. 
(NEB), Ipswich, MA, USA), in agarose gels comprised of 1 % (w/v) agarose in 1 x Tris-Borate-EDTA 
(TBE) buffer (89 mM Tris base, 89 mM boric acid, 2 mM EDTA) with 1x SYBR Safe DNA gel stain 
(Invitrogen; Thermo Fisher Scientific, Inc.). Gels were typically run at 85 V for 45 min and were 
visualised using an AlphaImager UV transilluminator (ProteinSimple, San Jose, CA, USA). 
 
When required for onward reactions, DNA was purified after electrophoretic separation by excising 
the DNA band of interest from the agarose gel with a clean, sharp scalpel and the DNA extracted 
using a QIAquick Gel extraction Kit (Qiagen GmbH) according to the manufacturer’s instructions. 
2.5.6 Nucleic acid quantification 
The concentration and purity of purified nucleic acids – genomic DNA, plasmid DNA and RNA - was 
analysed using the NanoDrop ND-1000 UV-Vis Spectrophotometer (Thermo Fisher Scientific, Inc.). 
2.5.7 Restriction enzyme digests  
Restriction digest reactions were performed using NEB enzymes and buffers according to 
manufacturer’s specifications. A typical reaction included at least 50 ng DNA, 1 μl of 10x NEB 
CutSmart buffer, 1 μl of restriction enzyme (total), bovine serum albumin (BSA) to a final 
concentration of 100 µg/ml, and H2O to 10 μl. Reactions were generally incubated at 37 °C for 1 
hour. Digests were purified using the QIAquick PCR purification kit (Qiagen GmbH) as per the 
manufacturer’s instructions. 
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2.5.8 Polymerase chain reaction (PCR) 
PCR reactions were performed using either KapaTaq polymerase (Takara Bio, Inc., Otsu, Japan) or 
PrimeSTAR HS polymerase (Takara Bio, Inc.) and standard procedures as described by the 
manufacturers. For colony PCR initial incubation at 95 °C was extended to 10 minutes. Reactions 
were conducted in 0.2 ml thin-walled PCR tubes. PCR products were purified using a QIAquick PCR 
purification kit (Qiagen GmbH) as per the manufacturer’s instructions.  
2.5.9 GeneArt seamless cloning 
Reactions were conducted using GeneArt Seamless Cloning and Assembly Kit (Invitrogen; Thermo 
Fisher Scientific, Inc.) and the purified linearised vector and insert(s) DNA according to the 
manufacturer’s instructions. Linearised vector and insert(s) were designed and prepared with at 
least 15 bp homologous overhangs to the next segment, then combined in a GeneArt reaction at a 
2:1 molar ratio of insert : vector. Reactions were incubated for 30 minutes at room temp, chilled on 
ice, and transformed into E. coli cells within 5 minutes of reaction termination. 
2.5.10 Ligation 
Reactions were conducted using NEB T4 ligase and the purified digested plasmid vector DNA and 
insert DNA according to the manufacturer’s instructions. Reactions were conducted using an insert: 
vector molar ration of 3:1. Reactions were generally incubated at 16 °C overnight, then enzymes 
heat inactivated at 16 °C for 15 mins. Reactions were then chilled on ice and 1-5 μl of the reaction 
transformed directly into 50 μl competent cells. 
2.5.11 Sequencing 
DNA sequencing was performed at the DNA Core Laboratory, Medical Research Council, Imperial 
College London. The oligonucleotides used to sequence (listed in Appendix 2.2 and the appropriate 
chapters) were purchased from Sigma-Aldrich; Merck Millipore and co-ordinated for maximal 
coverage of the region of interest. 
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2.5.12 Quantitative PCR (qPCR) 
qPCR was performed using SYBR Green Jumpstart™Taq ReadyMix™ (Sigma-Aldrich; Merck Millipore). 
Reactions contained 1 µl of each primer (10 µM), 10 µl of SYBR Green Jumpstart™Taq ReadyMix™, at 
least 25 ng of template DNA, and sterilised distilled water to a final volume of 20 µl. Reactions were 
conducted in a Rotor-Gene RG-3000 PCR cycler (Qiagen GmbH) with the following cycling 
parameters: 95 °C for 5 seconds, 55 °C for 5 seconds, 72 °C for 15 seconds, 78 °C for 5 seconds, 
which was repeated 40 times. Data were then analysed using the RotorGene 6 software, in which 
the amplification threshold was manually set at the maximum fluorescence level for the negative 
controls to generate Ct values. 
2.6 Low throughput protein techniques 
2.6.1 Protein extraction 
20 ml of fresh media (with antibiotic where appropriate) in a 100 ml Erlenmeyer flask was inoculated 
with an overnight culture of the appropriate bacterial strain to OD600 of 0.1. The cells were grown at 
37 °C with shaking at 180 rpm for 6 hours. After 6 hours, the OD600 of the sample was recorded, then 
15 ml of the culture transferred to a 15 ml Falcon tube and pelleted by centrifugation at 3220 x g for 
10 min at 4 °C. Pellets were resuspended in 500 µl 1 x Lysis buffer (0.25 M Tris, pH 8.0) and 
transferred to sterile 1.5 ml Eppendorf tubes. Samples were then frozen on dry ice for 5 min, then 
thawed in a 37 °C water bath. This freeze-thaw step was performed three times. The insoluble 
material was pelleted by centrifugation at 3220 x g for 10 min at 4 °C, and the supernatant 
transferred to a fresh, sterile, 1.5 ml Eppendorf tube and stored at – 20 °C. 
 
The total protein concentration of this supernatant was then quantified by bicinchoninic acid (BCA) 
assay and used for subsequent β-galactosidase (β–gal) and alkaline phosphatase (AP) transcriptional 
reporter assays. 
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2.6.2 Protein quantification 
Total protein concentration was quantified using the BCA Protein Assay Kit (Sigma-Aldrich; Merck 
Millipore) according to the manufacturer’s instructions. The BCA working solution was prepared by 
combining reagents A and B in a 50: 1 ratio immediately prior to use. 2 μl of the protein extract(s) of 
interest were pipetted into a clear, flat-bottomed 96-well microtitre plate, alongside a protein 
standard curve of 0-20 µg bovine serum albumin (BSA) and H20 and extraction buffer blanks. 200 μl 
of BCA working reagent was then added to every protein-containing well and incubated at 37 °C for 
up to 30 minutes, before absorbance at 540 nm (A540) was measured. 
2.6.3 Reporter assays 
2.6.3.1.1 β-galactosidase assays 
Activity of β-galactosidase from cells expressing lacZ-containing reporter constructs was quantified 
using a β-Gal Assay Kit (Invitrogen; Thermo Fisher Scientific, Inc.), with components listed in Table 
2.3. This assay measures hydrolysis of ortho-nitrophenyl-β-D-galactopyranoside (ONPG) to the ONP 
anion, which produces a bright yellow colour that can be quantified by reading the absorbance at 
405 nm (A405) using a spectrophotometer.  
Table 2.3. β-galactosidase assay components. 
Component Composition Storage 
10 x cleavage buffer 0.6 M Na2HPO4∙7H2O 
0.4 M NaH2PO4∙2H2O 
0.1 M KCl 
0.01 M MgSO4∙7H2O 
pH 7.0 
+4 °C 
1x cleavage buffer 1 in 10 dilution of 10 x cleavage buffer, with 
270 μl β-mercaptoethanol per 100 ml buffer 
+4 °C 
ONPG 4 mg/ml in sterile water -20 °C 
Stop buffer  1 M Sodium carbonate Room temperature 
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1-10 μl of the total protein extract (with dH2O to 10 μl), 50 μl of 1 x cleavage buffer, and 17 μl of 
ONPG (4 mg/ml in distilled water) were combined in a clear, flat-bottomed 96-well microtitre plate 
and incubated at 37 °C for 30-45 minutes. 125 μl of stop buffer was then added to stop the reaction, 
the absorbance read at 405 nm, and specific activity of the lysate calculated as below:  
Specific activity = nmoles of ONPG hydrolyzed/t/mg protein  
 
nmoles of ONPG hydrolyzed = (A405) (2.02 x 105 nanoliters) 
            (4500 nl/nmoles-cm)(1 cm) 
 2.6.3.1.2 Alkaline phosphatase 
Activity of alkaline phosphatase from cells expressing phoA-containing reporter constructs was 
quantified using a colorimetric alkaline phosphatase assay. This assay measures dephosphorylation 
of p-nitrophenyl phosphate (pNPP), which produces a bright yellow colour that can be quantified by 
reading the absorbance at 405 nm (A405) using a spectrophotometer.  
 
1 μl of the total protein extract was added to 200 μl pNPP liquid substrate (N7653; Sigma-Aldrich; 
Merck Millipore UK) in a clear, flat-bottomed 96-well microtitre plate and incubated in the dark at 
room temperature for 30 minutes. 50 μl of 3 M NaOH was then added to stop the reaction, the 
absorbance read at 405 nm, and specific activity of the lysate calculated as below: 
Specific activity = nmoles of pNPP dephosphorylated/t/mg protein  
 
nmoles of pNPP dephosphorylated = (A405) (2.51 x 105 nanoliters) 
                       (18000 nl/nmoles-cm)(1 cm) 
 
2.7 P. aeruginosa PA14 NR Library manipulation techniques 
2.7.1 Library culture conditions 
Mutants were picked manually from frozen 96-well working storage plates on dry ice or from 
selective LB agar plates, into 600 µl LB containing 15 µg/ml gentamicin in a 2 ml 96-deep well block 
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(Eppendorf, Hamburg, Germany). Small colony variants were avoided when inoculating from agar 
plates, except in cases where non-variants were not available. Blocks were sealed with sterile 
breathable films (Anachem Ltd., Luton, UK) and incubated at 37 °C with shaking at 180 rpm for 16 
hours, before being transferred to storage plates. 
2.7.2 Transfer to storage plates 
100 μl of culture was removed from each well of the cultured 2 ml 96-deep well block into a 0.2 ml 
96-well microtitre plate (Thermo Fisher Scientific, Inc.), from which the OD540 was read and 
recorded. To minimise aerosol production, 160 µl sterile 60% glycerol was transferred from a 
reservoir to each well of the cultured deepwell block and mixed by pipetting up and down, to give a 
final volume of 15 % (w/v) glycerol. Fresh tips were used to transfer 40 µl of the mixed cultures to 
each of 3 96-well storage plates (one master and two working plates) containing 160 µl LB with 15 
µg/ml gentamicin and 15% glycerol (w/v). Storage plates were immediately sealed with sterile 
aluminium seals (VWR International) and stored at – 80 °C. 
2.7.3 Conjugation in 96-well deepwell blocks 
Plasmids were mobilised from E. coli strains to P. aeruginosa by triparental mating. E. coli DH5α was 
used as the plasmid donor strain, alongside the helper strain E. coli 1047/pRK2013.  
 
The E. coli helper and donor strains were grown on LB agar (supplemented with appropriate 
antibiotics) overnight at 37 °C. Single colonies were then transferred to 10 ml LB broth 
(supplemented with appropriate antibiotics), and incubated at 37 °C with shaking at 180 rpm for 16 
hours. Recipient P. aeruginosa strains were picked manually from frozen 96-well working storage 
plates into 600 µl LB containing 15 µg/ml gentamicin in a 2 ml 96-deep well block (Eppendorf), and 
incubated at 37 °C with shaking at 180 rpm for 16 hours.  
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5 ml each of the helper and donor cultures were combined with 30 ml LB broth (without antibiotics) 
into a single 100 ml Erlenmeyer flask and incubated for 2 hours at 37 °C with shaking at 180 rpm 
(Figure 2.3A). Simultaneously, 100 µl of the 16 hour recipient cultures in the deep well block were 
transferred to a fresh 2 ml 96-deep well block (Eppendorf) and incubated at 43 °C for 2 hours to 
deactivate the host restriction modification system (Figure 2.3B). 400 µl of the donor/helper culture 
was then added to each recipient, and the block incubated for a further 4 hours at 37 °C with 
shaking at 180 rpm (Figure 2.3C). 5 µl of each conjugation mixture and the individual helper, donor 
and recipient strains were then spotted onto LB agar plates containing antibiotics as listed in Table 
6.1 (Figure 2.3D). Plates were incubated at 37 °C for 24-48 hours, then cooled to room temperature 
and stored at 4 °C for no more than 8 days before picking. 
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Figure 2.3 Experimental procedure for 96-well conjugation in liquid media. Helper strain = E. coli 1047/pRK2013. Donor 
strain = E. coli/pMP220-intA or pEVM2a. Recipient strain = P. aeruginosa PA14 (wt or mutant)/ pMP220-intA or pEVM2a. 
 
Control plates were examined to ensure appropriate growth of each strain on each antibiotic. From 
the experimental plates, a single colony with a morphology representative of the majority of 
colonies for a given mutant was used to inoculate 600 µl LB containing 15 µg/ml gentamicin in a 2 ml 
96-deep well Master block (Eppendorf). Small colony variants were avoided except in cases where 
non-variants were not available. Plates were incubated for 16 h at 37 °C before being transferred to 
storage plates. 
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2.7.4 Protein techniques in 96-well high-throughput format 
2.7.4.1 Protein extraction 
Mutants were picked manually from frozen 96-well working storage plates on dry ice, into 400 µl LB 
containing 15 µg/ml gentamicin and 30 µg/ml tetracycline in a 2 ml 96-deep well block (Eppendorf). 
Blocks were sealed with sterile breathable films (Anachem Ltd.) and incubated at 37°C with shaking 
at 180 rpm overnight. 1.2 ml LB containing 15 µg/ml gentamicin and 30 µg/ml tetracycline was then 
added directly to this overnight culture, resealed with sterile breathable films, and incubated at 37°C 
with shaking at 180 rpm for 24 hours. 100 µl was transferred to a clear, flat-bottomed 96-well 
microtitre plate and the OD600 recorded.  
 
The remaining cells were harvested by centrifugation at 3220 x g for 10 min at 4 °C. Pellets were 
resuspended in 50 µl 1 x Lysis buffer (0.25 M Tris, pH 8.0) and transferred to a clear, flat-bottomed 
96-well microtitre plate. The plate was then frozen on dry ice for 5 min then thawed in a 37 °C water 
bath. This freeze-thaw step was performed three times. The insoluble material was then pelleted by 
centrifugation at 3220 x g for 10 min at 4 °C, and the supernatant transferred to a fresh, clear, flat-
bottomed 96-well microtitre plate. Plates were sealed with sterile aluminium seals (VWR 
International) and stored at – 20 °C. 
 
The total protein concentration of this supernatant was quantified by BCA assay, and protein used 
for subsequent β–gal and AP transcriptional reporter assays. 
2.7.4.2 Protein quantification (BCA assay) 
Total protein concentration was quantified using the BCA Protein Assay Kit (Sigma-Aldrich; Merck 
Millipore) according to the manufacturer’s instructions. The BCA working solution was prepared by 
combining reagents A and B in a 50: 1 ratio immediately prior to use. 2 μl of the protein extract(s) of 
interest were pipetted into a clear, flat-bottomed 96-well microtitre plate, alongside a protein 
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standard curve of 0-20 µg bovine serum albumin (BSA) and H20 and extraction buffer blanks. 200 μl 
of BCA working reagent was then added to every protein-containing well and incubated at 37 °C for 
up to 30 minutes, before absorbance at 540 nm (A540) was measured. 
2.7.4.3 Reporter assays 
2.7.4.3.1 β-galactosidase assays 
Activity of β-galactosidase from cells expressing lacZ-containing reporter constructs was quantified 
using a β-Gal Assay Kit (Invitrogen; Thermo Fisher Scientific, Inc.) with components listed in Table 
2.3. 
 
1-10 μl of the total protein extract (with dH2O to 10 μl), 50 μl of 1 x cleavage buffer, and 17 μl of 
ONPG (4 mg/ml in distilled water) were combined in a clear, flat-bottomed 96-well microtitre plate 
and incubated at 37 °C for 30-45 minutes. 125 μl of stop buffer was then added to stop the reaction, 
the A405 read with a spectrophotometer, and specific activity of the lysate calculated as below:  
Specific activity = nmoles of ONPG hydrolyzed/t/mg protein  
 
nmoles of ONPG hydrolyzed = (A405) (2.02 x 105 nanoliters) 
            (4500 nl/nmoles-cm)(1 cm) 2.7.4.3.2 Alkaline phosphatase 
Activity of alkaline phosphatase from cells expressing phoA-containing reporter constructs was 
quantified using a colorimetric alkaline phosphatase assay.  
 
1 μl of the total protein extract was added to 200 μl pNPP liquid substrate (N7653; Sigma-Aldrich; 
Merck Millipore) in a clear, flat-bottomed 96-well microtitre plate and incubated in the dark at room 
temperature for 30 minutes. 50 μl of 3 M NaOH was then added to stop the reaction, the A405 read, 
and specific activity of the lysate calculated as below: 
Specific activity = nmoles of pNPP dephosphorylated/t/mg protein  
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nmoles of pNPP dephosphorylated = (A405) (2.51 x 105 nanoliters) 
                       (18000 nl/nmoles-cm)(1 cm) 
 
2.8 In vivo virulence analysis  
2.8.1 Murine Model of gastrointestinal tract colonization by P. aeruginosa 
All procedures involving animals were performed in accordance with the Animals Scientific 
Procedures Act 1986 and were approved by the Ethical Review Committee at Imperial College 
London. CD1 mice (18 – 22 g females) were purchased from Harlan UK Ltd. (Bicester, UK) or Charles 
River Laboratories (Harlow, UK) and allowed to acclimatise at the Central Biological Services (CBS) 
unit at South Kensington for at least 7 days prior to the commencement of infection studies. Mice 
were housed under specific-pathogen-free conditions in groups of 5, in sterilized, filter-topped 
cages, with unlimited access to autoclaved water and alfalfa-free food. Mice were fed sterile water 
containing 2 mg/ml streptomycin (S6501; Sigma-Aldrich; Merck Millipore) and 1500 U/ml penicillin G 
(PENNA; Sigma-Aldrich; Merck Millipore) for 4 days to deplete indigenous GI flora (confirmed by 
bacterial stool cultures). Mice were next fed sterile water with 1500 U/ml penicillin G (PENNA; 
Sigma-Aldrich; Merck Millipore) and P. aeruginosa strains (approximately 107 cfu/ml) for up to 6 
days (with water containing P. aeruginosa changed after 2 to 3 days to maintain bacterial levels). The 
drinking water was then replaced with sterile water containing either 1500 U/ml penicillin G 
(PENNA; Sigma-Aldrich; Merck Millipore) or the appropriate concentration of imipenem (Primaxin, 
Merck Millipore) for the remainder of the experiment.  
 
Bacterial levels were assessed by bacterial stool cultures, with stool samples collected from 
individual mice, weighed, resuspended and homogenised in PBS (1 ml per 0.1 g stool), and plated on 
selective agar to quantify bacterial levels.  
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2.8.2 In vivo 2D bioluminescent optical imaging of P. aeruginosa- gastrointestinally colonised 
mice 
Whole-animal bioluminescent imaging (BLI) was measured on day 4 post-infection using an IVIS 
Spectrum optical imaging system (PerkinElmer, MA). Mice were anaesthetized with isofluorane and 
each animal’s abdominal region was depilated using Veet depilating cream prior to BLI. BLI was 
performed by Dr. James Collins (Frankel lab). Regions of interest were identified and quantified 
(photons s−1 cm−2 sr−1; sr  =  Steradian) using Living Image 4.2 software (PerkinElmer, Inc., Waltham, 
MA, USA). 
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3 Identification and characterisation of a clinically-relevant model integron 
3.1 Introduction 
In the 27 years since the discovery of integrons [130], reports in the literature have been generally 
limited to descriptions of interesting new classes of integrons/cassettes and investigations of the 
mechanisms of integrase action and regulation. The limited availability of epidemiological data has 
made it difficult to gain an overview of the prevailing integron population and to understand the 
extent of integron involvement in the spread of last-line antibiotic resistance. However, the 
establishment, in 2009, of the INTEGRALL database has been of significant benefit to the community 
of researchers studying integrons by providing a dedicated repository for new integron data [178]. 
The database (available at http://integrall.bio.ua.pt/) compiles published and unpublished 
information (including sequence data where possible) on the phylogeny of bacteria which harbour 
integrons, the types of encoded integrase enzymes (contained within both mobile and chromosomal 
integrons), and the molecular diversity of integron-borne genes. The data provide an opportunity to 
gain a greater understanding of the role of integrons in genome evolution, the nature of integron-
borne genes persisting in the clinical and environmental niches, and the potential for interplay 
between these settings. A wide range of integron types are described in the database and are 
classified according to the sequence of their integrase (Chapter 1.2.2). Chromosomal integrons 
harbour very large arrays of cassettes encoding tens of hundreds of genes, mostly of unknown 
function, while mobile integrons (of interest in this project) belong to classes 1-3 and contain shorter 
cassette arrays, usually of fewer than 10 genes, encoding both antibiotic resistance genes and other 
genes for which functions have not yet been assigned (named either ‘orf’ or ‘gcu’). 
 
This study aimed to examine the regulation of mobile integron functionalities associated with 
carbapenem resistance in bacterial species of clinical relevance. Acquired resistance to carbapenems 
is governed largely by Ambler class B metallo-β-lactamases (MBLs). Two of the three most common 
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MBL variants involved in the international dissemination of carbapenem resistant pathogens are the 
VIM- and IMP-type carbapenemases, which are exclusively encountered within integrons [97]. 
Integrons provide an ideal vehicle for dissemination of such genes, and appear to also provide the 
conditions for frequent generation of new variants within certain bacterial species including P. 
aeruginosa and Acinetobacter species, although the mechanisms by which they are generated are as 
yet unknown [118]. 
 
At the time of commencing this PhD all previous studies of mobile integron regulation had been 
performed in non-pathogenic E. coli, with no investigations having been conducted in the organisms 
where carbapenem-resistance presents the greatest cause for concern, in particular the commonly 
antibiotic-resistant ESKAPE pathogens (E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. 
aeruginosa and Enterobacter spp) [46]. 
3.2 Objectives 
The research described in this chapter was undertaken to source the reagents and molecular tools 
required to study integron-associated carbapenem resistance in the clinically relevant bacterial 
pathogen P. aeruginosa.  
 
Objectives: 
• Interrogation of the INTEGRALL database to identify the class of integron most commonly 
associated with the spread of carbapenem resistance genes amongst bacterial species. 
• Identification of the bacterial pathogens of humans most commonly associated with 
integron-associated carbapenem resistance. 
• Identification and acquisition of a clinically-derived carbapenemase-expressing integron, and 
assessment of its utility for onward studies of integron functionality. 
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3.3 Results 
3.3.1 Analysis of integron structure, location and content through INTEGRALL database mining  
To assess the variety and frequency of integron-associated carbapenemase variants and the diversity 
of bacterial species that harbor them, the INTEGRALL database was interrogated. At the outset of 
the project, the database contained data on 1512 distinct integrase-encoding genes, occurring in 290 
distinct bacterial species and amongst 133 genera. Of the 7366 records in the database, 2415 
records documented mobile integrons based on integrase gene sequences, whereby 2285 integrons 
were classified as class 1 integrons, 119 as class 2, and 11 as class 3. The remainder of the classified 
integrons were chromosomally located (n = 51), and (other than two trimethoprim resistance 
cassettes) were reported as containing uncharacterised gene cassettes. The remaining integrons 
were unclassified, and were therefore excluded from analysis. 
 
Of 604 integrons documented as containing β-lactamase cassettes (including some containing 
multiple β-lactamase cassettes), 565 were identified as Class 1 integrons, 6 as class 2/3 mobile 
integrons and the remaining 33 were unclassified integrons. The carbapenem resistance-conferring 
class B metallo-β-lactamases (MBLs) were the most frequently encountered class of β-lactamase, 
accounting for 326 (47 %) of the 688 β-lactamase cassettes (Table 3.1). While carbapenemase-
containing integrons were found in a range of species, they were disproportionately prevalent in P. 
aeruginosa: 255 (37 %) of the β-lactamase cassettes reported in the database were isolated from P. 
aeruginosa isolates, with 188 of these encoding MBLs (Figure 3.1).  
 
The diversity of MBL variants was then examined in further detail. A comparative analysis of MBL 
cassettes present in the ESKAPE pathogens A. baumannii, Enterobacter spp., K. pneumoniae and P. 
aeruginosa revealed that the numerous variants of each gene are reported at varying frequencies 
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amongst the four species (Figure 3.1). No integrons containing β-lactamase cassettes were found in 
the two remaining Gram-positive ESKAPE pathogens, S. aureus and E. faecium.  
Table 3.1 Prevalence of β-lactamase variants documented in the INTEGRALL database, and Ambler classification. 
Carbapenem-hydrolysing variants in bold, italicised text. The number of cassettes is greater than the number of records (n 
= 604), as some integrons contain more than one β-lactamase cassette. aAlthough some OXA enzymes hydrolyse 
carbapenems, ‘OXA’ carbapenemases tend not to be integron associated. 
Ambler Class A Ambler Class B (metallo-β-lactamases) Ambler Class C Ambler Class D 
Variant 
Number 
of 
cassettes 
Variant 
Number 
of 
cassettes 
Variant 
Number 
of 
cassettes 
Variant 
Number 
of 
cassettes 
BEL 2 DIM 1 AmpC 1 NPS 1 
CARB 7 GIM 6 CMY 3 OXAa 200 
CTX 30 IMP 111 DHA 1 Total 201 
GES 35 SIM 4 Total 5   
PER 3 TMB 1       
PSE/P1/P2 55 VIM 203     
SHV 1 Total 326     
TEM 7        
TLA 1       
VEB 15 
  
    
Total 156 
  
    
 
BlaVIM enzymes, a family of MBL carbapenemases first reported in a P. aeruginosa isolate from Italy 
in 1999 [122], are the most frequently documented integron-associated carbapenemases amongst 
the four nosocomial pathogens investigated, being identified in 195 (32 %) of the 604 β-lactamase-
containing integrons in the database (Figure 3.1). 66 % of the 195 blaVIM cassettes identified in the 
INTEGRALL database were reported in P. aeruginosa isolates, further highlighting the significance of 
this particular species in integron associated β-lactamase distribution (Figure 3.1 A). Despite the 
varied prevalence of specific MBL variants by species, blaVIM-1 and -2 are particularly common 
across all the species of interest (Figure 3.1 A). 
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Figure 3.1 Frequency and species distribution of MBL-containing integrons reported in the INTEGRALL database 
(http://integrall.bio.ua.pt/) in P. aeruginosa, E. coli, K. pneumoniae and A. baumannii. Distribution of blaVIM cassette 
variants (A), blaIMP cassette variants (B) and other MBLs (C) in the four ESKAPE pathogens in which they have been 
recorded as occurring in INTEGRALL. 
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On the basis of this analysis, P. aeruginosa was found to be the human pathogen in which integron-
associated carbapenem resistance is most commonly identified and this species was therefore 
selected as the subject of further study. Carbapenem resistance conferred by blaVIM-type 
carbapenemases within class 1 integrons was found to be the most frequently identified integron 
variant across species within the integron population, as characterised in the INTEGRALL database, 
and more specifically in P. aeruginosa. 
 
Since much of the previous work on integron regulation has been performed in E. coli, an 
investigation conducted in a distantly related pathogen in which nosocomial carbapenem resistance 
poses a major threat to human health is a timely objective. Moreover, P. aeruginosa is a highly 
genetically versatile and notoriously multidrug resistant pathogen, and its study may provide further 
insight into the pathways leading to generation of new carbapenamases, as well as promoting a 
better understanding of the regulatory mechanisms operative in distantly related bacterial species 
that allow conserved genetic elements such as integrons to be active across species boundaries.  
3.3.2 Identification of pKOX105 as a nosocomially relevant integron reservoir for the study of 
mobile integron regulation 
Having identified P. aeruginosa as the species of choice for investigation, and blaVIM as the 
carbapenemase cassette of choice, the integron literature was interrogated for a functional, well-
defined and clinically relevant integron for onward studies. The requirements to be satisfied by this 
search were the identification of a well-characterised, sequenced, clinically relevant integron which 
could be sourced from a collaborator. Due to the highly conserved nature and promiscuity of 
clinically relevant integrons, it was not considered necessary to limit this search to examples found 
in P. aeruginosa isolates.  
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This search identified plasmid pKOX105 [300], which was isolated from a Klebsiella oxytoca gut 
clinical isolate, and harbours two apparently functional integrons (based on sequence integrity), 
here designated ‘A’ and ‘B’, one of which contains a VIM-type carbapenemase cassette (Figure 
3.2A).This plasmid was kindly provided by Neil Woodford for inclusion in this project. Scrutiny of the 
sequence data deposited in NCBI for this plasmid revealed characteristic features of integron 
architecture for both integrons, A and B, including integrase encoding genes, integrase (Pint) and 
cassette (Pc) promoters, attI and attC recombination sites, and various genes positioned 
downstream of the cassette promoters (Figure 3.2B). Comparative analysis of the nucleotide 
sequences of integrons A and B, reveals almost complete identity of the intI1 gene-encoding 
sequences up to the attI site, with the exception of two single nucleotide polymorphisms in Pc 
occurring in the -10 site and spacer regions (Figure 3.2C). Comparison with the Tn21 integron utilised 
in the regulation studies performed by Cagle et al. (Chapter 1.2.2 and 1.2.4) revealed identical 
polymorphisms in Pc, plus a 3 base pair insertion alongside Pint which results in the corruption of the 
conserved integron SOS box [207]. 
 
According to previously characterised Pc designations (Chapter 1.2.2), integron A contains the PcH1 
promoter variant (hybrid containing the ‘weak’ -35 sequence with the ‘strong’ -10 sequence) [182], 
while integron B contains PcWTGN-10 (‘weak’ Pc variant combined with expression-enhancing TGN 
extended -10 motif) [180, 301]. Expression from Pc is therefore likely to be higher (potentially 3-4 
times) in integron B compared with integron A. PcH1 (26.2 %) and PcWTGN-10 (16.8 %) are the first and 
third most commonly identified Pc variants respectively [180], and therefore can reasonably be 
considered representative of the wider clinical integron population for the purposes of this study. 
 
While the PcH1 promoter variant encodes the most common integrase variant, IntI1R32_H39, the TGN 
extended -10 motif in the spacer region of PcWTGN-10 results in a R32P substitution in the integron B 
integrase (IntI1P32_H39) [180]. The IntI1R32_H39 variant in integron A is the variant found in 
  78 
approximately 50 % of isolated integrons [180], while the IntI1P32_H39 variant in integron B is the third 
most common, being present in 17 % of integrons [180]. An inverse correlation between Pc potency 
and integrase activity has previously been noted [180], with the IntI1R32_H39 displaying greater 
integrase activity than IntI1P32_H39 in terms of both cassette excision (approximately 300 times 
higher) and integration (approximately 5 times higher) [180]. However, since the cause of this 
variation is to be found in the integrase coding sequence rather than through altered promoter 
regulation, we would not expect to see evidence of this in transcriptional reporter assays.   
 
The multiple overlapping regulator binding sites that were identified by Cagle et al. [207] for the four 
nucleoid-associated proteins LexA, HIS, FIS and HNS were mapped to the regulatory region from 
integron B, as this is the pKOX105 integron which contains a blaVIM-1 carbapenemase cassette. Due 
to the high degree of sequence homology between the pKOX105 clinical integrons and the non-
clinical In2 integron from Tn21 utilised by Cagle et al., (Figure 3.2C) all of the sites identified in their 
SOS-competent construct (Pi214: In2 with a 3 bp deletion which reinstates the SOS box, as is present 
in the majority of clinical integrons) were identified as expected (Figure 3.3). The sites identified in 
the vicinity of the cassette promoter in the Cagle et al. Pi217c construct [207] were also identified in 
the pKOX105 integrons, however the integrity of FIS sites F10, F13 and F15 may be affected by the 
single nucleotide polymorphism in the cassette promoter spacer (Figure 3.3, yellow boxed 
nucleotide). 
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Figure 3.2 Overview of pKOX105 integrons. A: Plasmid map of pKOX105, adapted from Carattoli et al. pKOX105 contains 
two integrons (boxed) of which Integron B contains the carbapenemase gene blaVIM-1. B: Schematic diagrams of the two 
integrons contained within the clinically-isolated plasmid pKOX105. Both integrons contain an intact 5’ conserved region, 
consisting of an integrase gene, intI1 (grey arrow); dedicated integrase promoter, Pint; a cassette promoter located within 
the coding region of intI1 (Pc) convergently with Pint; and an attI recombination site (green triangle). The variable region 
contains an array of promoterless gene cassettes (blue arrows) flanked by attC recombination sites (red/pink triangles).C: 
Alignment of the integrase coding sequence and regulatory region from the two pKOX105 integrons and Tn21 (source of 
Summers integron). Identical sequence in black, with mismatches in red. The only differences are two single nucleotide 
polymorphisms, located within the cassette promoter at positions 920 and 925, and a 3 base insertion in the Tn21 integron 
which mutates the Pint SOS box. 
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Figure 3.3 Regulatory region in pKOX105 carbapenemase-containing integron (integron B). Blue highlighted sequences are the 5’ terminii of the divergently orientated intI1 and blaVIM-1 
genes respectively. Promoters Pc (PcWTGN-10 variant) and Pint and their internal -35 and -10 sites are indicated by white arrows. Predicted regulatory binding sites for FIS (olive), H-NS (blue), IHF 
(red) and LexA (purple) are numbered as Cagle et al. 2011 [207]. Yellow boxed nucleotide indicates single nucleotide polymorphism between In2 and pKOX105 integron B, which may affect 
the integrity of FIS sites F10, F13 and F15 in the cassette promoter spacer. 
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3.3.3 pKOX105 integron B is active in conferring carbapenem resistance 
To study the impact of integron B in the absence of other, possibly confounding, pKOX105-encoded 
activities, integron B and the associated blaVIM-1 cassette and attC site were cloned into the 
Pseudomonas-compatible vector pMP220 to create plasmid pEVM2a (Appendix 2.3).  
 
pMP220 is a wide host-range promoter-probe plasmid with a lacZ gene lacking its native promoter, 
derived from pTJ575 in Rhizobium leguminosarum  [302], and is routinely used in studies of P. 
aeruginosa promoter activity [303, 304]. In order to devise a cloning strategy to create pEVM2a 
which could utilise either a homologous recombination approach or traditional restriction cloning, 
the nucleotide sequence of the multiple cloning region in pMP220 was required. A sequence of 
pMP220 was assembled from cited literary sources using the sequences of pCM51 [305], another 
derivative of pTJ575, and E. coli K12 lacZ. Double and single restriction digests of pMP220 were 
performed using BglII and PstI (Figure 3.4A), confirming the presence of co-located unique enzyme 
sites by linearisation of the 10.5 kb plasmid. The intergenic regions surrounding lacZ were then 
sequenced using outward facing primers designed within oriV, lacZ and tetR (Figure 3.4B, green 
lines, and Appendix 3.1).  
 
A homologous recombination approach was then adopted to create pEVM2a, combining pKOX105 
integron B and blaVIM-1 cassette with a Pseudomonas-compatible backbone. pMP220 was digested 
with SphI and NheI to remove the lacZ reporter gene, and amplified to add integron-homologous 
flanks, using primers “pICEX vec A” and “pICEX vec B” (Figure 3.5a and Appendix 2.2). pKOX105 
integron B and its associated blaVIM-1 cassette and flanking attC site were amplified from pKOX105 
using primers “pICEX 1a” and “pICEX 5c” to add pMP220-homologous flanks (Figure 3.5b and 
Appendix 2.2), before assembly of the insert and vector via GeneArt seamless cloning to form 
pEVM2a (Figure 3.5c). The sequence fidelity of the regulatory region and the attC recombination site 
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was confirmed by sequencing with primers “blaVIM circle A” and “blaVIM circle B” (Figure 3.5 and 
Appendix 3.2).  
 
A 
 
 
B 
 
Figure 3.4 Characterisation of pMP220. A: pMP220 plasmid DNA was digested for 1 hour at 37 °C with BglII and PstI, both 
doubly and singly. Digests were then visualised alongside uncut plasmid. B: Map of plasmid pMP220: oriV, origin of 
replication; lacZ, β-galactosidase; tetR, tet operon repressor gene; tetA, tetracycline resistance gene; trfA, replication 
initiation gene; traJ, transfer regulator gene; oriT, origin of conjugal transfer. Sequencing primer binding sites are indicated 
by green lines and restriction endonuclease recognition sites identified through sequencing are indicated. 
 
10 kb10 kb
PstIUncut BglIIBglII/PstI
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Figure 3.5 Construction of carbapenemase-containing integron plasmid pEVM2a. The Pseudomonas-compatible vector 
pMP220 was digested with SphI and NheI to remove the MCS and lacZ reporter gene, and amplified to add integron-
homologous flanks (a). pKOX105 integron B and its associated blaVIM-1 cassette and flanking attC site were amplified from 
pKOX105 to add pMP220-homologous flanks (b), then the insert and vector assembled using GeneArt seamless cloning to 
form pEVM2a (c). Map of plasmid pEVM2a: oriV, origin of replication; intI1, integrase; Pc, cassette promoter; Pint, integrase 
promoter; attI, cassette insertion site; blaVIM-1, carbapenem resistance gene; attC, cassette recombination site; tetR, tet 
operon repressor gene; tetA, tetracycline resistance gene; trfA, replication initiation gene; traJ, transfer regulator gene; 
oriT, origin of conjugal transfer. 
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In order to address the functional relevance of pKOX105 integron B, its ability to confer imipenem 
resistance in P. aeruginosa and E. coli was assessed using plasmid pEVM2a. pEVM2a was introduced 
to E. coli DH5α and P. aeruginosa PA14, through transformation or conjugation respectively, and 
growth (OD600) measurements performed in 96-well microtitre plates in a POLARstar Omega 
multiwell plate reader (BMG Labtech). Seed cultures of each strain were diluted 1 : 10 in a final 
volume of 200 µl of fresh LB medium containing 30 µg tetracycline ml−1 and doubling dilutions of 
imipenem (concentration range from 0.03125 – 2048 µg imipenem ml−1) and incubated in the plate 
reader at 37 °C, shaking at 500 rpm, for 18.5 hours. Growth curves were performed in biological 
duplicate. 
 
MIC breakpoints of 2048 µg/ml and 1024 µg/ml were determined for E. coli DH5α and P. aeruginosa 
PA14 respectively in the presence of pEVM2a, compared to 0.5 µg/ml and 2 µg/ml respectively 
without the plasmid (Figure 3.6). As the EUCAST MIC clinical breakpoints for resistance in both 
species are 8 µg/ml [306], the level of resistance conferred by blaVIM-1 in pEVM2a can therefore be 
considered highly significant.  
 
3.4 Discussion 
The main objective of this chapter was to compile a toolkit with which to dissect the regulation of 
integron-mediated carbapenamase activity. Interrogation of the INTEGRALL database revealed that, 
based upon the relative prevalence of integrons and species within the database, the integron of 
interest would belong to the class most frequently reported in the database, namely a class 1 
integron. Similarly, since blaVIM-1/2 cassettes were the most prevalent reported cause of 
carbapenem resistance (Figure 3.1), this should be the cassette type chosen, and that P. aeruginosa, 
as the most common source of such genes, would be the most appropriate host in which to study  
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Figure 3.6 Confirmation of functionality of pKOX105 integron B through expression of blaVIM-1 cassette via Pc. Growth 
curves of E. coli DH5α (A), E. coli DH5α with pEVM2a (B), P. aeruginosa PA14 (C), and P. aeruginosa PA14 with pEVM2a (D) 
in LB broth with and without imipenem. The solid black lines represent strains grown in LB without imipenem, the solid red 
line represents the MIC of each strain, while the dotted red line represents half the MIC concentration to demonstrate that 
growth is observed. The solid blue lines in (B) and (D) represent the EUCAST clinical breakpoint concentration of imipenem, 
where normal growth is observed.   
 
their regulation. pKOX105, a plasmid identified in K. oxytoca, and having been well characterised 
with respect to its nucleotide sequence and the antibacterial resistance genes it encodes, was 
identified and sourced as an example of a plasmid harbouring multiple integrons with these 
properties, and was found, through characterisation of the nucleotide sequence and the significant 
resistance phenotype conferred by the blaVIM-expressing integron, to likely be highly representative 
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of the clinical integron population. Taken together these data support the view that pKOX105 would 
provide an appropriate tool for the functional study of mobile integrons of clinical concern.  
 
Pathogens are heavily represented in the INTEGRALL database, most likely due to active bacterial 
infections representing the conditions under which resistance to antibiotics is most likely to be 
observed, and the underlying mechanism of such resistance to be investigated. This apparent bias 
within the database is also observed for class 1 integrons, which appear to be the dominant class 
being recovered and characterised. The fact that class 1 integrons are the most common source of 
clinically relevant antimicrobial resistance genes amongst the reported integron population might 
not necessarily mean that amongst all extant integrons they are the most prevalent. Nonetheless, a 
clear bias amongst available reports on nosocomial bacteria supports our choices as being the most 
relevant for the purposes of this study. P. aeruginosa accounts for 37 % (n = 255) of the β-lactamase 
cassettes in the database (n = 688), and 58 % (n = 188) of the MBL cassettes (n = 326) identified in 
this organism. P. aeruginosa is also the species in which many of the most clinically significant 
cassette variants, including the VIM-1 and VIM-2 type β-lactamases, were originally identified, and it 
is not clear whether this abundance is due to intraspecies proliferation prior to inter-species 
dissemination, or whether P. aeruginosa itself provides a particularly favourable habitat for 
sustenance of the genes.  
 
It is also significant that species that are primarily environmental organisms and act as opportunistic 
pathogens, rather than dedicated primary pathogens, are so heavily represented, for example P. 
aeruginosa and Acinetobacter species. This could be due to the high number of regulators in these 
bacteria [230] and their ability to adapt to stresses, which often results in a high mutation rate [307, 
308]. We therefore hypothesise that environmental species are key to accidentally generating 
variability amongst antibacterial resistance genes, which are subsequently selected for in the host 
and persist during infection. It would be interesting to examine whether the antibiotic-mediated 
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treatment of human/animal infections is the main driving force for the maintenance and persistence 
of antibiotic resistance genes in integrons, or whether there is any selection in the environment that 
contributes to survivability in animal hosts. While inappropriate antibiotic use is known to promote 
resistance in the nosocomial population, pollution from manufacturing facilities, poor water quality, 
and inadequate sanitation significantly exacerbates the problem [309-311]. The extent of the 
relative contributions from these and other sources of selective pressure is an important issue for 
future research. 
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4 Construction of P. aeruginosa integron reporter isolates, and 
optimisation of low- and high throughput assays of integron promoter 
activities. 
4.1 Introduction 
As with all routes of horizontal gene transfer, integrons play an important role in bacterial evolution 
under stress [131, 133, 158, 206]. Although the ability to incorporate and express exogenous genetic 
material may provide significant fitness benefits, plasticity of integron structure and content also has 
significant potential to be detrimental, for example, through loss of useful resistance functions or 
imposition of excessive biological burden. The capacity to limit such events would presumably be 
desirable, if not essential. We have therefore hypothesised that bacteria must possess mechanisms 
to regulate integron structure and activity. Mechanistic possibilities for exerting regulatory 
modulation of integron plasticity might lie with alteration of transcriptional activity of the integrase 
(Pint), or cassette (Pc), promoters, or the efficiency of cassette integration and excision. The 
embedding of Pc within the coding region of intI1 is known to exert a duplicitous influence upon 
integron activities, since single nucleotide changes affecting the potency of cassette promoter (Pc) 
activity also have a direct and measurable effect on the efficiency of the expressed integrase via 
polymorphisms; ‘weaker’ cassette promoter variants (in terms of levels of cassette expression) result 
in higher integrase excision activity, thereby increasing the likelihood of cassette excision [180]. 
Increased frequency of cassette excision is likely to result in increased frequency of cassette 
rearrangement, ensuring that the most valuable cassette is likely to have the highest expression 
within the array through its position in the front of the array. 
 
In E. coli, integrase expression has been shown to be subject to regulation by a number of global 
regulators including (but not limited to) LexA, the major repressor involved in the cellular SOS 
response to DNA damage [131, 132], FIS (Factor for Inversion Stimulation), IHF (Integration Host 
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Factor) and H-NS (Histone-like Nucleoid Structuring protein) [207] all of which are transcriptional 
regulators of distinct metabolic pathways and stress responses. In addition, CRP-dependent carbon 
catabolite control of the Vibrio cholerae chromosomal integron integrase intIA has also been 
demonstrated [133].  
 
It has also been established that introduction of foreign DNA via conjugative plasmid transfer (direct 
transfer of circular plasmids via cell-to-cell contact) and transformation (uptake of extracellular DNA 
from environment) in E. coli and V. cholerae results in upregulation of integron integrase 
transcription and protein expression via the induction of the SOS-induced alleviation of LexA-
mediated Pint repression, leading to a higher rate of integrase-dependent recombination in both 
artificial and natural systems [132]. 
 
To date, the notion of co-ordinated regulation of Pint and Pc has been largely overlooked, particularly 
in the context of clinical isolates, with all of the work performed by the Mazel group considering the 
integrase promoter in isolation in (non-pathogenic) E. coli and V. cholerae [131-133, 206]. A single 
study examining the expression of genes regulated by the converging integron promoters, Pint and Pc 
has been undertaken which used dual transcriptional reporters of the prototypical integron In2 in E. 
coli, using the narrow host-range vector pCB267 [207]. By fusing a lacZ reporter to a Pint promoter, 
and a phoA reporter to a convergent Pc promoter, Cagle et al. derived significant insights into the 
complex hierarchical governance of integron promoter activities under standard laboratory 
conditions [207]. However, Pint and Pc activities were examined in isolation and no attempt to assess 
simultaneously the activities of both Pint and Pc activities was made. Furthermore, due to the 
absence of LexA-mediated regulation of In2, it can be considered an atypical integron amongst those 
recently dominating the nosocomial environment [176, 180]. Additionally, at the time of 
commencing this PhD all previous studies of mobile integron regulation had been performed in non-
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pathogenic E. coli, with no investigations having been conducted in pathogenic bacteria where 
carbapenem resistance presents the greatest cause for concern.  
 
We hypothesised that, given the opposing physiological roles of integrase and cassette expression 
(i.e. stable maintenance of antibiotic resistance cassettes versus plasticity of integron architecture 
through mobilisation of these same cassettes), mutually exclusive expression from the two 
promoters would have physiological relevance.  
4.2 Objectives 
The work described in this chapter was intended to construct the tools required to simultaneously 
measure Pint and Pc activities. In order to achieve this, the pKOX105 clinical integron was manipulated 
to a) express Pint and Pc reporter fusions and b) to examine, via assessment of reporter activity, the 
potency of promoter activities in the pathogenic bacterium P. aeruginosa. Assays were established 
for low and high throughput analyses of reporter activity. 
Objectives:  
• Construction of a dual reporter of pKOX105 integron Pint and Pc promoter activities. 
• Establishment of assay conditions for low-throughput assessment of Pint and Pc activity in E. 
coli. 
• Manipulation of reporter construct for maintenance in P. aeruginosa. 
• Establishment of assay conditions for high-throughput assessment of Pint and Pc activity in P. 
aeruginosa. 
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4.3 Results 
4.3.1 Construction of a dual reporter of pKOX105 integron promoter activities in pCB267 for use 
in E. coli 
In order to examine the activity of the two clinical integron promoter regions from pKOX105, their 
promoter regions (Fig 3.2B) were fused to divergent lacZ and phoA reporter genes in the narrow 
host range vector pCB267 [208], in a manner identical to that described by Cagle et al. [4].  
 
To verify the DNA sequences at the 5’ ends of the lacZ and phoA reporter genes of the Cagle 
“Pi217c” plasmid (hereafter referred to as “pCB267-intSOSminus”) and the intergenic promoter 
region between them, sequencing was performed using oligonucleotide primers identical to 
“IP212L” and “IP212U” described by Cagle et al [207] (Figure 4.1 and Appendix 4.1).  
 
 
Figure 4.1. Schematic diagram of pCB267-intSOSminus and regions sequenced in this study. Sequencing primer binding 
sites in green, with the regions confirmed by sequencing indicated by grey bars. adrA’, truncated diguanylate cyclase (from 
E. coli phoA operon); ampR, ampicillin resistance gene; PampR, ampR promoter; lacZ, β-galactosidase (from E. coli); phoA, 
alkaline phosphatase (from E. coli phoA operon); psiF, phosphate starvation-induced protein (from E. coli phoA operon). 
 
Plasmid pCB267-intSOSminus was digested with BamHI and HindIII to excise the 206 bp In2 
promoter region (Figure 4.1, white box), and the remaining 6308 bp vector portion, containing the 
lacZ and phoA reporters, was gel purified (Figure 4.2a). Cloning primers (GA Pi214c A and GA Pi214c 
B, Appendix 2.2) were designed to amplify the promoter regions from pKOX105 and to 
simultaneously add pCB267-homologous flanks (Figure 4.2b). The promoters were gel purified and  
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Figure 4.2 Construction of dual transcriptional reporters of pKOX105 clinical integrons, pCB267-intA and pCB267-intB. 
The integron promoter region from pCB267-intSOSminus was removed from pCB267-intSOSminus by digestion with HindIII 
and BamHI and the pCB267 backbone amplified to add flanks homologous to the pKOX105 integrons (a). The equivalent 
promoter regions with integron promoters were amplified from both pKOX105 integrons, with pCB267-homologous flanks 
added (b). The vector and inserts were then assembled using GeneArt seamless cloning to form pCB267-intA and pCB267-
intB (c), placing the clinical integron promoters Pc and Pint in control of divergent transcriptional reporters phoA (orange) 
and lacZ (yellow) respectively. Primer binding sites shown in green, and homologous overhangs and recombination sites 
shown in orange. Map of plasmid pCB267-intA/B: lacZ, β-galactosidase; intI1’, 5’ integrase containing Pc; phoA, alkaline 
phosphatase; ampR, ampicillin resistance gene and promoter. 
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GeneArt Seamless cloning was used to fuse the vector and promoter inserts through homologous 
recombination, thereby creating plasmids pCB267-intA and pCB267-intB, which were transformed 
into E. coli DH5α (Figure 4.2c). As promoters A and B are almost indistinguishable at the nucleotide 
level, both were simultaneously amplified during the same PCR reaction and the GeneArt reaction 
contained a mixture of both promoter fragments. Nine colonies which were PCR-positive for the 
promoter insert were sequenced using primers IP212L/IP212U, yielding 6 clones confirmed as 
pCB267-intA and 3 clones as pCB267-intB. One clone of each type was selected for further study 
(Figure 4.3 and Appendices 4.2 and 4.3). 
 
 
Figure 4.3 Schematic diagram of pCB267-intA and pCB267-intB regions sequenced. Sequencing primer binding sites in 
green, with the regions covered by sequencing reactions indicated by grey bars. adrA’, truncated diguanylate cyclase (from 
E. coli phoA operon); ampR, ampicillin resistance gene; PampR, ampR promoter; lacZ, β-galactosidase (from E. coli); phoA, 
alkaline phosphatase (from E. coli phoA operon); psiF, phosphate starvation-induced protein (from E. coli phoA operon). 
 
4.3.2 Establishment of reporter assays for low-throughput assessment of integron activities in E. 
coli  
To ensure utility of the cloned constructs, and optimise assay conditions prior to expression in P. 
aeruginosa β-gal and AP assays were established in a low-throughput format using E. coli clones 
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expressing the narrow host-range constructs pCB267-intA and pCB267-intB. Two clones expressing 
control plasmids, both of which were supplied by the Summers group, were also included: pCB267-
intSOSminus (equivalent to Cagle et al. plasmid “Pi217c” [207]), containing a 3 bp insertion which 
eliminates the SOS box (Figure 4.4B); and pCB267-Pint, (equivalent to Cagle et al. plasmid “Pi” [207]) 
containing the minimal integrase promoter, with no other regulatory features (Figure 4.4, and 
Appendix 4.4). Previous studies [207] had shown that the SOS-minus construct, pCB267-
intSOSminus, displayed significantly higher Pint activity than a construct with an intact SOS box (but 
no Pc), while the pCB267-Pint construct, containing no converging cassette promoter or SOS box, 
resulted in Pint activity levels 6 times higher than in pCB267-intSOSminus. However, no construct 
containing both an intact SOS box and Pc has previously been evaluated in this manner, to the best 
of our knowledge. 
 
E. coli DH5α cells were cultured in a volume of 15 ml in 100 ml Erlenmeyer flasks to late exponential 
phase (6 hours), after which cells were pelleted and total protein was harvested by resuspension in 
500 µl lysis buffer (0.25 M Tris, pH 8.0) and freeze-thawing on dry ice, followed by quantification of 
protein concentration by BCA assay. β-galactosidase and alkaline phosphatase activities were then 
quantified to derive a measure of expression from Pint and Pc respectively. β-galactosidase (LacZ) 
activity was quantified using standard ortho-Nitrophenyl-β-galactoside (ONPG)- based colorimetric 
assays, while alkaline phosphatase (PhoA) activity was quantified using standard colorimetric para-
Nitrophenylphosphate (pNPP) assays. All assays were performed in biological triplicate, and in each 
instance with technical duplicate assays performed on each protein extract. 
 
The first important observation was that β-galactosidase and alkaline phosphatase activities were 
reproducibly detectable in reporter-expressing constructs, absent in chemical negative control 
assays (i.e. no protein controls), and that alkaline phosphatase activities were absent in biological 
negative control assays (constructs lacking Pc), indicating that the assays were working.  
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Figure 4.4 Constructs used to establish functionality of pKOX105 clinical integron promoters. (A) Schematic diagrams of 
pCB267-intA and pCB267-intB containing the full, intact, regulatory regions from pKOX105 integrons A and B respectively 
(constructed in house), and control constructs pCB267-intSOSminus and pCB267-Pint (kindly provided by Anne Summers). 
(B) Alignment of promoter regions in pCB267-intA, pCB267-intB, pCB267-intSOSminus and pCB267-Pint and positioning of 
cloned regions in relation to transcriptional reporters lacZ (yellow box) and phoA (orange box). Integron promoter 
sequence (including 5’ intI1 in grey box) shown in upper case, with identical sequence in black and mismatches in red. The 
only differences are two single nucleotide polymorphisms, located within the cassette promoter, Pc, and a 3 base insertion 
in pCB267-intSOSminus which mutates the Pint SOS box (pink box). 
 
Unfortunately, no biological negative control construct for β-galactosidase assays (i.e. a construct 
lacking Pint) was obtainable. Relative to activity of a minimal Pint promoter, the activity of Pint was 
found to be lower in the clinical integrons when measured in context with Pc (Figure 4.5A, pCB267-
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intA/B). As evidenced by a doubling in Pint activity in the absence of a functional SOS box (Figure 
4.5A, comparison between pCB267-intA/B and pCB267-intSOSminus), a component of this negative 
regulatory effect is likely to be SOS-dependent, however this effect was not found to be statistically 
significant. These findings demonstrate that (i) pKOX105 Pint promoters have lower Pint activity than 
pCB267-Pint (Figure 4.5A, comparison between pCB267-intA/B and pCB267-Pint), which lacks a Pc and 
which is therefore concordant with the hypothesis of context-dependent activity, but does not prove 
it, (ii) β-galactosidase expression in pCB267-intSOSminus is 17 times lower than pCB267-Pint (Figure 
4.5A, comparison between pCB267-intSOSminus and pCB267-Pint), demonstrating that factors other 
than SOS limit Pint activity, and (iii) pCB267-intA/B is lower than pCB267-intSOSminus (Figure 4.5A, 
comparison between pCB267-intA/B and pCB267-intSOSminus), indicating that SOS activity is 
additive with other factors in repression of Pint.  
 
Figure 4.5 Activity of the integrase promoter, Pint, and cassette promoter, Pc, in the narrow-host range vector pCB267 in 
E. coli DH5α. Expression of Pint assayed by LacZ activity (A) and expression of Pc assayed by PhoA activity (B). x ̄is the sample 
mean. Activity of the promoters is reliably demonstrated, indicating that both promoters are active and that the context in 
which they are measured has functional significance. The data points represent the mean average of 3 independent 
cultures, with each assay performed in technical duplicate. x ̄ is the sample mean, and error bars represent the standard 
deviations of the mean. Values which are significantly different by one way ANOVA, followed by Tukey’s multiple 
comparison post hoc test, indicated by asterisks (* ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001).  
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Additionally, high levels of Pc activity were observed in the pKOX105 integrons (Figure 4.5B, pCB267-
intA/B), in which Pint has been found by previous investigators to be subject to repression from 
factors including (but not limited to) LexA [131, 207]. However, in the construct lacking integrity of 
the SOS box and/or additional Pint promoter sequences, pCB267-intSOSminus, a 4-5 fold decrease in 
Pc activity is observed (Figure 4.5B, pCB267-intSOSminus vs. pCB267-intB), possibly through 
alleviation of Pint repression. The pCB267-Pint plasmid, which is lacking the cassette promoter 
entirely, is effectively silenced for alkaline phosphatase activity (Figure 4.5B, pCB267-Pint). The 
integrity of the SOS box in Pint therefore has functional relevance to PhoA expression. 
 
In conclusion, these data, produced in non-stressed conditions, revealed mutually exclusive 
expression from Pint and Pc, with Pc being the default ‘active’ integron promoter until Pint repression 
(by factors including DNA damage) is lifted. This indicates that the spatial context of the two 
integron promoters has regulatory significance and further suggests that mutually exclusive 
expression of the integrase and cassette promoters serves a physiological purpose.  
4.3.3 Construction of a dual reporter of integron promoter activity for examination in P. 
aeruginosa  
In order to investigate integron promoter activities in P. aeruginosa, it was necessary to transfer the 
integron promoter regions and reporters from the narrow-host range pCB267-based constructs into 
a Pseudomonas-compatible vector. Vector pMP220 was chosen for this purpose as it is a wide host-
range plasmid which is routinely used for expressing transcriptional reporters in P. aeruginosa [302, 
312]. This tetracycline resistance-conferring plasmid encodes its own lacZ gene with 5’ multiple 
cloning region and 3’ NheI site. To allow us to utilise the previously validated lacZ reporter from 
pCB267-intA rather than the intrinsic pMP220 gene, pMP220 was digested with SphI and NheI and 
amplified with primers “GA pICP vec A” and “GA pICP vec B” to add flanks homologous to the 3’ ends 
of the pCB267-intA reporters (Figure 4.6 a). The promoter region and divergent reporters from  
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Figure 4.6 Construction of Pseudomonas-compatible dual reporter plasmid pMP220-intA. The Pseudomonas-compatible 
vector pMP220 was digested with SphI and NheI to remove the lacZ reporter gene, and amplified to add pCB267-intA-
homologous flanks (a). The lacZ gene, promoter region and phoA gene from pCB267-intA were amplified to add pMP220-
homologous flanks (b). The vector and inserts were then assembled using GeneArt seamless cloning to form pMP220-intA 
(c). Primer binding sites shown in green, and homologous overhangs and recombination sites shown in orange. Map of 
plasmid pMP220-intA: oriV, origin of replication; phoA,alkaline phosphatase; pKOX105 integron A regulatory region; lacZ, 
β-galactosidase; tetR, tet operon repressor gene; tetA, tetracycline resistance gene; trfA, replication initiation gene; traJ, 
transfer regulator gene; oriT, origin of conjugal transfer. 
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pCB267-intA were then amplified with primers “GA pICP C” and “GA pICP D”, adding pMP220-
homologous flanks (Figure 4.6 b). The gel purified insert and vector components were then 
recombined using GeneArt seamless cloning to create plasmid pMP220-intA (Figure 4.6 c – 
recombination points in orange), before transformation into E. coli DH5α. This approach, using the 
same primer pairs, was also used to generate pMP220-Pint from pCB267-Pint, providing us with a 
minimally-regulated Pint control construct for use in assays of activity in P. aeruginosa. Integrity of 
the integron promoter regions in these plasmids was confirmed by sequencing with primers as 
shown in Figure 4.7 (Appendices 4.5 and 4.6). 
 
 
Figure 4.7 Schematic diagram of pMP220-intA and pMP220-Pint regions sequenced. Sequencing primer binding sites in 
green, with the regions covered by sequencing reactions indicated by grey boxes. oriV, origin of replication; phoA, alkaline 
phosphatase; lacZ, β-galactosidase; tetR, tet operon repressor gene; tetA, tetracycline resistance gene; trfA, replication 
initiation gene; traJ, transfer regulator gene; oriT, origin of conjugal transfer. 
 
It was not possible to generate the equivalent constructs from pCB267-intB or pCB267-intSOSminus 
using this method. Five separate attempts were performed, during which pMP220-intA was 
reproducibly generated as a parallel control, confirming that the vector and insert preparations were 
satisfactory and that the enzymes were functional. An alternative strategy was then employed, 
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involving PciI digestion of the pMP220-intA construct (Figure 4.7) to cut within the lacZ and phoA 
reporters, allowing substitution of the equivalent regions which were similarly digested from 
pCB267-intB and pCB267-intSOSminus and ligated with T4 ligase. However, despite this method 
being predicted to yield an equal number of constructs with the insert ligated in each orientation, 
only colonies with the insert reversed were recovered. Site-directed mutagenesis was then 
attempted in order to directly mutate the appropriate bases in pMP220-intA. However, it did not 
prove possible to appropriately optimise the PCR reactions to produce the correct product, 
therefore it was decided to pursue the mutant library regulatory screen using the pMP220-intA 
construct. Although the regulatory region from pKOX105 integron B was our preferred choice for the 
screen, as this was the integron containing the blaVIM-1 carbapenemase cassette, integron A was 
also deemed to be sufficiently appropriate due to this being the most commonly isolated integron 
variant, with integron B the second most common [180]. 
4.3.4 Differential Pint activity and comparable Pc activity in E. coli and P. aeruginosa  
Since the majority of published experimentation on the integrase promoter activity has been 
performed in the model organism E. coli, few conclusions regarding the clinical relevance of such 
data are possible. Additionally, the potentially confounding role of the cassette promoter has been 
largely ignored in the literature to date.  
 
In order to address this discrepancy by simultaneously examining the activity of both promoters in 
the pathogen P. aeruginosa, the broad host-range constructs pMP220-intA and pMP220-Pint were 
introduced into E. coli DH5α and P. aeruginosa PA14 through heat-shock transformation and tri-
parental mating, respectively. β-galactosidase and alkaline phosphatase assays were then performed 
as previously, on protein extracts obtained from cells cultured in a volume of 15 ml in 100 ml 
Erlenmeyer flasks to late exponential phase (6 hours). All assays were performed in biological 
triplicate, with technical duplicate assays performed on each protein extract. 
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Basal expression from Pint was observed to be more than 7 times higher in P. aeruginosa than in E. 
coli, indicating a higher potential for integrase-mediated genome reorganisation within the 
pathogenic species compared with the non-pathogenic model organism (Figure 4.8A, pMP220-intA). 
The maximum unregulated level of Pint expression, is also significantly higher in P. aeruginosa than in 
E. coli, again indicating generally stronger expression regardless of regulatory factors (Figure 4.8A, 
pMP220-Pint).  
 
 
Figure 4.8 Comparative analysis of integron promoter activity in E. coli DH5α and P. aeruginosa PA14, in a modified 
broad host-range vector, pMP220. Expression of Pint assayed by LacZ activity (A) and expression of Pc assayed by PhoA 
activity (B). Activity of the promoters is reliably demonstrated in both E. coli DH5α (light grey bars) and P. aeruginosa PA14 
(dark grey bars) hosts. Data are presented as the mean average of 3 independent cultures, with each assay performed in 
technical duplicate. x̄ is the sample mean, and error bars represent the standard deviations of the mean. Values which are 
significantly different by one way ANOVA, followed by Tukey’s multiple comparison post hoc test, indicated by asterisks (ns 
= not significant, *** ≤ 0.001). 
 
Expression from Pc under normal growth conditions was not found to be significantly different 
between the two species (Figure 4.8B, pMP220-intA). However, a higher level of basal expression 
was observed from the promoterless constructs in P. aeruginosa, although this effect was not found 
to be statistically significant (Figure 4.8B, pMP220-Pint). This indicates that although novel regulators 
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of the cassette promoter may be uncovered, inter-species differences are more likely to be found 
upon examination of integrase expression and activity. 
 
The dynamic range of both reporter assays in this small scale screen demonstrates that it should be 
feasible to distinguish high and low levels of promoter activity for onward screens. 
4.3.5 Validation of high-throughput reporter assays for use in library screen 
In order to perform a high-throughput screen in 96-well format, the process of culturing and protein 
extraction was scaled down. The P. aeruginosa strains carrying pMP220-intA and pMP220-Pint were 
cultured in a volume of 1.5 ml in 2 ml 96-well deepwell plates with breathable seals. It was observed 
that growth in deepwell plates was significantly slower than in Erlenmeyer flasks, but similar to 
growth in sealed 50 ml Falcon tubes in a 15 ml volume (Figure 4.9). It is therefore feasible that 
oxygen limitation was responsible for this slower growth in the deepwell plates and Falcon tubes 
due to the decreased surface area for gas exchange.  
 
 
Figure 4.9 Effect of culture vessel on growth dynamics of P. aeruginosa PA14 harbouring dual reporter plasmid pMP220-
intA. Growth was assessed in cultures grown for 24 hours in 100 ml Erlenmeyer flasks (black line), sealed 50 ml Falcon 
tubes (blue line) and 2 ml 96-deep well blocks (red line). n = 2.  
 
Following culture for 18 hours to late exponential phase, cells were pelleted and total protein was 
harvested by freeze-thawing on dry ice, into a volume of 50 µl lysis buffer. Protein concentration was 
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then quantified by BCA assay and found to be comparable to the samples produced from 15 ml 
cultures, with no significant difference in concentration found between samples produced from the 
same strains, regardless of culture vessel (Figure 4.10).  
 
 
Figure 4.10 Comparative analysis of protein concentration from P. aeruginosa PA14 grown in 15 ml culture in 
Erlenmeyer flasks with protein extracted into 500 µl lysis buffer (dark grey bars) and 1.5 ml culture in 96-well deepwell 
plate with protein extracted into 50 µl lysis buffer (grey hatched bars). Data are presented as the mean average of 3 
independent cultures, with each assay performed in technical duplicate. x ̄is the sample mean, and error bars represent the 
standard deviations of the mean. No values were significantly different by one way ANOVA, followed by Tukey’s multiple 
comparison post hoc test. 
 
β-galactosidase and alkaline phosphatase activity was then measured from this total protein extract 
as a measure of expression from Pint and Pc respectively. No difference between culture vessels was 
observed in Pint or Pc activity from the construct in which promoter context and integrity had been 
maintained (Figure 4.11A and B, pMP220-intA). β-galactosidase activities were significantly different 
between culture vessels with the pMP220-Pint construct (Figure 4.11A, pMP220-Pint), which acts as a 
biological positive control in β-galactosidase assays. A small, statistically insignificant, reduction was 
seen in alkaline phosphatase activities with the pMP220-Pint construct when transferred into 96-well 
format (Figure 4.11B, pMP220-Pint). Since pMP220-Pint contains no Pc, it acts as a biological negative 
control in alkaline phosphatase assays, and may therefore represent a more effective negative 
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control strain in 96 well format than in Erlenmeyer flasks. A decrease in maximal Pint activity (Figure 
4.11A, pMP220-Pint) was however observed in the 96 well format, suggesting that the dynamic range 
of the assay may be reduced during the regulatory screen. 
 
 
Figure 4.11 Comparative analysis of integron promoter activity in P. aeruginosa PA14 grown in 15 ml culture in 
Erlenmeyer flasks (dark grey bars) and 1.5 ml culture in 96-well deepwell plate (grey hatched bars). Expression of Pint 
assayed by LacZ activity (A) and expression of Pc assayed by PhoA activity (B). Data are presented as the mean average of 3 
independent cultures, with each assay performed in technical duplicate. x ̄is the sample mean, and error bars represent the 
standard deviations of the mean. Values which are significantly different by one way ANOVA, followed by Tukey’s multiple 
comparison post hoc test, indicated by asterisks (ns = not significant, *** ≤ 0.001). 
 
4.4 Discussion 
The present study was designed to determine how the co-ordinated regulation of two integron-
mediated activities, integrase-associated cassette recombination and antibiotic resistance, are 
achieved in context, through examination of the regulation of their convergent promoters. In 
reviewing the literature, no data was found which addressed the simultaneous expression levels 
from both promoters, despite the tools to do so being available in at least one instance. Cagle et al. 
performed an in silico analysis of the In2 promoter region to identify potential binding sites for FIS, 
H-NS and IHF, which were then confirmed in vitro using a dual reporter of promoter activities in the 
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pCB267 vector [207]. However, their study did not take advantage of the dual nature of the 
constructs to examine transcription from both promoters in the same biological samples, instead 
choosing to examine one promoter at a time. 
 
This study used the same promoter screening vector as Cagle et al. [207], pCB267, to create dual 
transcriptional reporters of the two clinical integrons obtained from plasmid pKOX105 (Chapter 
3.3.2): pCB267-intA and pCB267-intB. Promoter expression in these constructs was then examined 
alongside two of the Cagle constructs, pCB267-intSOSminus and pCB267-Pint, which acted as positive 
controls of Pint expression and negative controls of Pc expression respectively [207]. Assays were 
performed upon whole cell lysates rather than permeablised cells in order to perform duplicate 
assays of both reporter activities on the same samples. Results were therefore reported in terms of 
the moles of substrate (ONPG or pNPP as appropriate) per mg of protein per minute, rather than in 
terms of Miller units as β-galactosidase assays have previously been described [207]. The current 
study would have benefitted from a Pc-only control equivalent to the Pint-only control, pCB267-Pint, 
to demonstrate the maximum possible level of expression from the unregulated Pc promoter and to 
act as a biological negative control of Pint expression, but this was not possible due to time 
constraints. The use of pCB267-intSOSminus as an SOS-negative control for Pint regulation may also 
have been improved by confirmation of its efficacy through comparison with chemical alleviation of 
SOS-mediated Pint repression using drugs such as mitomycin C (MMC). This may have been 
advantageous as pCB267-intSOSminus does not contain the exact same promoter variants as either 
pCB267-intA or pCB267-intB (Figure 4.4B), varying at the same two nucleotides as they differ 
between each other. However, since alleviation of Pint repression was observed as expected in 
samples containing pCB267-intSOSminus compared with pCB267-intA and pCB267-intB (Figure 
4.5A), this was deemed unnecessary. 
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Activity of the promoters was reliably demonstrated in E. coli DH5α, indicating that both of the Pc 
and Pint promoters are active, and that the context in which they are measured has functional 
significance (Figure 4.5). These results suggest that under normal growth conditions, expression 
from Pc is active (Figure 4.5B, pCB267-intA/B), and Pint regulation is primarily repressive in nature 
(Figure 4.5A, pCB267-intA/B). Upon encountering SOS-inducing stress, for example antibiotic-
induced DNA damage, integrase expression is induced (Figure 4.5A, pCB267-intSOSminus), and takes 
precedence over cassette expression although transcription from Pc is not eliminated (Figure 4.5B, 
pCB267-intSOSminus). Further induction of integrase expression beyond the levels produced 
through alleviation of SOS-mediated repression is possible however (Figure 4.5A, pCB267-Pint), 
indicating that Pint is subject to additional transcriptional regulatory controls. A model of regulatory 
governance is therefore suggested, in which multiple regulatory controls are integrated to govern 
integrase expression, whereby SOS-mediated regulation, uncharacterized regulatory motifs present 
throughout the promoter region, and, potentially, expression of antibiotic resistance cassettes per se 
act to repress integrase expression. The importance of promoter context remains to be fully 
characterised and its impact upon integron activities could prove to be crucial in understanding the 
full nature of integron regulation in a clinical setting. 
 
The transformation of the dual reporter promoter screening constructs pCB267-intA and pCB267-Pint 
into the broad-host range vector pMP220 provides the first opportunity we are aware of to study 
integron promoter activities in a wider range of bacterial hosts than E. coli, including, for the first 
time, the significant human pathogen P. aeruginosa. We were unable to clone either the pCB267-
intB or pCB267-intSOSminus constructs using any of three cloning strategies, nor to generate a 
feasible hypothesis for this failure (Chapter 4.3.4). This was initially disappointing as pKOX105 
integron B was the clinical integron containing the blaVIM-1 carbapenemase cassette, so had been 
hypothesised to be the integrase variant and promoter combination most likely to yield novel 
insights into carbapenemase cassette recruitment. However, the integron A variant, which was 
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successfully transformed into pMP220, is in fact the most commonly isolated integron variant [180] 
and varies from the integron B variant by only two single nucleotide polymorphisms in Pc, located in 
the -10 site and spacer regions (Figure 4.4B). There are also numerous examples in the INTEGRALL 
database of records showing carbapenemase cassettes contained within integrons with the A-type 
promoter combination, including 6 with the same blaVIM-1 type cassette as in integron B. Integron 
A was therefore deemed to be entirely as valid as integron B, particularly as all interesting results 
were to be further validated using both integron variants if possible.  
 
Activity of both Pint and Pc was again reliably demonstrated in the broad-host range vector pMP220 
in both E. coli DH5α and P. aeruginosa PA14 hosts (Figure 4.8). The differences observed between 
the same promoter variant, pKOX105 integron A, when carried in E. coli in two different vector 
backbones, pCB267 (Figure 4.5, pCB267-intA) and pMP220 (Figure 4.8, pMP220-intA), can be 
explained by the transfer from a high to a low copy plasmid. This tool is of significant advantage in 
allowing integron activities in other bacterial species than E. coli to be examined for the first time.  
 
Despite the similarity in basal cassette promoter activity between E.coli and P. aeruginosa (Figure 
4.8B, pMP220-intA), the 7-fold difference in basal integrase promoter activity is revealing (Figure 
4.8A, pMP220-intA). This is the first step to validating our hypothesis that integron activity, and 
potentially regulation, differs between bacterial species, and may begin to explain the increased 
incidence of new gene variants in some species more than others. The higher basal level of Pint 
expression in P. aeruginosa (Figure 4.8A, pMP220-intA) is also advantageous as it allows decreases in 
Pint activity to be visible, potentially allowing identification of Pint-activating regulators during 
transcriptional screening. 
 
The process of culturing strains, extracting protein and performing reporter assays was successfully 
scaled down from 100 ml Erlenmeyer flasks to 96 well deepwell format, to allow a high-throughput 
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screen of potential regulatory mutants to be performed. Protein extraction efficiency was 
unaffected by the scale-down (Figure 4.10), as were the enzyme activity levels in samples containing 
pMP220-intA (Figure 4.11A and B, pMP220-intA). However, β-galactosidase activities in samples 
containing the pMP220-Pint construct were found to be significantly different (Figure 4.11A, pMP220-
Pint), indicating that differences between the two culture methods may have an impact upon 
observed integron promoter activities. This is also implied by the observed difference in growth 
dynamics between Erlenmeyer flasks and 96 well deepwell blocks (Figure 4.9). Culture vessel-
dependent variations in integron promoter activities are unsurprising as integrons are known to be 
acutely tuned to detect and respond to environmental cues such as DNA-damaging drugs and carbon 
source [131-133]. One may not, therefore, assume that mutants that display aberrant promoter 
phenotypes in a high-throughput screen will necessarily show significant differences when examined 
in alternative culture formats (Erlenmeyer flasks). However, since growth dynamics in sealed 50 ml 
Falcon tubes were more similar to growth in 96 well deepwell blocks than Erlenmeyer flasks, despite 
identical culture volumes in Falcons and Erlenmeyer flasks (Figure 4.9), these differences are likely to 
be due to the aerophilic properties of the vessel. The limited availability of oxygen in the 96 well 
deepwell block may be more similar to the situation in vivo during an infection, and so be the more 
biologically relevant condition. An alternative explanation for these differences in integron promoter 
activities may lie in the unexplored growth phase effects of the 96 well deepwell blocks. In 
preliminary work performed by Cagle et al. [207], it was found that activities from the integrase and 
cassette promoters were all optimally detectable in late exponential to early stationary phase 
cultures, therefore we selected a 6 hr time point as the optimal sampling time for cultures in low-
throughput form as this is where late exponential/early stationary phase lay in our Erlenmeyer flask 
cultures (Figure 4.9, black line). However, although the growth curves performed with the 96 well 
deepwell blocks appeared to be levelling off by 24 hr (Figure 4.9, red line), it is possible that they had 
not yet reached the equivalent late exponential/early stationary phase stage, and, therefore, the 
optimal detection point for β-galactosidase activity. It would therefore be beneficial in future 
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experiments to perform such growth curves over a significantly longer period, and possibly assess 
activities from the integrase and cassette promoters over the entire period, to determine precisely 
where late exponential/early stationary phase lies in this format, and what the optimal sampling 
times are.  
 
The tools generated in this study, including the pMP220-intA and pMP220-Pint broad host-range 
transcriptional reporters and the accompanying assays validated in both low and high-throughput 
format, will be invaluable for future investigations of integron promoter activity in a wider range of 
bacterial hosts than has previously been possible. Primarily, for the purposes of this study, they 
allow for the possibility of a transcriptional screen of a library of mutants, to identify mutants in 
which promoter expression is aberrant. 
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5 Targeted analysis of integron promoter transcriptional regulation 
5.1 Introduction 
Integron gene expression has been demonstrated to be responsive to changes in the ambient 
environment: it has been shown that extracellular stresses such as drug-induced DNA damage can 
influence integron gene expression in both the Vibrio chromosomal integron and mobile integrons 
via induction of the SOS response, and that despite their differences, the same stresses affect both 
types of integrons [131-133]. However, the effect of such stresses on integron promoter 
transcription has not yet been examined, in mobile integrons contained within any bacterial species 
other than non-pathogenic E. coli.  
 
Previous studies have demonstrated that carbon source, independently of SOS, controls expression 
of the Vibrio chromosomal integron integrase, intIA, via a cAMP receptor protein (CRP)-dependent 
mechanism [133]. However, carbon source regulation in mobile integrons has not been examined to 
date. CRP is the prototypical bacterial transcriptional activator protein, and acts by responding to 
intracellular levels of cAMP [199] (Chapter 1.2.4). Despite the dominance of CRP-dependent 
regulation in bacteria, carbon catabolism and transport is regulated very differently in P. aeruginosa 
compared with Enterobacteriaceae [204]: the P. aeruginosa CRP homologue, Vfr, has no known role 
in carbon source regulation in P. aeruginosa [204, 313]. P. aeruginosa employs hierarchical control 
of growth substrate uptake and metabolism via the translational repressor Crc, its associated two 
component system CbrAB, and the small interfering RNA CrcZ [204, 269, 314]. Within this hierarchy, 
organic acids are preferentially utilised in favour of carbohydrates: the preferred carbon source for 
growth of P. aeruginosa is succinate, glucose and arabinose are intermediate carbon sources, and 
fructose is non-preferred [204, 315]. 
  111 
5.2 Objectives 
The work described in this chapter assesses whether carbon source and other infection-related 
stresses play a role in the expression of integron genes in P. aeruginosa.  
 
Objectives:  
• Investigation into the effect of carbon source on integron promoter activities. 
• Targeted analysis of integron promoter activity profiles in crc, cbrA and cbrB mutants. 
• Investigation into functional differences in integron-associated carbapenem resistance in crc, 
cbrA and cbrB mutants. 
• Investigation into the effect of antibiotic stress on integron promoter transcription. 
5.3 Results 
5.3.1 Influence of carbon source on integron promoter activities 
In order to examine the effect on integron promoter transcription in P. aeruginosa PA14 of shifting 
growth from a preferred carbon source to a non-preferred source, strains carrying the dual reporter 
plasmid pMP220-intA (Chapter 4.3.3) were cultured to late exponential stage in minimal media 
(MM) with 85 mM (1 %) succinate as the sole carbon source in a volume of 1.5 ml in 2 ml 96-well 
deepwell plates. After 18 hours, cells were pelleted and resuspended in minimal media with either 
85 mM succinate (no shift), 5 µM succinate (carbon starvation), 5 mM (1 %) glucose, 55 mM (1 %) 
fructose, or 55 mM (1 %) arabinose as the sole carbon source, and incubated for a further two hours. 
Cells were then pelleted, and total protein harvested by freeze-thawing on dry ice, into a volume of 
50 µl lysis buffer. Protein concentration was quantified by BCA assay and β-galactosidase and 
alkaline phosphatase activity assays performed to measure expression from Pint and Pc respectively. 
Enzyme activity was expressed as a function of that of the unshifted sample (85 mM succinate), by 
dividing the activity value for each carbon source by the activity from the samples in which no shift 
occurred (85 mM succinate) for the appropriate assay. 
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This media shift, from a preferred carbon source to a state of carbon starvation (5 µM succinate) or 
to an intermediate carbon source (glucose or arabinose) had no significant effect on Pint activity 
(Figure 5.1A). A small but statistically significant increase in Pc activity was observed following the 
shift to arabinose and 5 µM succinate, but no effect was observed upon Pc activity following a shift 
to glucose (Figure 5.1B). However, upon shifting to the non-preferred carbon source, fructose, 
activity from both promoters fell to less than half of that of the unshifted strains (Figure 5.1A and 
5.1B, fructose).  
 
Figure 5.1 Expression from integron promoters in wild type P. aeruginosa PA14 containing pMP220-intA following 
growth in 85 mM succinate followed by 2 hour stimulation in alternative (less preferred) carbon sources. Data 
normalized to 85 mM succinate (no shift), with expression of Pint assayed by LacZ activity (A) and expression of Pc assayed 
by PhoA activity (B). Data are presented as the mean average of 3 independent cultures, with each assay performed in 
technical duplicate. Error bars represent the standard deviations of the mean. Values which are significantly different by 
one way ANOVA, followed by Dunnett’s multiple comparison post hoc test, from the strain with no media shift are 
indicated by asterisks (ns = not significant, * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001). 
 
The experiment was then recapitulated with an intermediate carbon source, 55 mM glucose, as the 
original sole carbon source. Following 18 hours growth, cells were pelleted and shifted into minimal 
media containing 55 mM fructose (non-preferred carbon source), 55 mM arabinose (alternative 
intermediate carbon source) or 85 mM succinate (preferred carbon source) as the sole carbon 
  113 
source for a further two hours. As previously, cells were then pelleted, total protein harvested, 
concentration quantified by BCA assay and β-galactosidase and alkaline phosphatase activity assays 
performed to measure expression from Pint and Pc. Enzyme activity was again expressed as a function 
of that of the unshifted sample (55 mM glucose).  
 
Shifting from one intermediate carbon source to an alternative intermediate source was found to 
have no significant effect on either integron promoter (Figure 5.2A and 5.2B, arabinose). The 
dampening effect of fructose on expression from both integron promoters of fructose was 
maintained, with activity from both promoters again less than half of that of the unshifted strains 
(Figure 5.2A and 5.2B, fructose). Shifting up the hierarchy to a preferred carbon source reduced 
relative expression from Pint (Figure 5.2A, succinate), while increasing expression from Pc (Figure 
5.2B, succinate). 
 
 
Figure 5.2 Expression from integrase promoters in wild type containing pMP220-intA following growth in 55 mM glucose 
followed by 2 hour stimulation in alternative carbon sources. Data normalized to 55 mM glucose (no shift), with 
expression of Pint assayed by LacZ activity (A) and expression of Pc assayed by PhoA activity (B). Data are presented as the 
mean average of 3 independent cultures, with each assay performed in technical duplicate. Error bars represent the 
standard deviations of the mean. Values which are significantly different by one way ANOVA, followed by Dunnett’s 
multiple comparison post hoc test, from the strain with no media shift are indicated by asterisks (ns = not significant, * ≤ 
0.05, *** ≤ 0.001). 
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It was not possible to perform such a shift experiment from the non-preferred carbon source 
fructose to preferred carbon sources, as initial growth was so limited as to make protein extraction 
unfeasible.  
 
These data are the first evidence of carbon catabolite control in mobile integrons, and suggest 
examination of the major P. aeruginosa carbon source regulators crc, cbrA and cbrB as possible 
sources of this control. 
5.3.2 Transcriptional screening of carbon catabolite control mutants 
As carbon source had been shown to have an effect on integron promoter transcription in wild type 
P. aeruginosa, transposon mutants of three of the key regulators of carbon source in P. aeruginosa 
were isolated from the P. aeruginosa PA14 non-redundant knockout library [281] and examined for 
differential transcription (compared with wild type) from Pint and Pc via enzymatic activity assays: crc 
(PA14_70390), cbrA (PA14_62530) and cbrB (PA14_62540). These mutants were conjugated with the 
pMP220-intA dual reporter plasmid, then grown alongside a pMP220-intA-conjugated wild type 
control for 24 hr in 96 deep well culture in a volume of 1.5 ml in LB (in biological quadruplicate), and 
in MM with 85 mM succinate as the sole carbon source (in biological triplicate). Transconjugated 
mutants were cultured in media with gentamicin 15 µg/ml and tetracycline 30 µg/ml, while the wild 
type was grown in media with tetracycline 30 µg/ml. Cells were then harvested by centrifugation, 
total protein harvested by freeze-thawing on dry ice in 50 µl TE lysis buffer and quantified by BCA 
assay. β-galactosidase and alkaline phosphatase activity from these total protein extracts was 
assessed as a measure of expression from Pint and Pc respectively (Figure 5.3).  
 
This screen revealed that mutation of crc and cbrA has no effect on integron promoter expression 
from either promoter, in either media type (Figure 5.3, crc::Tn and cbrA::Tn). Mutation of cbrB 
caused an increase in Pint activity compared with wild type when assessed in LB (Figure 5.3Ai, 
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cbrB::Tn), but had no effect in minimal media (Figure 5.3Bi, cbrB::Tn) or on Pc in either media type 
(Figure 5.3Aii and Figure 5.3Bii, cbrB::Tn). 
 
 
Figure 5.3 Transcriptional screen of crc::Tn, cbrA::Tn and cbrB::Tn containing pMP220-intA in LB (A) and minimal medium 
with 85 mM succinate as the sole carbon source (B). Expression of Pint assayed by LacZ activity (i) and expression of Pc 
assayed by PhoA activity (ii). The data points in (A) represent the mean average of 4 independent cultures, with each assay 
performed in technical triplicate, while the data points in (B) represent the mean average of 3 independent cultures, with 
each assay performed in technical duplicate. Error bars represent the standard deviations of the mean. Values which are 
significantly different by one way ANOVA, followed by Dunnett’s multiple comparison post hoc test, from wt are indicated 
by asterisks (ns = not significant, * ≤ 0.05). 
 
5.3.3 Functional screening of crc::Tn, cbrA::Tn and cbrB::Tn 
As demonstrated in Chapter 3.3.3, Pc-mediated expression of blaVIM-1 in plasmid pEVM2a confers a 
high level of imipenem resistance to P. aeruginosa, with a MIC breakpoint of 1024 µg/ml in wild type 
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P. aeruginosa PA14 harbouring pEVM2a, compared to 2 µg/ml without the plasmid. We 
hypothesised that despite there being little evidence of transcriptional regulation of the integron 
promoters by crc, cbrA and cbrB, alterations in blaVIM-1 expression from Pc would result in altered 
susceptibility to imipenem if these genes did play a role in regulating integron cassette promoter 
activity. 
 
crc, cbrA and cbrB transposon mutants were conjugated with plasmid pEVM2a, containing pKOX105 
integron B and the associated blaVIM-1 cassette (Figure 3.3). Stationary phase cultures were then 
diluted 1:20 into a final volume of 200 µl media containing 512 µg/ml imipenem (0.5 x MIC) and 
incubated at 37 °C (200 rpm) in a POLARStar Omega 145 multiwell plate reader. Growth was 
monitored by measuring OD600 every 30 minutes for a total of 18.5 hours.  
 
Severe growth retardation of cbrA and cbrB mutant strains was observed in both LB (Figure 5.4 A, 
light blue lines) and minimal media with 85 mM succinate as sole carbon source (Figure 5.4 B, light 
blue lines), indicating that expression from Pc is repressed in cbrAB under antibiotic-induced 
pressure. The crc mutant displayed the same severe growth retardation in the minimal media (Figure 
5.4 B, dark blue line), but only a mild effect in LB (Figure 5.4 A, dark blue line). 
5.3.4 Effects of antibiotic stress on integron promoter transcription 
The effect of antibiotics upon transcription from both integron promoters in P. aeruginosa PA14 was 
then examined. Strains carrying the dual reporter plasmid pMP220-intA were cultured to late 
exponential stage in minimal media (MM) with 55 mM (1 %) glucose as the sole carbon source in a 
volume of 1.5 ml in 2 ml 96-well deepwell plates. After 18 hours, cells were pelleted and 
resuspended in MM+ 55mM glucose plus a range of antibiotics at concentrations which would result 
in killing or DNA damage [211, 306] (50 µg/ml imipenem, 30 µg/ml trimethoprim, 15 µg/ml 
gentamicin, 50 µg/ml meropenem, 50 µg/ml ciprofloxacin, 50 µg/ml metronidazole, 1 mM hydrogen 
peroxide and 1 µg/ml mitomycin C) and incubated for a further two hours. Cells were then pelleted, 
  117 
and total protein harvested by freeze-thawing on dry ice, into a volume of 50 µl lysis buffer. Protein 
concentration was quantified by BCA assay and β-galactosidase and alkaline phosphatase activity 
assays performed to measure expression from Pint and Pc respectively. Enzyme activity was 
expressed as a function of that of an unshifted control sample (resuspended in 55 mM glucose 
without drug), by dividing the activity value for each antibiotic sample by the activity from the 
sample in which no shift occurred for the appropriate assay for each biological replicate (Figure 5.5). 
 
 
Figure 5.4 Mutations in CCR genes affect blaVIM-1 expression from Pc. Growth in LB (A) or minimal media with 85 mM 
succinate as sole carbon source (B) containing 512 µg/ml imipenem (0.5 x MIC) as determined by OD600 measurements. 
Data represent the means of 4 independent experiments, each in triplicate. Error bars represent the standard deviation of 
the mean. 
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Figure 5.5 Expression from integron promoters in wild type P. aeruginosa PA14 containing pMP220-intA, following 
growth in 5 mM glucose plus 2 hour antibiotic stimulation. Data normalized to no-antibiotic control, with expression of 
Pint assayed by LacZ activity (A) and expression of Pc assayed by PhoA activity (B). Data are presented as the mean average 
of 4 independent cultures, with each assay performed in technical duplicate. Error bars represent the standard deviations 
of the mean. Values which are significantly different by one way ANOVA, followed by Dunnett’s multiple comparison post 
hoc test, from the control sample with no antibiotic stimulation are indicated by asterisks (ns = not significant, * ≤ 0.05). 
 
These assays revealed that the majority of the antibiotics under investigation did not result in 
altered expression from Pint (Figure 5.5A), and none resulted in altered expression from Pc (Figure 
5.5B). This indicates that, with one exception, the integron module is not intrinsically able to 
moderate expression of integrase or cassettes in response to antibiotic mediated pressure after 2 
hours, at the concentrations tested.  
 
Hydrogen peroxide, a classic SOS inducer in bacterial species such as E. coli [316], resulted in an 
increase in Pint expression, which was unsurprising due to the presence of an intact SOS box in 
pMP220-intA. However, another classic SOS inducer, mitomycin C (MMC) [317], and ciprofloxacin, 
which is a confirmed inducer of the SOS response in P. aeruginosa [318], did not cause any change in 
expression from Pint.  
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These data are in keeping with the expectations from our hypothesis (Chapter 1.4), that the primary 
regulatory response route to antibiotic stress at these drug concentrations is via activation of Pint, i.e. 
through reorganisation of integron cassette content.  
5.4 Discussion 
Investigations into the role of antibiotics and carbon source in integron regulation as a result of 
suggestions in the integron literature have been revealing.  
 
Using the laboratory P. aeruginosa strain PA14, we were not able to replicate the SOS-mediated 
induction of Pint using metronidazole, ciprofloxacin, or mitomycin C that was recently identified in a 
clinical P. aeruginosa strain [211]. This discrepancy between our data (Figure 5.5A) and the previous 
report may have been due to strain-associated regulatory differences, or to the sensitivity of the 
expression reporter systems used: our study utilised a transcriptional reporter system, compared 
with the potentially increased sensitivity of the quantitative reverse-transcriptase PCR (qRT-PCR) 
approach taken by Hocquet et al. [211]. It may be worth future examination of the effects of 
antibiotics on the laboratory strain using a similar qRT-PCR assay. Additionally, additional infection-
related stresses such as iron and nitrogen starvation should be explored at a later date using one or 
more of these methods [319-324].  
 
In this chapter, we have provided the first evidence we are aware of for regulatory control of mobile 
integrons via carbon catabolite repression. Previous studies had functionally demonstrated CRP-
mediated regulation of the Vibrio cholerae chromosomal integron, and identified that this control 
was via binding of CRP to a specific site in the intergenic region between intIA and the attI 
recombination site [133]. Despite the identified CRP binding site not being present in the conserved 
region of mobile integrons, we postulated that carbon source regulation as a stress response may 
still have relevance to regulation of mobile integrons. We demonstrated that a switch from a 
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preferred or intermediate carbon source to fructose, a non-preferred carbon source for P. 
aeruginosa, resulted in significantly reduced expression from both integron promoters. While this 
may be a result of carbon source regulation of integron promoters, it is a distinct possibility that the 
effect was due to cells having spent the 2 hr stimulation period in lag phase, while cells in the other 
conditions moved into log phase. Cultures in log phase would inevitably contain higher 
concentrations of β-galactosidase and alkaline phosphatase than lag phase cultures, therefore giving 
the false impression of promoter repression in the fructose cultures. Investigations into carbon 
source-associated growth dynamics are therefore required to determine whether growth in fructose 
has an effect on integron promoter expression, or whether the effects observed in this study were a 
side-effect of growth difference.  
 
However, growth phase effects are unlikely to be the reason for the significant effects on integron 
promoter expression in response to succinate, as the effect is one of differential expression, with 
increased expression from Pc and reduced expression from Pint. This therefore represents the first 
evidence, to the best of our knowledge, of carbon source influencing expression from mobile 
integron promoters.  
 
Carbon catabolite regulation is a complex process which is closely linked to pathogenicity [133, 325, 
326], since bacteria need to be able to rapidly respond to diverse carbon source availabilities in 
different niches. Despite carbon source regulation in P. aeruginosa being regulated by the 
translational repressor Crc as opposed to CRP [204, 272], Crc has also been demonstrated to play a 
role in regulation of virulence factors and susceptibility in P. aeruginosa [327, 328].  
 
We therefore investigated and confirmed a role for the major P. aeruginosa carbon source regulator, 
crc (Chapter 5.3.1). Despite having confirmed a role for Crc in the regulation of both Pint and Pc, no 
Crc binding motif (AAnAAnAA) [271] was identified in relation to either the integrase or cassettes, 
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indicating that control is not via the classical mechanism of translational regulation. Regulation is 
therefore either controlled directly via entirely novel protein-DNA interactions, or indirectly via 
other regulators within the crc regulon, for example cbrAB. We have provided evidence for a 
regulatory role for cbrAB both through transcriptional analysis (Figure 5.3Ai), which revealed an 
increase in expression from Pint in a cbrB mutant, and functionally, by demonstrating that mutations 
in cbrAB result in altered susceptibility to imipenem, potentially through alterations in blaVIM-1 
expression from Pc. However, as no mutant of the small regulatory RNA crcZ, which links crc and 
cbrAB regulation, was available to investigate at the time these experiments were undertaken, 
further work is required to clarify the role of this Pseudomonas-specific regulatory system in mobile 
integron regulation. In addition, despite the crc, cbrA and cbrB mutants investigated in this chapter 
having been obtained from an ordered library of transposon mutants, these mutants were not 
independently validated by confirmation that they did indeed contain transposons in the designated 
genes. To increase confidence in the findings of this study, is it necessary to confirm the location of 
transposons in the current mutants, followed by confirmation of the observed phenotypes using 
mutants with clean deletions of the appropriate genes, and demonstration of restoration of the wild 
type phenotype using complemented mutants.  
 
While the limited a priori investigations we performed to examine the role of infection-related 
stresses in integron regulation have revealed a role for carbon source regulation, and contributed to 
the field’s knowledge of the effect of antibiotic stress on integron promoter transcription, the scope 
for such examinations is limited and inefficient. Since in silico analysis has also revealed little [207], a 
compendium approach is the next appropriate step, to allow investigation of large numbers of 
potential regulatory targets simultaneously. 
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6 Screen for transcriptional regulators of integron promoters  
6.1 Introduction 
To date, published investigations of integron transcriptional regulation have been undertaken via a 
targeted approach, assessing known global transcriptional regulators FIS, IHF, H-NS, and, most 
significantly, LexA [131-133, 206, 207]. However, the scope of such a targeted approach is limited 
once identified regulators have been explored. Additionally, previous investigations of mobile 
integrons have focussed entirely on regulation of Pint in non-pathogenic E. coli [131-133, 180, 193, 
206, 207] and have largely ignored regulation of Pc [131-133, 206]. Despite the known involvement 
of these global transcriptional regulators, little is known about the specific signals that are being 
responded to, i.e., which stress responses and metabolic pathways are implicated in the regulation 
of integron functions. Exploratory work to expand this knowledge through in silico analysis has 
revealed little [207], therefore a compendium approach is the next appropriate step, to allow 
investigation of large numbers of potential regulatory targets simultaneously.  
 
In deciding to adopt a large-scale screen approach to uncovering pathways involved in integron 
promoter regulation, three potential P. aeruginosa mutant libraries were identified for the purpose. 
The P. aeruginosa PA14 non-redundant knockout library created by Liberati et al. presents a valuable 
resource to discover novel pathways to integron regulation using such an approach [281]. This 
ordered, non-redundant transposon library provides maximally saturated coverage of the genome of 
a clinically-derived strain of P. aeruginosa, and was created primarily using the gentamicin resistant 
transposon MAR2xT7 (denoted MrT7), plus a small subset created using the kanamycin resistant 
Tn5-based transposon, TnPhoA. 
6.2 Objectives 
In order to identify novel regulators of integron-mediated gene expression, a methodology was 
developed to promote high throughput, simultaneous measurements of Pint and Pc activities in 
  123 
(n=532) P. aeruginosa transposon mutants using the previously described dual reporter plasmid 
pMP220-intA (Section 4.3.3). 
 
Objectives:  
• Establishment of in-broth conjugation protocol suitable for high-throughput transfer of 
reporter plasmid pMP220-intA, from E. coli donor to multiple P. aeruginosa recipients. 
• Introduction of pMP220-intA dual reporter construct into P. aeruginosa transposon mutants 
• High-throughput transcriptional screening of P. aeruginosa mutant sub-library for mutants 
with aberrant integron promoter activity profiles 
 
6.3 Results 
6.3.1 Establishment of in-broth protocol for conjugation in high-throughput format  
In order to develop a reliable method for introducing a single plasmidic construct simultaneously to 
a large number of P. aeruginosa recipient strains, a standardised conjugation procedure for liquid 
media was developed. Optimisation of the conjugation protocol was performed using extant 
triparental mating methodology (kindly provided by the Filloux lab) [277, 304]. Initially developed for 
use on solid selection media, and in low-throughput, it provided the basis upon which to assess 
reproducibility, and efficiency, of conjugative plasmid transfer prior to use in a liquid format, and 
then scale-up. P. aeruginosa PA14 was used as the recipient strain in these experiments, pMP220 as 
the conjugative plasmid (harboured within the donor strain E. coli TG1), and E. coli 1047/pRK2013 as 
the helper strain. Transconjugants were therefore defined as P. aeruginosa PA14 harbouring 
pMP220. 
 
In order to identify the most potently selective media with which to discriminate between donor, 
helper, recipient and transconjugate isolates, initial growth experiments explored the sensitivity of a 
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panel of bacterial isolates to multiple selection media (data not shown). Selection of transconjugants 
was achieved by plating conjugation reactions onto LB containing ampicillin 50 μg ml−1 and 
tetracycline 50 μg ml−1. Growth of P. aeruginosa was confirmed by replating onto PIA + tetracycline 
90 μg ml−1, a strategy which proved universally successful, thereby verifying that the selection 
strategy using LB containing ampicillin 50 μg ml−1 and tetracycline 90 μg ml−1 was reliable. There was 
no significant difference between the number of transconjugants isolated after 2 and 4 hours 
(p=0.2225) of incubation, suggesting that in routine lab conjugations where only a few 
transconjugant clones are sought, a 2 hour co-incubation is sufficient (Figure 6.1). 
 
Figure 6.1 Transconjugants obtained following conjugation on solid and liquid media, with incubation times of 2 and 4 
hours. Conjugation reactions were either spotted onto LB plates (light grey bars) or added to LB broth (dark grey spotted 
bars) and incubated for 2 or 4 hours, before plating onto LB containing ampicillin 50 μg ml−1 and tetracycline 50 μg ml−1and 
incubated at 37 °C for 24 hr. The differences between media types (solid vs liquid) and time points were found not to be 
significant at the 5 % level by two-way ANOVA with Bonferroni post hoc tests (n = 3). 
 
To scale up the protocol for large scale transfer of reporter constructs during library screens, this 
method was adapted for liquid media as described in Section 2.7.3, maintaining the previous ratios 
of helper, donor and recipient strains (1:1:2 ratio) in the conjugation reaction. Conjugations were 
performed in sealed 2 ml microcentrifuge tubes to approximate the microaerobic environment likely 
to be encountered within deep well 96 well blocks (used for library conjugation experiments). Again, 
no significant difference (p = 0.6325) was observed in the number of transconjugants recovered 
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after 2 and 4 hours’ incubation (Figure 6.1, dark grey spotted bars). Crucially, similar numbers of 
transconjugants were recovered from conjugations performed in liquid media compared with those 
recovered on solid media (Figure 6.1). 
6.3.2 P. aeruginosa mutant sub-library  
The P. aeruginosa whole-genome knockout library (PA14NR Set) provides an invaluable resource for 
P. aeruginosa researchers [281]. In order to identify novel regulators of integron-mediated gene 
expression a sub-library of predicted regulatory mutants, generated by Jennifer Wilson (MRes 
student, Huw Williams), was used to perform the reporter screen. Mutants for inclusion in the sub-
library had been selected on the basis of their annotations within the P. aeruginosa genome 
database as two component systems, transcriptional regulators, SerThr kinases, catalases, 
superoxide dismutases or Gac related genes. The sub-library was replicated according to the method 
described in 2.7.1, from Huw Williams’ copy of the PA14 NR Set (full list of selected strains in 
appendix 5.1). All mutants from plates 1-6 were successfully cultured, with the exception of 
PA14_27690, a putative RNA polymerase sigma factor originally located in library plate 
PAPho_nr_mas_01_1:A11, which failed to grow in Plate 1:E2. One master storage plate and two 
working storage plates of each sub-library plate were produced from the cultured deep well blocks 
and stored at – 80 °C as described in 2.7.2. 
6.3.3 Introduction of integron dual reporter construct pMP220-intA into P. aeruginosa 
transposon mutants 
To provide the sub-library with the transcriptional reporter construct with which transcriptional 
regulation of the integron promoters could be examined, plasmid pMP220-intA was first conjugated 
into the sub-library, as described in chapter 2.7.3. An antibiotic selection panel was devised (Table 
6.1) to confirm that all strains necessary for conjugation of pMP220-intA into PA14NR set mutants 
were present within the conjugation reactions and were growing appropriately.  
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Table 6.1 Antibiotic selection panel used for conjugation of pIPCi214c_A into PA14NR Set mutants on solid media. All 
three components of each conjugation reaction (helper, donor and recipient strains) plated on all media types. 
 
 
Helper Donor Recipient Transconjugants 
(E. coli 
1047/pRK2013) 
(E. coli 
DH5α/pMP220-
intA) 
(P. aeruginosa 
PA14::MrT7) 
(P. aeruginosa 
PA14:: 
MrT7/pMP220-
intA) 
LB √ √ √ √ 
PIA X X √ √ 
LB + kanamycin 50 µg/ml √ X √ √ 
LB + ampicillin 50 µg/ml X X √ √ 
LB + gentamicin 15 µg/ml X X √ √ 
LB + tetracycline 90 µg/ml X √ X √ 
LB + ampicillin 50 µg/ml + 
tetracycline 90 µg/ml X X X √ 
LB + gentamicin 15 µg/ml + 
tetracycline 90 µg/ml X X X √ 
LB + gentamicin 15 µg/ml + 
ampicillin 50 µg/ml + 
tetracycline 90 µg/ml 
X X X √ 
 
5 µl spots of the conjugation mixtures and all three individual reaction components (helper, donor 
and recipient strains) were plated on all 9 media types and incubated for 24-48 hours at 37 °C. Plates 
were manually examined for correct growth on all control plates (Figure 6.2). Transconjugants were 
then selected from the triple selection plate (preferentially) or from one of the double selection 
plates and inoculated into 600 µl LB broth containing gentamicin 15 µg/ml (to ensure growth of 
strains retaining transposon insertion rather than revertants) + tetracycline 30 µg/ml (to select for 
plasmid), from which storage plates were made as previously. 10 mutants failed to grow either on 
conjugation selection plates or following inoculation into liquid culture, and were therefore 
considered not to have been successfully conjugated: Plate 1:A9, Plate 3: H3, Plate 4:F5, Plate 4:G5, 
Plate 5:B4-8, Plate 5:H8. 
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Figure 6.2 Example 96-well conjugation plates after 48 hours of incubation at 37 °C. Concentrations of selective agents as 
given in Table 6.1. Expected growth (green) or non-growth (red) of conjugation mixtures and all individual reaction 
components (recipient, donor and helper strains) indicated by plate label. Transconjugated mutants were selected from 
the double/triple selection plates (blue box).  
 
6.3.4 Transcriptional screening of sub-library 
A total of 532 transconjugants (corresponding to transposon mutants of n=440 genes, due to 
duplications in the library), harbouring the dual reporter construct pMP220-intA, were examined, via 
enzymatic activity assays, for transcription initiated from Pint and Pc. Strains were grown in 96 deep 
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well culture, for 24 hr in 1.5 ml LB with gentamicin 15 µg/ml and tetracycline 30 µg/ml, and 
harvested by centrifugation. Each plate included a pMP220-intA-conjugated wild type control 
(grown in LB with tetracycline 30 µg/ml) and a well containing uninoculated LB to verify relevance of 
selective pressure and absence of cross-contamination respectively. The majority of the 
transconjugants achieved similar OD600 values as the wild type, but some strains had clear growth 
defects (Figure 6.3). 21 strains with OD600≤ 66% of that of the wild type (n=3 biological replicates) 
were excluded from further analysis (Figure 6.3, red bars). Although 20 of these 21 slow growing 
strains were contained within Plate 2, this is likely to be related to the clustering of mutants with 
related functions within the sub-library rather than experimental error, as growth was found to be 
deficient in multiple iterations of the experiment.  
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Figure 6.3 Growth (OD600) of transconjugants used for high-throughput transcriptional screen. Strains were grown in LB 
with gentamicin 15 µg/ml and tetracycline 30 µg/ml. Wells are shown along x axis, and mutants eliminated from further 
analysis due to poor growth shown in red. 
 
Total protein was extracted from harvested transconjugant cells by freeze-thawing in TE buffer, and 
quantified by BCA assay. The efficiency of protein extraction was found to be consistently high, with 
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62 %, 88 % and 79 % of sample concentrations falling within 20 % of the mean for biological 
replicates 1, 2 and 3 respectively (Figure 6.4). 
 
Figure 6.4 Histograms of concentration of total protein extracts compared with the replicate mean concentration 
(µg/ml). The distribution of percent fold change compared with the mean concentration of total protein for each biological 
replicate is given along the x axis, with frequency on the y axis. 
 
All transconjugants were assigned a unique identifier number (UID) to ensure a blinded analysis, 
such that data was analysed solely with respect to enzyme activity, without reference to functional 
similarity or genomic co-localisation of strains (Appendix 6.1). β-galactosidase and alkaline 
phosphatase assays were performed on total protein extracts in technical duplicate, and the enzyme 
activity calculated (Figure 6.5A and Appendix 6.2, columns B - M). 
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Figure 6.5 Data analysis pipeline for library transcriptional screen.  
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Enzyme activity for each transconjugant was expressed as a function of that of the wild type (Figure 
6.5B and Appendix 6.2, columns N - S), by dividing the mutant activity value by the wild type activity 
for the appropriate assay (Figure 6.6). Wild type reporter assays (performed in biological and 
technical triplicate) were performed in 96 well format using the parental wild type strain (Figure 
6.6), with all mutant activities normalised to the average wild type activity: 25.68 nmol ONPG 
hydrolysed/min/mg protein for β-galactosidase assays (Figure 6.6A) and 243.27 nmol pNPP 
hydrolysed/min/mg protein for alkaline phosphatase assays (Figure 6.6B). 
 
 
Figure 6.6 Integron promoter activities from library parental strain, P. aeruginosa PA14. Expression of Pint assayed by LacZ 
activity (A) and expression of Pc assayed by PhoA activity (B). Each data point represents a single technical replicate, from 
one of three independent cultures. x ̄is the sample mean, and error bars represent the standard deviations of the mean. 
 
Wild type normalised values were then transformed to the binary logarithm (log2), so that positive 
values indicated up-regulation compared with the wild type and negative values indicated down-
regulation (Figure 6.5C and Appendix 6.2, columns T - Y). The two technical replicate values for each 
biological replicate were then averaged (Figure 6.5D and Appendix 6.2, columns Z - AB) to produce 
the biologically relevant output for each assay (Figures 6.7 and 6.8).  
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Figure 6.7 β-galactosidase mean log2 of fold change for n = 532 mutants. Each data point represents a single independent 
culture, with each assay having been performed in technical duplicate. Error bars represent the standard deviations of the 
mean. 
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Figure 6.8 Alkaline phosphatase mean log2 of fold change for n = 532 mutants. Each data point represents a single 
independent culture, with each assay having been performed in technical duplicate. Error bars represent the standard 
deviations of the mean. 
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Although within-replicate activity was generally very consistent (data not shown), significant 
variability was observed between biological replicates (Figure 6.9A). In order to normalise for inter-
replicate variation, thereby permitting direct comparisons of multiple experimental replicates and 
standardise the data distributions, the datasets were subjected to quantile normalisation using 
microarray analysis software GeneSpring GX (Agilent Technologies, CA) (Figure 6.5E and Appendix 
6.2, columns AC - AE). This technique replaces the absolute value of enzyme activity for each 
mutant, with a ranking of the magnitude of activity for each mutant within each biological replicate, 
therefore normalising the distributions of the data (Figure 6.9B). Using this approach it is possible to 
identify mutants falling consistently at the extremes of the data distributions without reference to 
the actual magnitude of effect. 
 
Figure 6.9 Transformation of data through quantile normalization. 
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The quantile normalised data (Figure 6.5E and Appendix 6.2, columns AC - AE) were then subjected 
to t-tests against zero (i.e. zero change compared with the median activity) using statistical analysis 
software GraphPad Prism 5 (GraphPad Software Inc., CA), revealing a total of 253 mutants with 
reproducibly significant differences compared with wild type at the 5 % level (Appendix 6.2, column 
AF; p < 0.05 highlighted in yellow). 41 mutants displayed a significantly different phenotype at the 5 
% level in tests of β-galactosidase activity, 3 of which were significant at the 1 % level. 237 mutants 
with p < 0.05 were revealed from the alkaline phosphatase assays, 75 of which were significant at 
the 1 % level. 
 
A large number of type 1 errors are expected among such a large sample set, particularly with so 
many statistically significant results by t-test: at least 5 % of the 253 statistically significant results 
are expected to be false positives. In order to eliminate these type 1 errors and to identify mutants 
exhibiting significant defects in integron promoter regulation, a downselection and conformational 
rescreen process was undertaken. The means of the quantile normalised activities were calculated 
(Figure 6.5F and Appendix 6.2, column AG), and those from mutants displaying statistically 
significant phenotypes were extracted from the data set (Appendix 6.3). These mean quantile 
normalised values (Appendix 6.3, columns F and K) were then ranked according to magnitude of 
change compared with wild type (Figure 6.11 and Figure 6.12). From this ranking, 30 mutants 
exhibiting behaviours which deviated significantly (at the 5 % level) from that of the wild type and 
which fell into the top or bottom 20 positions within the ranked data were chosen for further 
analysis (Table 6.2). According to this prioritisation strategy, only one mutant exhibited alterations in 
both reporter assays at the 5 % level and was positioned within the top/bottom 20 mutants by 
magnitude of effect: UID 393 (PA14_72690), which exhibited lower activity than wild type in both 
assays. 
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Figure 6.10 Distribution of transcriptional screen significant hits within sub-library. Wells labelled by unique identifier 
numbers (UID) as listed in Appendix 6.1. Wells containing strains omitted due to failed conjugation or non-growth crossed 
through. Wells containing significant results in the test screens are highlighted in yellow, according to the assay in which 
they demonstrated a significant difference compared with wild type (β-galactosidase assay results in first column alkaline 
phosphatase in second column).  Wells highlighted in orange demonstrated a significant difference in tests of both β-
galactosidase and alkaline phosphatase activities.  
 
 
1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12
A - - 1 2 3 4 5 6 7 8 9 A - - 1 2 3 4 5 6 7 8 9
B 10 11 12 13 14 15 16 17 18 19 20 21 B 10 11 12 13 14 15 16 17 18 19 20 21
C 22 23 24 25 26 27 28 29 30 31 32 33 C 22 23 24 25 26 27 28 29 30 31 32 33
D 34 35 36 37 38 39 40 41 42 43 44 45 D 34 35 36 37 38 39 40 41 42 43 44 45
E 46 47 48 49 50 51 52 53 54 55 56 E 46 47 48 49 50 51 52 53 54 55 56
F 57 58 59 60 61 62 63 64 65 66 67 68 F 57 58 59 60 61 62 63 64 65 66 67 68
G 69 70 71 72 73 74 75 76 77 78 79 80 G 69 70 71 72 73 74 75 76 77 78 79 80
H 81 82 83 84 85 86 87 88 89 90 91 92 H 81 82 83 84 85 86 87 88 89 90 91 92
1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12
A - - 93 94 95 96 97 98 99 100 101 102 A - - 93 94 95 96 97 98 99 100 101 102
B 103 104 105 106 107 108 109 110 111 B 103 104 105 106 107 108 109 110 111
C 112 113 114 115 116 117 118 119 120 121 122 C 112 113 114 115 116 117 118 119 120 121 122
D 123 124 125 126 127 128 129 130 131 132 133 D 123 124 125 126 127 128 129 130 131 132 133
E 134 135 136 137 138 139 140 141 E 134 135 136 137 138 139 140 141
F 142 143 144 145 146 147 148 149 F 142 143 144 145 146 147 148 149
G 150 151 152 153 154 155 156 157 158 G 150 151 152 153 154 155 156 157 158
H 159 160 161 162 163 164 165 166 H 159 160 161 162 163 164 165 166
1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12
A - - 167 168 169 170 171 172 173 174 175 176 A - - 167 168 169 170 171 172 173 174 175 176
B 177 178 179 180 181 182 183 184 185 186 187 188 B 177 178 179 180 181 182 183 184 185 186 187 188
C 189 190 191 192 193 194 195 196 197 198 199 200 C 189 190 191 192 193 194 195 196 197 198 199 200
D 201 202 203 204 205 206 207 208 209 210 211 212 D 201 202 203 204 205 206 207 208 209 210 211 212
E 213 214 215 216 217 218 219 220 221 222 223 224 E 213 214 215 216 217 218 219 220 221 222 223 224
F 225 226 227 228 229 230 231 232 233 234 235 236 F 225 226 227 228 229 230 231 232 233 234 235 236
G 237 238 239 240 241 242 243 244 245 246 247 248 G 237 238 239 240 241 242 243 244 245 246 247 248
H 249 250 251 252 253 254 255 256 257 258 259 H 249 250 251 252 253 254 255 256 257 258 259
1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12
A - - 260 261 262 263 264 265 266 267 268 269 A - - 260 261 262 263 264 265 266 267 268 269
B 270 271 272 273 274 275 276 277 278 279 280 281 B 270 271 272 273 274 275 276 277 278 279 280 281
C 282 283 284 285 286 287 288 289 290 291 292 293 C 282 283 284 285 286 287 288 289 290 291 292 293
D 294 295 296 297 298 299 300 301 302 303 304 305 D 294 295 296 297 298 299 300 301 302 303 304 305
E 306 307 308 309 310 311 312 313 314 315 316 317 E 306 307 308 309 310 311 312 313 314 315 316 317
F 318 319 320 321 322 323 324 325 326 327 328 F 318 319 320 321 322 323 324 325 326 327 328
G 329 330 331 332 333 334 335 336 337 338 339 G 329 330 331 332 333 334 335 336 337 338 339
H 340 341 342 343 344 345 346 347 348 349 350 351 H 340 341 342 343 344 345 346 347 348 349 350 351
1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12
A - - 352 353 354 355 356 357 358 359 360 361 A - - 352 353 354 355 356 357 358 359 360 361
B 362 363 364 365 366 367 368 B 362 363 364 365 366 367 368
C 369 370 371 372 373 374 375 376 377 378 379 380 C 369 370 371 372 373 374 375 376 377 378 379 380
D 381 382 383 384 385 386 387 388 389 390 391 392 D 381 382 383 384 385 386 387 388 389 390 391 392
E 393 394 395 396 397 398 399 400 401 402 403 404 E 393 394 395 396 397 398 399 400 401 402 403 404
F 405 406 407 408 409 410 411 412 413 414 415 416 F 405 406 407 408 409 410 411 412 413 414 415 416
G 417 418 419 420 421 422 423 424 425 426 427 428 G 417 418 419 420 421 422 423 424 425 426 427 428
H 429 430 431 432 433 434 435 436 437 438 439 H 429 430 431 432 433 434 435 436 437 438 439
1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12
A - - 440 441 442 443 444 445 446 447 448 449 A - - 440 441 442 443 444 445 446 447 448 449
B 450 451 452 453 454 455 456 457 458 459 460 461 B 450 451 452 453 454 455 456 457 458 459 460 461
C 462 463 464 465 466 467 468 469 470 471 472 473 C 462 463 464 465 466 467 468 469 470 471 472 473
D 474 475 476 477 478 479 480 481 482 483 484 485 D 474 475 476 477 478 479 480 481 482 483 484 485
E 486 487 488 489 490 491 492 493 494 495 496 497 E 486 487 488 489 490 491 492 493 494 495 496 497
F 498 499 500 501 502 503 504 505 506 507 508 509 F 498 499 500 501 502 503 504 505 506 507 508 509
G 510 511 512 513 514 515 516 517 518 519 520 521 G 510 511 512 513 514 515 516 517 518 519 520 521
H 522 523 524 525 526 527 528 529 530 531 532 - H 522 523 524 525 526 527 528 529 530 531 532 -
β-galactosidase Alkaline phosphatase
Plate 1
Plate 2
Plate 3
Plate 4
Plate 5
Plate 6
  138 
 
Figure 6.11 Mean quantile normalized fold change β-galactosidase output for n = 253 mutants exhibiting significantly 
altered β-galactosidase or alkaline phosphatase activity. The quantile normalised data are coded from red (highest QN 
ranking value = 4.135) through yellow (0) to green (lowest QN ranking value = -4.422). Mutants differing significantly from 
wild type in β-galactosidase tests in black, while those significant in alkaline phosphatase tests in grey. Top and bottom 20 
ranked mutants in double boxes, and those with significant p values (p<0.05) selected for further analysis (highlighted in 
grey).  
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Figure 6.12 Mean quantile normalized fold change alkaline phosphatase output for n = 253 mutants exhibiting 
significantly altered β-galactosidase or alkaline phosphatase activity. The quantile normalised data are coded from red 
(highest QN ranking value = 4.258) through yellow (0) to green (lowest QN ranking value = -4.146). Mutants differing 
significantly from wild type in alkaline phosphatase tests in black, while those significant in alkaline phosphatase tests in 
grey. Top and bottom 20 ranked mutants in double boxes, and those with significant p values (p<0.05) selected for further 
analysis (highlighted in grey). 
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Table 6.2 Mutants selected for rescreening in 96-well format. Heatmaps represent the quantile normalised fold change 
data for each test (n = 3), and are coded from red (highest QN ranking) through yellow (0) to green (lowest QN ranking). 
 
 
6.3.5 Confirmational transcriptional rescreen of selected significant mutants  
The 30 pMP220-intA-conjugated mutants selected for rescreening (Table 6.2) were inoculated into a 
new 2 ml 96-deep well block and rescreened again in biological triplicate exactly as previously. The 
parental wild type strain was this time included within the plate, so that each biological replicate 
could be normalised to a within-plate wild type control. 
 
β-galactosidase and alkaline phosphatase activity in protein extracts was again assessed in technical 
duplicate (Figure 6.13A and Appendix 6.4, columns L - Q) and normalised to the within-plate wild 
type control (Figure 6.13B and Appendix 6.4, columns R - W). The noise in the data was significantly 
less in the rescreen, possibly due to the reduced number of samples being processed leading to 
improved accuracy. Quantile normalisation was therefore deemed unnecessary. Log2 of normalised 
Bio 1 Bio 2 Bio 3
p value 
(yellow 
p<0.05)
Bio 1 Bio 2 Bio 3
p value 
(yellow 
p<0.05)
2 PA14_30650 gacA response regulator GacA Gac-related gene 0.0065 0.0306
12 PA14_06330 putative putative homoserine kinase type II SerThr Kinase 0.0170 0.0159
15 PA14_10770 putative sensor/response regulator hybrid SerThr Kinase 0.0617 0.0136
21 PA14_36810 katE catalase HPII Catalase 0.6034 0.0181
25 PA14_58000 sodM superoxide dismutase SOD 0.2424 0.0299
27 PA14_64700 putative sigma-70 factor, ECF subfamily Sigma factors 0.6388 0.0009
32 PA14_33260 pvdS sigma factor PvdS Sigma factors 0.0159 0.0129
48 PA14_06950 putative transcriptional regulator, LuxR family Transcriptional regulator 0.0882 0.0159
59 PA14_19670 putative transcriptional regulator, LysR family Transcriptional regulator 0.1258 0.0004
62 PA14_14480 putative transcriptional regulator Transcriptional regulator 0.8661 0.0005
74 PA14_23060 hexR putative transcriptional regulator, RpiR family Transcriptional regulator 0.7398 0.0031
79 PA14_71070 putative transcriptional regulator, AraC family Transcriptional regulator 0.1255 0.0021
150 PA14_34660 gntR transcriptional regulator GntR Transcriptional regulator 0.0249 0.0624
191 PA14_19850 putative transcriptional regulator Transcriptional regulator 0.0124 0.0215
279 PA14_21720 putative transcriptional regulator, AraC family Transcriptional regulator 0.8546 0.0047
285 PA14_67550 putative transcriptional regulator Transcriptional regulator 0.4853 0.0089
291 PA14_67170 putative LysR-family transcriptional regulator Transcriptional regulator 0.9238 0.0082
393 PA14_72690 putative glutamine synthetase TCS 0.0371 0.0330
394 PA14_13660 putative protein phosphatase TCS 0.0351 0.0944
403 PA14_20750 putative chemotaxis signal transduction protein TCS 0.2830 0.0176
421 PA14_38140 putative glutamine synthetase TCS 0.0743 0.0036
438 PA14_31900 putative efflux transporter TCS 0.0173 0.0082
455 PA14_30840 putative signal transduction histidine kinase TCS 0.0276 0.3667
494 PA14_68290 dctM probable C4-dicarboxylate transporter TCS 0.0094 0.5597
495 PA14_27810 putative two-component response regulator TCS 0.0198 0.0171
520 PA14_36420 putative histidine kinase TCS 0.0478 0.0084
525 PA14_06060 creB two-component response regulator CreB TCS 0.0219 0.7123
527 PA14_49180 phoP two-component response regulator PhoP TCS 0.0018 0.4936
531 PA14_11630 probable two-component sensor TCS 0.0291 0.0215
532 PA14_26810 putative two-component sensor histidine kinase TCS 0.0228 0.0368
Alkaline phosphatase output
UID Locus Gene Function Group
β-galactosidase output
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activity was therefore calculated (Figure 6.13C and Appendix 6.4, columns X – AC) and this time 
directly heatmapped and subjected to t-tests against zero without prior quantile normalisation 
(Figure 6.13D and Appendix 6.4, column AD). 
 
 
Figure 6.13 Data analysis pipeline for rescreen of mutants with significant phenotypes in the library transcriptional 
screen.  
 
As observed in the original screen, alkaline phosphatase activity was largely higher in 
transconjugated transposon mutants than in the transconjugated wild type isolates (Table 6.3). This 
suggests that transcriptional regulation of Pc activity occurs mostly via repression. Five mutants that 
had displayed a significant deviation from wild type behaviours in the original screen were 
reproducibly deviant in the rescreen: PA14_30650 (UID 2), PA14_72690 (UID 393), PA14_20750 (UID 
403), PA14_36420 (UID 520) and PA14_11630 (UID 531) (Table 6.3). PA14_13660 (UID 394) was also 
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selected as worthy of further study, as it (a) displayed highly significant decreased alkaline 
phosphatase activity compared with wild type in the rescreen, having (b) been one of only 5 mutants 
exhibiting lower alkaline phosphatase activity compared with wild type in the original screen. In the 
original screen, this mutant had narrowly failed to meet the 5 % significance threshold due to one 
biological replicate (rep number 2) displaying an extremely low phenotype compared to the other 
two replicates.  
 
β-galactosidase activity in the rescreen was not observed to be biased towards either activating or 
repressing regulation (Table 6.4). This suggests that the activity of the integrase promoter is 
governed by both activating regulators and repressing regulators. β-galactosidase activity in the 
protein extracts from biological replicate 1 was abnormally high across both technical replicates 
when compared with biological replicates 2 and 3. This is possibly due to unknown differences in 
environmental conditions during culture or protein extraction, but as these assays behaved 
inconsistently with the other biological replicates in the rescreen as well as the original screen, it was 
decided that this biological replicate should be eliminated from statistical analyses of the rescreen. 
Statistical analysis of the remaining replicates revealed two mutants that retained significance in the 
rescreen: PA14_06330 (UID 12) and PA14_33260 (UID 32).  
 
Taken together, the data obtained during this study identified 8 genes in P. aeruginosa PA14 whose 
mutation reproducibly impacts on transcription from either Pint or Pc.  
 
 
  143 
Table 6.3 Alkaline phosphatase assay output from mutants rescreened in 96 well high-throughput format. 
 
  
  144 
 
 
Table 6.4 β-galactosidase assay output from mutants rescreened in 96 well high-throughput format. 
 
 
  145 
6.3.6 Further examination of integron promoter activities in the putative glutamine synthetase 
homologue mutant, PA14_72690::Tn. 
PA14_72690::Tn, the mutant strain which displayed reduced transcription from both integron 
promoters, is annotated as a putative glutamine synthetase homologue. Upon further investigation 
[329], this gene was discovered to be an orthologue of PA5508 from P. aeruginosa PAO1, which 
encodes an enzyme that exhibits γ-glutamyl aromatic monoamine ligase activity [330]. Although the 
primary substrate and product of this enzyme is currently unknown, the enzyme appears to utilise 
glutamate as a substrate in the conversion of biogenic amines to their corresponding γ-glutamyl 
derivatives [330]. Therefore, to examine whether the reduced expression we observed in this 
mutant from both integron promoters could be explained by an accumulation of substrate, we 
examined transcription of the wild type and mutant with and without an excess of glutamate. 
 
Duplicate wells of pMP220-intA-conjugated wild type and PA14_72690::Tn were grown for 24 hr in 
96 deep well culture in a volume of 1.5 ml in LB with tetracycline 30 µg/ml (plus gentamicin 15 µg/ml 
for the mutant). Glutamate was then added to one of the wild type and one mutant well to a final 
concentration of 10 mM, and the plate incubated for a further two hours. Cells were then harvested 
by centrifugation, and total protein harvested by freeze-thawing on dry ice in 50 µl TE lysis buffer 
and quantified by BCA assay. β-galactosidase and alkaline phosphatase activity from these total 
protein extracts was assessed as a measure of expression from Pint and Pc respectively. The activity 
levels for each assay were then normalised to the wild type strain (without excess glutamate) by 
dividing activity levels by the mean wild type activity for each biological replicate (Figure 6.14). 
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Figure 6.14 Effect of excess glutamate on expression from integron promoters in wild type and PA14_72690::Tn 
containing pMP220-intA, following growth in LB followed by 2 hour stimulation +/- xs glutamate. Expression of Pint 
assayed by LacZ activity (A) and expression of Pc assayed by PhoA activity (B). Each data point represents a single technical 
replicate, from one of four independent cultures, with each assay performed in technical triplicate. Error bars represent 
the standard deviations of the mean. Values which are significantly different from the Wild type LB control by one way 
ANOVA, followed by Dunnett’s multiple comparison post hoc test, indicated by asterisks (ns = not significant, *** ≤ 0.001). 
 
This screen suggested that the reduced activity observed in the transcriptional screen was not due to 
an excess of glutamate substrate in the mutant: the addition of glutamate to the wild type did not 
cause a decrease in transcriptional activity from either promoter, nor did it exacerbate the effect on 
the mutant (Figure 6.14).  
6.4 Discussion 
The main objective of this chapter was to establish a rational high-throughput screen approach to 
identification of novel transcriptional regulators of Pint and Pc in P. aeruginosa. In order to 
accomplish this, a targeted selection of strains was extracted from the PA14 NR Set [281] to be 
screened for phenotypic changes in integron promoter expression. Ideally, the entire non-redundant 
transposon library would have been screened for novel transcriptional regulators, but the large 
number of mutants (n = 5850) made this impractical. The screened sub-library, generated by 
Jennifer Wilson (MRes student, Huw Williams), had been designed to include predicted regulatory 
mutants. However, we observed that mutants of a number of key regulators were absent from this 
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sub-library, including the catabolite repression control protein Crc, and RecA, the SOS sensor protein 
[195, 331].  
 
The reliability of the assay was good, as demonstrated by consistency between reporter assay 
technical replicates, however, a lot of noise was observed between samples (biological replicates – 
Figure 6.9A), hence the need to quantile normalise the data before between-replicate comparisons 
could be made. This might indicate a high degree of sensitivity to environmental conditions in the 
integron system. The cassette promoter in particular appears very sensitive to disturbance, as 
demonstrated by the high number of mutants in the large library screen displaying a significant 
difference compared to wild type (Figure 6.12, mutants in bold font).  
 
Upon ranking the significant mutants from both assay conditions according to the magnitude of 
change (Figures 6.11 and 6.12), it becomes apparent that there is a strong trend towards inverse 
correlation of the significant phenotypes for each reporter assay: the significant hits for the β-
galactosidase screen of Pint regulation tend to be clustered at the lower end of the ranking, indicating 
a propensity for reduced Pint activity in these mutants (Figure 6.11), while the significant hits for the 
alkaline phosphatase screen of Pc regulation tend to be clustered at the upper end of the ranking, 
indicating a tendency for increased Pc activity in these mutants (Figure 6.12). 8 of the 10 mutants 
which displayed significant phenotypes in both screens demonstrated increased alkaline 
phosphatase activity paired with reduced β-galactosidase activity (Figure 6.13), providing support for 
our model of interdependent regulation of the integron promoters (Chapter 1.4). Eight hits, in which 
both the high-throughput screen and conformational rescreen returned statistically significant 
results in the same direction (i.e. the same promoter was consistently either up- or down-regulated), 
were identified from the transcriptional screen, with the % change in expression compared with wild 
type shown in Table 6.5. 
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Table 6.5 Average % change in expression compared with wild type for the 8 mutants which were identified as 
significantly different in both the high throughput transcriptional screen and the confirmational rescreen. % change 
calculated from wild type normalised activities (Figure 6.5B), and is the average of 3 biological replicates, with each assay 
performed in technical duplicate. 
 
 
Two of these hits displayed reduced Pint activity, four displayed increased Pc activity, and two showed 
decreased Pc activity. Seven of these mutants have roles with relevance to P. aeruginosa existing as 
part of a host- colonising bacterial community: four are involved in chemotaxis/motility 
(PA14_30650 [332], PA14_13660 [333-335], PA14_20750 [273, 336-339] and PA14_11630 [340]), 
three in biofilm formation (PA14_30650 [341], PA14_13660 [333-335], and PA14_36420 [342]), one 
in antibiotic resistance (PA14_06330 [343]), and one in iron starvation (PA14_33260 [344, 345]).  
 
The remaining mutant was PA14_72690, the mutant strain which displayed reduced transcription 
from both integron promoters in the high-throughput screen, and is annotated as a putative 
glutamine synthetase homologue that exhibits γ-glutamyl aromatic monoamine ligase activity [329, 
330]. Further examination of this mutant showed that the reduced activity observed in the 
transcriptional screen was not due to an excess of glutamate substrate in the mutant (Figure 6.14), 
but we are yet to establish the mechanism of this resistance. However, as an enzyme with a single 
High 
throughput 
screen
Rescreen
2|PA14_30650-i 373 157
393|PA14_72690 69 41
394|PA14_13660 53 22
403|PA14_20750 329 158
520|PA14_36420 143 133
531|PA14_11630-ii 148 157
12|PA14_06330 51 82
32|PA14_33260 53 62
UID | Gene_ID
Alkaline phosphatase hits
β-galactosidase hits
Average % change 
compared with wild type
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active site [330], inactivation of which results in decreased transcription from both Pint and Pc 
(average activity levels of 40 % and 69 % respectively compared with wt in high-throughput 
transcriptional screen), and for which effective inhibitors may already exist [346, 347], this could 
represent an extremely interesting drug target for inhibition of integron activities.  
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7 Screen for regulators of integron-mediated drug resistance 
7.1 Introduction 
In chapter 6, we looked at transcriptional regulation of integron promoters to identify novel 
transcriptional regulators. However, the more fundamental question is whether this results in 
functional differences in response to carbapenem exposure. 
 
As demonstrated in Chapter 3.3.3, Pc-mediated expression of blaVIM-1 in plasmid pEVM2a confers a 
high level of imipenem resistance to P. aeruginosa, with a MIC breakpoint of 1024 µg/ml in wild type 
P. aeruginosa PA14 harbouring pEVM2a, compared to 2 µg/ml without the plasmid. We 
hypothesised that alterations in blaVIM-1 expression from Pc as a result of mutations in genes 
regulating integron cassette promoter activity would result in altered susceptibility to imipenem. We 
therefore performed a second screen of the previously examined P. aeruginosa PA14 sub-library, 
this time expressing blaVIM-1 under the control of Pc, to examine the more directly biologically 
relevant question of drug susceptibility.  
 
7.2 Objectives 
The work described in this chapter involves re-examination of the PA14NR Set regulatory sub-library 
which was screened in chapter 6 for novel transcriptional regulators, to identify mutants conferring 
functionally significant differences in imipenem tolerance upon expression of a blaVIM-1 
carbapenemase cassette from Pc. 
 
Objectives:  
• High-throughput functional screen of PA14NR Set sub-library 
• Low throughput functional screen of sample of significant hits from functional screen. 
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7.3 Results 
7.3.1 High-throughput functional screen 
To provide the sub-library mutants with an appropriate Pc- regulated carbapenemase cassette from 
which the functional differences in expression could be examined, plasmid pEVM2a was first 
conjugated into the sub-library, as described in chapter 2.7.3. A similar selection strategy to that 
employed in chapter 6.1 was used to confirm that all strains necessary for conjugation of pEVM2a 
into PA14NR set mutants were present within the conjugation reactions (Table 7.1); pEVM2a (Figure 
3.3) and pMP220-intA (Figure 4.6) share a pMP220-based backbone, allowing tetracycline to be used 
as a marker for plasmid acquisition. However, since the donor strain is β-lactam resistant due to the 
blaVIM-1 cassette carried on pEVM2a, ampicillin was removed from the panel as a P. aeruginosa 
selection agent, leaving gentamicin as the most appropriate means of selecting PA14NR Set MarxT7 
transposon mutants.  
 
Table 7.1 Antibiotic selection panel used for conjugation of pEVM2a into PA14NR Set mutants. All three components of 
each conjugation reaction (helper, donor and recipient strains) plated on all media types. 
 
 
Helper Donor Recipient Transconjugants 
(E. coli 
1047/pRK2013) 
(E. coli 
DH5α/pEVM2a) 
(P. aeruginosa 
PA14::MrT7) 
(P. aeruginosa 
PA14:: 
MrT7/pEVM2a) 
LB √ √ √ √ 
PIA X X √ √ 
LB + kanamycin 50 µg/ml √ X √ √ 
LB + gentamicin 15 µg/ml X X √ √ 
LB + tetracycline 120 µg/ml X √ X √ 
LB + gentamicin 15 µg/ml + 
tetracycline 120 µg/ml X X X √ 
 
5 µl spots of the conjugation mixtures and all three individual reaction components (helper, donor 
and recipient strains) were plated on all 6 media types and incubated for 24-48 hours at 37 °C. Plates 
were manually examined for correct growth on all control plates, and successfully conjugated 
mutants were inoculated into 600 µl LB broth containing gentamicin 15 µg/ml + tetracycline 30 
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µg/ml, from which storage plates were made as previously. 36 mutants failed to grow either on 
conjugation selection plates or following inoculation into liquid culture, and were therefore 
considered not to have been successfully conjugated (Table 7.2). 
 
Table 7.2 PA14NR Set mutants into which pEVM2a was not successfully conjugated.  
Plate Unconjugated wells 
1 C12, D7, D9, D11, D12, E2  
2 C9, E8, G11, H8 
3 A8, D7, D8, E3, F4, G2, G5, G6, H7 
4 F5 
5 B4-B9, E2 
6 A8, A10, B3, B6, C2, C3, G2, G5, G8, H5 
 
To conduct the screen, overnight cultures of strains harbouring pEVM2a were set up in 400 µl LB 
containing 30 µg/ml tetracycline and 15 µg/ml gentamicin in a 2 ml 96-well deepwell block and 
incubated overnight at 37 °C with shaking at 180 rpm. Each plate included a pEVM2a-conjugated 
wild type control (A1) and an uninoculated LB well (A2) to ensure confidence in the inoculation of 
other wells. 100 µl samples were then taken from each overnight culture and the OD600 measured to 
provide a measure of intrinsic growth rate (Figure 7.1A and Appendix 7.1, pEVM2a data - columns F 
– H). 1 ml LB containing 30 µg/ml tetracycline and 512 µg/ml imipenem (½ MIC) was then added to 
each of the remaining overnight wells, and blocks incubated at 37 °C for a further 18.5 hours, before 
the OD600 was read in duplicate (Figure 7.1B and Appendix 7.1, pEVM2a data - columns L – Q). The 
technical duplicate OD600 readings were then averaged to give a single mean value for each of the 
three biological replicates (Figure 7.1C and Appendix 7.1, pEVM2a data - columns R - T).  
 
In order to correct for intrinsic differences in growth rate between mutants, individual correction 
factors were calculated by dividing the OD600 reading of the overnight starter culture by the OD600 for 
the wild type control (Figure 7.1A and Appendix 7.1, pEVM2a data - columns I - K). The mean OD600 
test readings were then corrected for growth by multiplying by this correction factor (Figure 7.1D 
and Appendix 7.1, pEVM2a data - columns U - W). Finally, data were normalised to the within-plate 
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wild type control (Figure 7.1E and Appendix 7.1, pEVM2a data - columns X - Z), transformed to the 
binary logarithm (Figure 7.1F and Appendix 7.1, pEVM2a data - columns AA - AC), and quantile 
normalised using Genespring GX (Figure 7.1G and Appendix 7.1, pEVM2a data - columns AD - AF). 
Quantile normalised values were then subjected to t-tests against zero (Figure 7.1G and Appendix 
7.1, pEVM2a data - column AG), identifying 57 mutants with altered resistance phenotypes 
compared with wild type (Figure 7.2A). 
 
To establish that any altered resistance profiles identified were due to altered expression of a 
carbapenemase cassette rather than intrinsic resistance arising as a result of the mutation, this same 
process was also followed for the same strains containing pMP220-intA (Figure 7.1 and Appendix 
7.1, pMP220-intA control data). This construct functions as an appropriate and blaVIM-1-negative 
control as it is a similar sized plasmid, constructed in the same tetracycline resistant pMP220 vector 
backbone. These strains were treated in LB containing 30 µg/ml tetracycline and 1 µg/ml imipenem 
(½ wild type MIC) in a 2 ml 96-well deepwell block, and the resulting OD600 data analysed in the same 
manner, leading to identification of 58 strains exhibiting a statistically significant difference 
compared to the wild type (Figure 7.2B).  
 
In both the test (+pEVM2a) and control (+pMP220-intA) screens, mutants in which the overnight 
cultures failed to grow were identified on a plate-by-plate basis and excluded from analysis (Figure 
7.2A and B, pink crossed through wells). Strains exhibiting a statistically significant difference 
compared with wild type were then compared between screens: three mutants displayed significant 
effects in both screens (Figure 7.2C, red highlighted wells), indicating that any difference in 
carbapenem tolerance observed in these strains was due to the mutation itself rather than a result 
of differential of blaVIM-1 expression. Further confidence in the validity of the assay was 
demonstrated by the varied within-plate distribution of the 54 remaining significant strains 
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throughout the 96-well plates, as the statistically significant strains did not appear to cluster and 
therefore do not appear to indicate any unintended experimental bias (Figure 7.2C). 
 
The greatest difference between control and mutant came when resistance was increased (Figure 
7.3). Decreased resistance resulted in a much smaller difference compared with wild type, but much 
tighter replicates (Figure 7.3, green crosses). Increased resistance resulted in a much wider data set 
with a greater magnitude of change (Figure 7.3, red crosses).  
 
 
Figure 7.1 Data analysis pipeline for functional screen of mutant library.  
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1 2 3 4 5 6 7 8 9 10 11 12
A WT - 2 3 4 5 6 7 8 9 10 11
B 12 13 14 15 16 17 18 19 20 21 22 23
C 24 25 26 27 28 29 30 31 32 33 34 35
D 36 37 38 39 40 41 42 43 44 45 46 47
E 48 49 50 51 52 53 54 55 56 57 58 59
F 60 61 62 63 64 65 66 67 68 69 70 71
G 72 73 74 75 76 77 78 79 80 81 82 83
H 84 85 86 87 88 89 90 91 92 93 94 95
1 2 3 4 5 6 7 8 9 10 11 12
A WT - 2 3 4 5 6 7 8 9 10 11
B 12 13 14 15 16 17 18 19 20 21 22 23
C 24 25 26 27 28 29 30 31 32 33 34 35
D 36 37 38 39 40 41 42 43 44 45 46 47
E 48 49 50 51 52 53 54 55 56 57 58 59
F 60 61 62 63 64 65 66 67 68 69 70 71
G 72 73 74 75 76 77 78 79 80 81 82 83
H 84 85 86 87 88 89 90 91 92 93 94 95
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E 48 49 50 51 52 53 54 55 56 57 58 59
F 60 61 62 63 64 65 66 67 68 69 70 71
G 72 73 74 75 76 77 78 79 80 81 82 83
H 84 85 86 87 88 89 90 91 92 93 94 95
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B 12 13 14 15 16 17 18 19 20 21 22 23
C 24 25 26 27 28 29 30 31 32 33 34 35
D 36 37 38 39 40 41 42 43 44 45 46 47
E 48 49 50 51 52 53 54 55 56 57 58 59
F 60 61 62 63 64 65 66 67 68 69 70 71
G 72 73 74 75 76 77 78 79 80 81 82 83
H 84 85 86 87 88 89 90 91 92 93 94 95
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A WT - 2 3 4 5 6 7 8 9 10 11
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A WT - 2 3 4 5 6 7 8 9 10 11
B 12 13 14 15 16 17 18 19 20 21 22 23
C 24 25 26 27 28 29 30 31 32 33 34 35
D 36 37 38 39 40 41 42 43 44 45 46 47
E 48 49 50 51 52 53 54 55 56 57 58 59
F 60 61 62 63 64 65 66 67 68 69 70 71
G 72 73 74 75 76 77 78 79 80 81 82 83
H 84 85 86 87 88 89 90 91 92 93 94 95
Plate 5
Plate 6
+ pEVM2a
Plate 1
Plate 2
Plate 3
Plate 4
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1 2 3 4 5 6 7 8 9 10 11 12
A WT - 2 3 4 5 6 7 8 9 10 11
B 12 13 14 15 16 17 18 19 20 21 22 23
C 24 25 26 27 28 29 30 31 32 33 34 35
D 36 37 38 39 40 41 42 43 44 45 46 47
E 48 49 50 51 52 53 54 55 56 57 58 59
F 60 61 62 63 64 65 66 67 68 69 70 71
G 72 73 74 75 76 77 78 79 80 81 82 83
H 84 85 86 87 88 89 90 91 92 93 94 95
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Figure 7.2 Distribution of functional screen significant hits within sub-library. (A) Test screen, with sub-library + pEVM2a. 
(B) blaVIM-1 negative control screen, with sub-library + pMP220-intA. (C) Merge of test and control screens. Wells labelled 
by plate-specific functional screen unique identifier (FS_UID). Strains omitted due to non-growth of overnight cultures 
highlighted by pink crossed-through boxes. Wells containing significant results in the test screen are highlighted in yellow, 
significant results from the blaVIM-1-negative control screen are highlighted in blue, with three strains significant in both 
screens highlighted in red in C. 
.
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Figure 7.3 Significant hits from functional screen of n = 532 mutants under carbapenem stress. Each data point represents a single independent culture, with each assay 
having been performed in technical duplicate. Error bars represent the standard deviations of the mean. All mutants displayed significantly different quantile normalised 
log2 growth compared with wild type by Student t test (p ≤ 0.05). 
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Table 7.3. Identification of functional screen significant hits, sorted by sub-library location, alongside quantile 
normalised data output. Data coloured according to magnitude of change of effect compared to wild type.Wild type 
normalised to zero, with red coloured boxes indicating increased tolerance in that replicate, and green indicating reduced 
tolerance compared to wild type. 
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Figure 7.4 Venn diagram summarising the mutants highlighted in the functional screen of Pc-regulated β-lactamase 
expression (chapter 7), the transcriptional screen for differential Pint transcription (chapter 6 – β-galactosidase screen 
output), and the transcriptional screen for differential Pc transcription (chapter 6 – alkaline phosphatase screen output). 
The mutants within each sector are listed in Appendix 7.2 
 
7.4 Discussion 
This chapter aimed to establish a rational high-throughput screen to identify mutants in the 
previously examined sub-library of P. aeruginosa mutants that displayed an integron-mediated 
functional difference in response to carbapenem exposure. 
 
In our model of co-ordinated integron promoter regulation, decreased survival in this screen, as was 
observed in 30 mutants (Table 7.3), implies a lack of Pc induction by IntI1, due to lower levels of 
expression from Pint compared with wt. These mutants would make good drug targets for the 
purpose of co-treatments alongside antibiotic therapy, in order to reduce the spread of integron-
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associated resistance determinants. The remaining 24 mutants which exhibit increased carbapenem 
tolerance may also warrant investigation as drug targets, but via means other than inhibition of 
target expression or activity. 
 
The reliability of this assay methodology appears to be good, since there are multiple examples of 
mutant duplications in the library being repeatedly selected: two distinct mutants each of 
PA14_10770 and PA14_43380 were both selected, as was a single rhlR mutant (PA14_19120) which 
appears to have been accidentally duplicated within the library, with both inclusions being selected 
(Table 7.3). 
 
The overlap of results from the transcriptional screen is encouraging, since 24 (44 %) of the 54 hits 
from the functional screen described in this chapter were also identified in the high-throughput 
transcriptional screen (Chapter 6.3.4). None of the 8 final hits from the transcriptional screen also 
emerged from the functional screen, although 10 of the functional screen hits with increased 
carbapenem tolerance also displayed increased transcription from Pc in the original transcriptional 
screen (PA14_05410, PA14_22370, PA14_27230, PA14_31620, PA14_31900, PA14_35540, 
PA14_43380, PA14_47240, PA14_47270 and PA14_65450 – data not shown), despite this effect not 
being maintained during rescreening. Three of these hits, PA14_05410, PA14_27230 and 
PA14_31900, were identified in all three screens (Figure 7.4 and Appendix 7.2), as exhibiting 
decreased Pint activity and increased Pc activity under normal growth conditions (Table 6.2), and 
increased imipenem tolerance (Table 7.3).  
 
PA14_05410 encodes an orthologue of PA0415 from P. aeruginosa PAO1 [329], which encodes 
ChpC, a CheW homologue in the pilGHIJKchpABCD operon which is involved in twitching motility 
[348, 349]. Along with the other CheW homologue in the operon, PilI, ChpC is responsible for 
coupling the methyl accepting chemotaxis protein, PilJ, to the CheA-like histidine kinase of this 
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complex chemosensory pathway, ChpA; the presence of two CheW homologues in the system has 
been suggested to facilitate the input of multiple environmental signals to the bacterium, to control 
twitching motility [348]. Despite mutation of the chpC component resulting in increased colonisation 
of the lung and liver in a mouse model of acute pneumonia, the Chp system is required for full 
virulence [348]. Since the Chp system has been demonstrated to directly affect intracellular levels of 
cAMP through modulation of adenlate cyclase activity, with chpC mutants producing increased 
cAMP [349], it is likely that the effect of chpC mutation on the expression of integron genes is an 
indirect result of increased cAMP levels activating another regulator (for example, Vfr [350]) that 
either directly or indirectly affects integron regulation. To investigate whether this is the case, future 
experiments may involve investigations of integron gene expression in P. aeruginosa strains with 
overexpressed and/or mutated adenylate cyclase genes, cyaA and cyaB [329]. 
 
PA14_27230 is an orthologue of PA2849, which encodes the hydroperoxide sensor OhrR [329], and 
regulates the expression of an organic peroxide-specific peroxiredoxin, ohr. Despite the lack of an 
identifiable integron-associated OhrR box, as identified in Agrobacterium tumefaciens [351] and P. 
aeruginosa [352], as a DNA binding protein that plays a global regulatory role in sensing and 
responding to oxidative stress in pathogenic bacteria including B. subtilis and Xanthomonas 
campestris [353-356], OhrR may represent a direct novel transcriptional regulator of integron 
activities. As a DNA binding protein, future work to determine whether OhrR is a direct regulator of 
the integron platform will include techniques to identify DNA-protein interactions, such as 
electrophoretic mobility shift and DNase footprinting assays. Alternatively, since overlap exists 
between many signalling pathways, including OhR and SOS which both respond to reactive oxygen 
species [318, 357], the effect of ohrR mutation on integron gene expression may be through 
induction of an alternative pathway.  
 
  163 
PA14_31900 is an orthologue of the muxC component of the MuxABC-OpmB RND-type multidrug 
efflux pump, PA2526 [329, 358]. MuxC is one of two essential RND (Resistance-Nodulation-Division) 
components in this RND family transporter [358], which is one of a widespread group of active efflux 
pumps in Gram negative bacteria that are responsible for the active export of many antibiotics and 
chemotherapeutic agents [359].  
 
Future work to examine whether the regulatory effect of these mutants is via induction of SOS could 
involve mutating the SOS box of pEVM2a and rescreening these mutants. A loss of regulatory effect 
under these conditions would confirm that the effect was indirect and due to the previously 
described LexA-mediated repression of Pint. 
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8 Analysis of integron activities in a murine gut model of Pseudomonas 
aeruginosa infection 
8.1 Introduction 
In vitro work can only take us so far before it becomes necessary to confirm relevance of findings in 
a real-life infection situation. Therefore animal studies are required. One of the main challenges is to 
identify and implement an appropriate model. As P. aeruginosa is most frequently encountered in 
human populations as a chronic coloniser of epithelial surfaces such as the lung, with acute 
infections generally a result of subsequent dissemination, chronic in vivo colonisation models with 
the potential for induction of dissemination are ideal. A gut colonisation model was selected rather 
than one of the more commonly used chronic lung infection models (Chapter 1.3.4) since, although 
the GI tract is not a common site for Pseudomonas infection per se, the human GI tract is commonly 
colonised by P. aeruginosa and endogenous P. aeruginosa strains in the GI flora have repeatedly 
been shown to be the source of lung infections in both CF and intensive-care populations [216, 360]. 
The GI tract is also a major human reservoir from which integron-associated carbapenemases are 
identified, so is further clinically relevant [291]. 
 
At the time of commencing this PhD, no chronic models of P. aeruginosa infection/colonisation were 
in use at Imperial College London, much less anything involving bioluminescent strains. Furthermore, 
a model that could facilitate experiments involving simultaneous introduction and detection of 
multiple bacterial strains was deemed desirable. 
8.2 Objectives 
The research described in this chapter was undertaken to develop the tools required to study 
integron-associated carbapenem resistance in an in vivo model of chronic P. aeruginosa colonisation.  
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Objectives: 
• Establishment of in vivo murine model of P. aeruginosa gastrointestinal colonisation based 
on Kamei et al. [293]. 
• Assessment of bioluminescence as an in vivo reporter of P. aeruginosa colonisation. 
• Utilisation of model to assess fitness of P. aeruginosa strains identified as having a role in 
integron-mediated activities from transcriptional and functional library screens.  
8.3 Results 
8.3.1 Establishment of in vivo murine gastrointestinal colonisation model  
In order to establish a stable P. aeruginosa colonisation model using the method described by Kamei 
et al. [293], CD1 mice were colonised as outlined in Figure 8.1 and further described in Chapter 2.9. 
 
 
Figure 8.1 Murine gastrointestinal colonisation timeline. Mice were provided with drinking water containing 2 mg/ml 
streptomycin and 1500 U/ml penicillin G for 4 days prior to the introduction of bacteria in order to deplete the 
gastrointestinal microflora (days -4 – 0 – blue line). Water containing 1500 U/ml penicillin G and P. aeruginosa (107 cfu/ml) 
was then provided for six days, with the water replaced on day 3 to maintain bacterial levels (days 0 - 5 – red line). Sterile 
water containing 1500 U/ml penicillin G was then provided for a further 9 days (days 6 – 15, purple line). Stool samples 
were collected from individual mice on days 0, 2, 3, 4, 5, 6, 11 and 15, as indicated by black stars.  
 
No bacteria were recovered from the stools collected on day 0, indicating that the native 
gastrointestinal flora had been successfully eliminated by the prophylactic antibiotics to below the 
level of detection. P. aeruginosa strains PAO1 and PA14 both colonized the murine GI tract, with 
colonisation levels of 109 cfu/g stool attained two days after the start of oral feeding of bacteria with 
both strains. This level of colonisation was maintained for at least 9 days after withdrawal of bacteria 
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from the water. This suggests a stable bacterial colonisation as opposed to transient colonisation as 
a result of the continual intake of new bacteria from the drinking water. However, this apparently 
stable colonisation could be due to ingestion of bacteria shed in the stools, as it is well known that 
mice are coprophagic. 
 
Figure 8.2 Gastrointestinal colonisation levels in CD1 mice by P. aeruginosa strains PA01 (A) and PA14 (B). Crosses 
represent results from individual animals, and horizontal lines represent the mean (n = 4 per strain). Removal of bacteria 
from drinking water indicated by red dashed line. 
 
Next, in order to test the utility of bioluminescence as an alternative read out of in vivo colonisation, 
we utilised the same gastrointestinal colonisation model, this time employing two bioluminescent P. 
aeruginosa isolates supplied by Kevin Francis (Xenogen, Alameda, CA): Xen41 and Xen05. Both 
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strains carry genomic integrations of the lux operon, one in a PA01 background (Xen 41), one in a 
clinical strain background (Xen05) (http://www.perkinelmer.com/Content/TDLotSheet/119228-
%20Xen05.pdf). Four CD1 mice received prophylactic antibiotics as previously (2 mg/ml 
streptomycin and 1500 U/ml penicillin G) to deplete the native GI microbiota, after which they were 
separated into individual cages and fed water with 1500 U/ml penicillin G and approximately 107 
cfu/ml P. aeruginosa strains (PA01, Xen41, Xen5 and sterile control) for 4 days. Mice were imaged on 
day 4 post-infection using an IVIS Spectrum optical imaging system (PerkinElmer, MA). BLI was 
performed by Dr. James Collins (Frankel lab). No luminescent signal was visible from the uninfected 
control (Figure 8.3A) or the non-luminescent PA01 wild type control (Figure 8.3B), while the two 
animals carrying bioluminescent Pseudomonas displayed strong luminescent signals (Figure 8.3C and 
D). 
 
Figure 8.3 In vivo optical imaging of bioluminescent P. aeruginosa at day 4 p.i. No luminescence was detectable in the 
uninfected control (A) or the PA01 wild type control (B), while strong signals were observed in the mice colonised with 
Xen41 (C) and Xen05 (D).  
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When this signal was further examined, by dissection of the mice and ex vivo imaging of their 
digestive tracts and contents (Figure 8.4), it was established that the bacteria were localised to the 
tissue of the caecum and stomach, as well as the luminal contents. It may be worth considering 
whether the difference in primary location of the bioluminescent signal between mice colonised 
with different P. aeruginosa strains (caecum in Xen41-colonised mouse (Figure 8.4 A) c.f. stomach in 
Xen05-colonised mouse (Figure 8.4 B)) could be indicative of altered colonisation preferences of the 
clinical and non-clinical P. aeruginosa strains, or whether this may just be inter-host variation. 
However, this is an observation to be examined in future experiments with larger sample sizes, as n 
= 1 is insufficient to consider this a true difference between strains. 
 
Figure 8.4 Localisation of bacteria with ex vivo 2DBLI. The gastrointestinal tracts of the euthanised mice were extracted, 
dissected, washed in sterile PBS, and imaged. The bioluminescent signal was found to be most strongly located in the 
caecum of the Xen41-colonised mouse (A) and the stomach of the tissue of the Xen05-colonised mouse (B), as well as 
strongly in the caecal contents and stools of both mice. 
 
8.3.2 In vivo parallel fitness assay 
Having established a robust model of P. aeruginosa colonisation, the susceptibility to carbapenems 
and fitness for pathogenicity of P. aeruginosa mutants carrying integron-associated carbapenem 
resistance genes was assessed during murine GI colonization, using an in vivo parallel fitness assay. 
We hypothesised that this model could be used to perform a pooled mutant study of P. aeruginosa 
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mutants which had been shown in previous screens to contain mutations in genes regulating 
integron cassette promoter activity. These mutants, carrying integron-associated blaVIM-1 genes on 
plasmid pEVM2a (Chapter 3.3.3), would be examined for their fitness for pathogenicity as previously 
with low dose imipenem treatment, while a second group of mice receiving a high dose imipenem 
treatment would simultaneously inform us about altered susceptibility to imipenem through 
alterations in blaVIM-1 expression from Pc.  
 
As this experiment essentially constitutes an in vivo investigation of Pc regulation, the strains 
selected for this experiment were the 54 mutants displaying a significant phenotype in the 
functional screen described in chapter 7, plus 6 mutants displaying a significant phenotype in tests of 
Pc transcriptional regulation in chapter 6 (Table 8.1). Mice were to be simultaneously colonised with 
the entire pool of carbapenem-resistant mutants, then would receive either a high dose of 
imipenem (1333 µg/ml imipenem: 1.3 x MIC. Highest dose tested and safety reported in literature), a 
low dose of imipenem (512 µg/ml imipenem: ½ x MIC), or no drug. Stool samples were then to be 
assessed by qPCR to determine whether specific strains were more/less frequently recovered after 
treatment.  
 
A single primer was designed against the T7 promoter contained at each end of the MAR2xT7 
transposon (Appendix 8.1) used to make each of the mutants under investigation (5’ 
TAATACGACTCACTATAGGG 3’). A gene-specific primer was then designed for each mutant, to 
produce a PCR product of 250 – 350 bp when combined in a PCR reaction with the MAR2xT7 primer 
(Table 8.1). All primers were designed using the online primer design tool, Primer3 
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi).  
 
In order to determine whether each primer pair returned a single, clear product of the size expected, 
test qPCR reactions were performed with the T7 primer and each gene specific primer, using 
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SYBRGreen and the genomic DNA extracted from the input pool of water that was fed to the mice as 
template. Reactions were visualised on agarose gels (not shown) and the presence/absence of the 
expected product recorded (Table 8.1, final column). 46 of the 60 mutants in the pool did return a 
single, clear product in the test reactions with a 55 °C annealing temperature, therefore qPCR 
analysis of these mutants in the faecal DNA pools was deemed feasible. 
 
Table 8.1 Mutants selected for in vivo parallel fitness study due to their significance in either the functional screen (FS) 
or the alkaline phosphatase assays in the regulatory screen (RS-AP). A single oligonucleotide primer was designed within 
the mutated gene of each target, to amplify a PCR product of 250 – 350 bp in a reaction with the MAR2xT7 primer. 
 
 
CD1 mice were colonised as outlined in Figure 8.5 (n = 10 mice per group), and within-condition 
stool samples pooled at each time point and frozen at -80 °C within 30 mins of collection. Cages and 
Plate Well
PA14_30650 gacA response regulator GacA Gac-related gene 2 RS-AP 1 A4 CTCTTCGCAGACGGTGACTA Yes
PA14_10770 putative sensor/response regulator hybrid SerThr Kinases 15 FS 1 B6 CGAGTTCCTCGTTCTCCTTG No
PA14_26600 putative sigma-70 factor, ECF subfamily Sigma factors 26 FS 1 C5 AATACCTCGCGCTGTTCCTC Yes
PA14_10120 putative LysR family transcription regulator Transcriptional regulator 64 FS 1 F8 AACAGGTGCGGTAGAACGTC Yes
PA14_69980 putative transcriptional regulator Transcriptional regulator 83 FS 1 H3 CTTCGTGGTTGAGCATTTCC No
PA14_27250 putative transcriptional regulator, LysR family Transcriptional regulator 84 FS 1 H4 GGCTATTGGCTTTCCAGGTT Yes
PA14_02750 putative transcriptional regulator Transcriptional regulator 85 FS 1 H5 CCTTGAACGTCGAGTGACTG No
PA14_30620 putative transcriptional regulator, AraC family Transcriptional regulator 87 FS 1 H7 AGGCGGACCAGTTCCAGAT Yes
PA14_46480 putative transcriptional regulator Transcriptional regulator 100 FS 2 A10 CTCTGCGTAGTGGCGATTG Yes
PA14_04160 putatitve transcriptional regulator Transcriptional regulator 121 FS 2 C11 ATGTAGATGGTGCCCTCGTC Yes
PA14_65950 putative transcriptional regulator Transcriptional regulator 123 FS 2 D1 GTGATCACCCAGAGCACCA Yes
PA14_22470 putative transcriptional regulator, LysR family Transcriptional regulator 130 FS 2 D9 AACCCAGACCGTGCAACAG Yes
PA14_34210 putative transcriptional regulator Transcriptional regulator 131 FS 2 D10 TCAGCAAGGTATGGTGGATG Yes
PA14_48830 putative transcriptional regulator Transcriptional regulator - FS 2 E4 GTGATGACCAGGATGCGTTC Yes
PA14_38300 putative glutamate uptake regulatory protein Transcriptional regulator 139 FS 2 E10 GAAGCTGGACTTGGTCTTGC Yes
PA14_19800 putative transcriptional regulator, AraC family Transcriptional regulator 143 FS 2 F2 CCGACAGCGAATTGAAGC Yes
PA14_03480 putative transcriptional regulator, GntR family Transcriptional regulator 146 FS 2 F8 GCCTTCGGTTTCCTTGTAGA No
PA14_27400 putative ranscriptional regulator, LysR family Transcriptional regulator - FS 2 F9 AGGGTGATCAGCACGTCCA Yes
PA14_35380 ptxR  transcriptional regulator PtxR Transcriptional regulator 160 FS 2 H2 ATGACCCTTACCGATCGC No
PA14_11180 putative transcriptional regulator Transcriptional regulator - FS 2 H4 TCGACCACGTCGCAGAT Yes
PA14_27700 putative transcriptional regulator Transcriptional regulator 162 FS 2 H7 CAGGACGGATATCATTGACG Yes
PA14_27810 putative two-component response regulator Transcriptional regulator 195 FS 3 C7 GGCTTCACCAGGTAATCGTC Yes
PA14_16550 putative transcriptional regulator, TetR family Transcriptional regulator 202 FS 3 D2 GGTGTCGGTGATGAGATCG Yes
PA14_19120 rhlR acylhomoserine lactone dependent transcriptional regulator Transcriptional regulator 205 FS 3 D5 GGAAATGGTGGTCTGGAGC No
PA14_48420 putative transcriptional regulator Transcriptional regulator 225 FS 3 F1 CATCACGCAGTCGACATAGG Yes
PA14_41870 cysB transcriptional regulator CysB Transcriptional regulator 251 FS 3 H4 CTGCTTGATGCTCTCGACCT Yes
PA14_70970 betI TetR-family regulatory protein Transcriptional regulator 260 FS 4 A3 CTCGGACTGTCGTCGTAGAG Yes
PA14_45250 putative transcriptional regulator Transcriptional regulator 264 FS 4 A7 CATCCTCTGCATGCCCAAC Yes
PA14_35540 bkdR  transcriptional regulator BkdR Transcriptional regulator 284 FS 4 C3 AATGCAGGTCAGGGTATTGG Yes
PA14_13150 putative transcriptional regulator Transcriptional regulator 289 FS 4 C8 GTACTGTCGCAAGCCATCG Yes
PA14_47240 putative transcriptional regulator Transcriptional regulator 294 FS 4 D1 CGGTCTTGGCTTGGAAGTAG Yes
PA14_16790 putative transcriptional regulator, tetR family Transcriptional regulator 308 FS 4 E3 TCGAAGAACAGCTCGGAAAG Yes
PA14_06710 heme d1 biosynthesis protein NirD Transcriptional regulator 316 FS 4 E11 AGCAGGTAGCGCAGGTGTT Yes
PA14_27230 putative transcriptional regulator, MarR family Transcriptional regulator 341 FS 4 H2 GTGCGGGTAATCAGACCTTC Yes
PA14_47270 putative LysR family transcriptional regulator Transcriptional regulator 345 FS 4 H6 CGAGTCTTGAGGAAGTCGATG No
PA14_02660 putative transcriptional regulator, LysR family Transcriptional regulator 349 FS 4 H10 AAGCAGCCGATGTCGATCT Yes
PA14_68680 envZ two-component sensor EnvZ TCS 365 FS 5 B9 CAAACCCGTCGAGTATCAGG No
PA14_43380 kdpB potassium-transporting ATPase, B chain TCS 366 FS 5 B10 ACGCCATAGATCAGCAGGTT Yes
PA14_22370 putative signal-transduction protein TCS 385 FS 5 D5 ACAACTGGTGGAAGCAACTG Yes
PA14_31620 putative ABC-type periplasmic phosphate-binding protein TCS 390 FS 5 D10 AGTTCGTTTTCCCGTTCTCC Yes
PA14_72690 putative glutamine synthetase TCS 393 RS-AP 5 E1 GAGTTCGGAGAGATCGTTGG No
PA14_13660 putative protein phosphatase TCS 394 RS-AP 5 E2 GATGAAGCTGACCACCGTCT No
PA14_16470 putative chemotaxis sensor/effector fusion protein TCS 396 FS 5 E4 GCTCCTCGTCGTTGTCGT Yes
PA14_20750 putative chemotaxis signal transduction protein TCS 403 RS-AP 5 E11 GTTGAGCGCGGTCATTTC Yes
PA14_37690 putative sensory box protein TCS 407 FS 5 F3 AGGCGATCGTCTGTTCCT Yes
PA14_65450 motA chemotaxis protein MotA TCS 415 FS 5 F11 GTGATGACGATGCCGAGTA Yes
PA14_10700 putative bacteriophytochrome TCS 426 FS 5 G10 TCATGACGGAAACGGTAGG Yes
PA14_05410 cheR putative chemotaxis protein methyltransferase CheR TCS 428 FS 5 G12 GAATTTCACATGGGGTCGTC Yes
PA14_31900 putative efflux transporter TCS 438 FS 5 H11 CAGTGCTTGTCGTCCTTCTC Yes
PA14_31950 putative heavy metal sensor histidine kinase TCS 443 FS 6 A6 ACCAGCAGGTTGCAGATCG Yes
PA14_49170 phoQ two-component sensor PhoQ TCS 461 FS 6 B12 AGCGGCGTCTTCAGACTGT Yes
PA14_43380 kdpB potassium-transporting ATPase, B chain TCS 475 FS 6 D2 ACTTGGCGATCACGTTCAG No
PA14_60250 pilS kinase sensor protein of two component regulatory TCS 478 FS 6 D5 GGAAGAAGGTCAGGTAGAGCA Yes
PA14_19190 putative NAD-linked malate dehydrogenase TCS 498 FS 6 F1 ATACCTCGTCGCTGGTATGC Yes
PA14_10770 putative sensor/response regulator hybrid TCS 502 FS 6 F5 CGGAGTCAGTTGCTGGATG No
PA14_19120 rhlR acylhomoserine lactone dependent transcriptional regulator TCS 505 FS 6 F8 GGAAATGGTGGTCTGGAGC No
PA14_27550 putative sensor/response regulator hybrid TCS 515 FS 6 G6 ACTTCGCGATTGATGGATG No
PA14_49440 probable two-component response regulator TCS 516 FS 6 G7 CACCTCGTTGATCCAGTGC Yes
PA14_36420 putative histidine kinase TCS 520 RS-AP 6 G11 GATGTCACGGGTTACCTTGG Yes
PA14_11630 probable two-component sensor TCS 531 RS-AP 6 H10 TTCTCCAGCAGGTTGAACAG Yes
Does primer pair work 
with input DNA pool in 
test PCR? (55°C anneal)
Gene specific qPCR primer (5' - 3')
Significant 
screen from 
which mutant 
was selected
Locus
Sub-library 
location
Gene Function Group RS_UID
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bedding were changed daily from day 2 onwards to limit reinoculation with excreted strains. The 
native GI microflora was successfully reduced below the level of detection in the day 0 stool 
samples. The drinking water containing the bacterial input pool was generated by growing the 
selected strains in 96 deep well culture overnight in 1.5 ml LB with gentamicin 15 µg/ml and 
tetracycline 30 µg/ml, then pooling these strains into a single vessel and diluting in sterile water 
containing 1500 U/ml penicillin G to an estimated concentration of 107 cfu/ml. This single batch of 
water was then split between the 3 mice conditions. Unfortunately, it was revealed upon plating the 
drinking water that the inoculating concentration of bacteria was in fact 3 x 105 cfu/ml. 
Nevertheless, average colonisation levels of 3-8 x 108 cfu/g stool were attained two days after the 
start of oral feeding of bacteria.  
 
 
Figure 8.5 In vivo parallel fitness assay timeline. Mice were provided with drinking water containing 2 mg/ml streptomycin 
and 1500 U/ml penicillin G for 4 days prior to the introduction of bacteria in order to deplete the gastrointestinal 
microflora (days -4 – 0 – blue line). Water containing pooled P. aeruginosa mutants (approximately 107 cfu/ml) was then 
provided for two days (days 0 - 1 – red line). Sterile water was then provided for a further 5 days (days 2 – 7, purple line), 
containing either no drug, 1333 µg/ml imipenem (high dose) or 512 µg/ml imipenem (low dose). Stool samples were 
collected from individual mice on days 0, 2, 4 (48 hr time point) and 7 (120 hr time point), as indicated by black stars.  
 
Total DNA was then extracted from the stool samples extracted on days 2, 4 and 7 (subsequently 
referred to as 0 hr treatment, 48 hr treatment and 120 hr treatment respectively) using the QIAamp 
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DNA stool kit (Qiagen GmbH) and concentration quantified using the Nanodrop 2000 
spectrophotometer. DNA yields were 6 – 16 ng/µl.  
 
Upon examination of the input gDNA pool (i.e. drinking water), of the 46 strains with optimised PCR 
pairs, 3 strains did not return good signals from at least 2 of 3 technical replicates: PA14_65950, 
PA14_16470 and PA14_37690 (Figure 8.6, highlighted in red on x axis). These strains were therefore 
removed from further analysis. The remaining 43 strains were strongly identified in the input pool, 
returning at least 2 strong signals (Figure 8.6). This indicates that the qPCR assay was working well, 
and that a failure to return a signal in future reactions is more likely due to a real absence of the 
template in question rather than a failure of the reaction. 
 
Figure 8.6 qPCR analysis of genomic DNA extracted from input pool in drinking water. 3 technical replicates were 
performed for each primer pair, alongside a template negative control reaction which lacked a gene-specific primer. The 
reaction thresholds were set at the maximum fluorescence level for the negative controls. All samples except PA14_65950, 
PA14_16470 and PA14_37690 (shown in red) returned at least 2 strong and reproducible signals.  
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In order to correct subsequent outputs for the prevalence of each strain within the input pool, an 
individual correction factor for each strain was calculated. The mean Ct value in the input pool was 
calculated for each strain, then divided by the overall mean to produce strain-specific input-
correction factors. 
 
qPCR reactions were then performed on each of the faecal DNA extracts, using each of the 
remaining 43 primer pairs and 25 ng DNA as template, alongside a negative control reaction lacking 
a gene-specific primer for each sample. Data was analysed by setting reaction thresholds at the 
maximum fluorescence level for the negative controls, then multiplying each Ct value by the 
previously calculated input-correction factor. For each condition, two technical replicates were 
performed, and mutants returning only 1 x Ct value were removed from further analysis. The 
majority of strains did not deliver a signal until the 120 hr time point, suggesting a lag in achieving a 
cfu count that was detectable in vivo, therefore the 0 hr and 48 hr data were removed (data not 
shown).  
 
The 120 hr no-drug group reflects the bacterial burden at 120 hr in the absence of drug treatment 
(Figure 8.7), where a low average Ct value compared with the group mean (Figure 8.7, red line) 
indicates a high bacterial burden (since these were the first strains detectable by the assay), and, 
conversely, a high Ct value indicates a low bacterial burden. 12 strains (PA14_26600, PA14_11180, 
PA14_48420, PA14_41870, PA14_45250, PA14_35540, PA14_43380, PA14_22370, PA14_20750, 
PA14_10700, PA14_05410 and PA14_31950) returned a single Ct value in this group and so were 
removed from further analysis (data not shown). Strains within this treatment group which were 
reproducibly undetectable would have been putatively considered attenuated for virulence, 
however, no such strains were observed. The only strain found to display a significantly different Ct 
value than the group mean (Figure 8.7, red line) was PA14_60250, indicating a particularly low 
bacterial burden from this strain and therefore potential attenuation in the murine gut. 
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Figure 8.7 Strains detected through qPCR analysis of DNA extracted from faecal samples from 120 hr no-drug control 
mice. The data points represent the mean average of two technical replicates for each primer pair, performed alongside a 
template negative control reaction which lacked a gene-specific primer. Reaction thresholds were set at the maximum 
fluorescence level for the negative controls, then Ct values corrected to the input correction factor. Error bars represent 
the standard deviation of the mean, and overall input-corrected mean Ct indicated by red line. One sample, indicated by 
asterisk (* ≤ 0.05), was found to be significantly different from the group mean by Student t test, with all others not 
significant. 
 
In the 120 hr low-dose imipenem group, 8 strains were removed from analysis for having returned 
one Ct value: PA14_10120, PA14_46480, PA14_48830, PA14_27400, PA14_27810, PA14_31950, 
PA14_19190 and PA14_49440 (data not shown). Seven strains were reproducibly detectable in this 
group (Figure 8.8), one of which (PA14_36420) displayed a significantly higher Ct value than the 
group mean (Figure 8.8, red line), indicating that this strain was less efficient at colonising the 
murine gut than the other six strains detected under this condition.  
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Figure 8.8 Strains detected through qPCR analysis of DNA extracted from faecal samples from mice receiving low dose 
imipenem treatment at 120 hr. The data points represent the mean average of two technical replicates for each primer 
pair, performed alongside a template negative control reaction which lacked a gene-specific primer. Reaction thresholds 
were set at the maximum fluorescence level for the negative controls, then Ct values corrected to the input correction 
factor. Error bars represent the standard deviation of the mean, with input-corrected group mean Ct value indicated by red 
line. One sample, indicated by asterisk (* ≤ 0.05), was found to be significantly different from the group mean by Student t 
test, with all others not significant. 
 
In the 120 hr high-dose imipenem group, 27 strains which returned only one Ct value were removed 
from the analysis: PA14_30650, PA14_26600, PA14_10120, PA14_30620, PA14_46480, PA14_04160, 
PA14_34210, PA14_48830, PA14_38300, PA14_19800, PA14_27700, PA14_16550, PA14_48420, 
PA14_45250, PA14_35540, PA14_47240, PA14_06710, PA14_43380, PA14_22370, PA14_31620, 
PA14_20750, PA14_65450, PA14_10700, PA14_31950, PA14_60250, PA14_49440 and PA14_11630 
(data not shown). Six strains were reproducibly detectable in this group (Figure 8.9), with none 
showing significantly different Ct values from the group mean (Figure 8.9, red line), indicating that 
none had a significant colonisation advantage or disadvantage under this condition. 
 
  176 
 
Figure 8.9 Strains detected through qPCR analysis of DNA extracted from faecal samples from mice receiving high dose 
imipenem treatment at 120 hr. The data points represent the mean average of two technical replicates for each primer 
pair, performed alongside a template negative control reaction which lacked a gene-specific primer. Reaction thresholds 
were set at the maximum fluorescence level for the negative controls, then Ct values corrected to the input correction 
factor. Error bars represent the standard deviation of the mean, with input-corrected group mean Ct value indicated by red 
line. No samples were found to be significantly different from the group mean by Student t test. 
 
Six strains were undetectable in animals receiving either dose of imipenem treatment, but were 
detected in the 120 hr no-drug group: PA14_70970, PA14_13150, PA14_16790, PA14_27230, 
PA14_02660 and PA14_49170. These strains are candidates for drug sensitive mutants in vivo, and 
therefore represent potential drug development targets.  
 
Three strains, PA14_31900, PA14_36420 and PA14_22470, were detected in animals in all treatment 
groups at 120 hr (Figure 8.10). This suggests that mutations in these genes provides a fitness 
advantage for growth in high concentrations of imipenem, in addition to the carbapenemase gene 
that grants enhanced resistance to all strains under investigation.  
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Figure 8.10 Imipenem tolerant mutants in vivo. Strains detected through qPCR analysis of DNA extracted from faecal 
samples from mice receiving no drug, low dose and high dose imipenem treatments at 120 hr. The data points represent 
the input-corrected mean average of two technical replicates for each primer pair and error bars represent the standard 
deviation of the mean. 
 
8.4 Discussion 
The main objective of this chapter was to establish a reliable murine model of P. aeruginosa 
gastrointestinal colonisation, and to use this model to examine integron-associated carbapenem 
resistance in vivo.  
 
The first part of this objective was met through replication of the murine gastrointestinal 
colonisation model developed by Koh et al. [293, 296], in which we were able to achieve P. 
aeruginosa colonisation levels of 109 cfu/g stool after two days, and maintain this level for at least 9 
days after withdrawal of bacteria from the water. While it initially seemed possible that murine 
coprophagia may be partly responsible for the stability of this colonisation level, we were able to 
identify individual bacterial strains after 5 days in the subsequent parallel fitness assay during which 
cages were changed daily to prevent re-inoculation, indicating that this was not a significant problem 
with the model. 
 
  178 
During the parallel fitness assay to examine integron-associated carbapenem resistance, the limited 
quantity of template from faecal DNA extractions meant that only two technical replicates were 
performed for each primer pair for each condition. This was unfortunate as it led to the exclusion of 
many strains that may have been included in analyses if another replicate had been possible. The 
limited quantity of template DNA could have been due to lower than expected colonisation levels or 
to the efficiency of the commercial stool DNA extraction kit. As we were keen to extract the 
maximum possible genetic material from the limited stool samples obtained and colonisation levels 
using this model have generally been very stable and predictable, no stools were plated for 
confirmation of cfu levels. If reduced extraction efficiency compared to that promised in the manual 
was experienced, it is difficult to ascribe a cause in the current experiment. As recommended, 
samples were weighed and frozen at -80 °C within 30 minutes of the last sample having been 
collected, but time to freezing for the earliest collected samples was up to 120 mins longer. 
However, no difference in extraction efficiency between the groups was noted, suggesting that time 
to freezing was not the cause of the unexpectedly low DNA concentrations obtained. As far as we 
are aware, no other deviation from the kit protocol was experienced, so we are not sure of the 
source of the unexpectedly low DNA concentrations extracted. For future experiments it would be 
beneficial to obtain extra stool samples to plate for cfu, as well as to compare extraction efficiencies 
using different extraction methods within our lab.  
 
However, despite these potential shortcomings, all of the genes that showed effects in the in vivo 
parallel fitness assay could have clinical significance and may warrant further examination to 
determine their role in the ability of P. aeruginosa to colonise the mammalian gastrointestinal tract 
and/or respond to carbapenem treatment in vivo.  
 
Two genes were identified that resulted in lower than average colonisation levels in their conditions. 
PA14_60250, which colonised less well in the absence of carbapenem stress, encodes the two-
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component sensor, PilS [329], involved in regulation of type 4 fimbriae [361]. Since fimbriae are 
known virulence factors involved in adhesion [362], the apparent colonisation deficiency of this key 
regulatory mutant would appear to validate the experimental methodology. 
 
PA14_36420, which displayed a lower than average bacterial burden in the presence of low dose 
imipenem, encodes a probable sensor/regulator response hybrid [329], whose orthologue PA2177 is 
a member of the σ²² regulon of P. aeruginosa, required for cell envelope homeostasis [342]. σ²² is an 
alternative sigma factor, released in response to cell wall stress [363]. Despite having revealed no 
functionally significant phenotype in response to carbapenem stress in vitro, this result suggests 
reduced BlaVIM action in vivo, as a result of either decreased enzyme production or activity. Given 
the mode of action of carbapenems in preventing cell wall synthesis, this gene product may have 
functional significance. However, as PA14_36420 was one of the three strains that were detected in 
all treatment groups at 120 hr, it may be that rather than demonstrating a reduced fitness in low 
concentrations of imipenem, this strain may represent a slow growing persistor. 
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9 Discussion and future work 
This study aimed to explore the mechanisms by which mobile integron-mediated antibacterial 
resistance is regulated in the pathogenic bacterial species P. aeruginosa. Work leading to this study 
had begun to explore the mechanisms of transcriptional regulation in E. coli, but had not yet 
broached their regulation in species of clinical significance despite the highly promiscuous nature of 
these mobile structures.  
 
The primary source of integron control so far explored in the literature has been LexA-mediated 
repression of Pint [131-133, 206, 207, 211]. However, with respect to LexA-mediated Pint activation 
during conjugative plasmid transfer [132] it is difficult, based on currently available evidence, to 
reconcile the importance of such regulation with the requirement to mobilise single cassettes, as 
straightforward plasmid transfer alone would suffice to provide antibacterial resistance. However, in 
a screen of intI promoter sequences from a variety of plasmidic and chromosomal integrons of all 
classes, and originating from multiple bacterial species, LexA-binding sequences were found to be 
highly conserved, suggesting that SOS-mediated control of intI genes arose early in integron 
evolution and that this mode of regulation serves an important role in the natural environment 
[206]. Moreover, numerous case studies have been described which support the frequent 
occurrence of cassette mobilisation events through the wide and varied dispersal of relatively few 
cassette variants in both plasmidic and chromosomal integrons [364], implying the selective 
evolution of this mechanism. This study demonstrated that in P. aeruginosa, 2 hr stimulation with 
the SOS-inducing compound hydrogen peroxide [365] resulted in increased expression from Pint, 
however, 2 other classic SOS-inducers, mitomycin C and ciprofloxacin [318, 366], did not have any 
effect on expression from Pint. Therefore, the SOS response has not been confirmed to be of 
significance to the transcriptional regulation of integron promoters in P. aeruginosa in this study, in 
contrast to previous findings in a clinical strain of P. aeruginosa [211], or in multiple studies in E. coli 
[131-133, 206]. However, an omission in our study was to use only transcriptional reporters to 
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examine stress-induced changes rather than expanding this analysis to investigate the functional 
outputs of responses to host-imposed stress.  
 
Baharoglu et al. obtained data that strongly suggest that plasmid transfer, even abortive, can trigger 
chromosomal gene rearrangements and transcriptional switches in the recipient cell through the 
induction of integron integrase via the SOS response [132]. While they explain this SOS induction as 
an effect of the transfer of conjugative plasmids as single stranded DNA molecules, we postulate 
that this effect might be further explained by the transient production of high levels of single 
stranded DNA via the recipient restriction modification system, including during the degradation of 
incompatible plasmids. It is possible that integron-mediated capture of cassettes has a role to play in 
transcending the barriers imposed by plasmid incompatibility, by integrating useful genes that would 
otherwise have been lost. It is therefore reasonable to propose that, in mixed populations of 
bacteria, host incompatibility as a barrier to exchange of genetic information becomes surmountable 
when resident plasmid or chromosomal integrons can actively capture cassettes. Some antibiotics, 
including β-lactams (including carbapenems), are known to be strong inducers of SOS [318, 367], and 
horizontal gene transfer [367], both of which are proven inducers of Pint [132, 211]. As SOS appears 
to be a major regulator of integron integrase, despite the present study having failed to identify Pint 
induction in P. aeruginosa in response to 2 out of 3 of the classic SOS inducers investigated, it could 
be pertinent to establish in a future study whether the predominance of certain resistance genes in 
clinically isolated integrons, such as those providing aminoglycoside (and increasingly carbapenem) 
resistance, can be explained by a heightened capacity of those antibiotics to induce SOS, or whether 
other regulatory factors are responsible.  
 
Furthermore, the present study is the first to observe a role for carbon catabolite control in the 
regulation of mobile integrons. We observed a clear effect of specific carbon sources upon 
transcriptional regulation of both Pint and Pc (Chapter 5.3.1): a shift to the preferred carbon source, 
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succinate, results in increased Pc activity and decreased Pint activity (Figure 5.2), while a shift to the 
non-preferred carbon source, fructose, leads to reduced expression of both promoters (Figures 5.1 
and 5.2). We hypothesise that as well as being able to utilise a wide range of carbon and nitrogen 
sources as metabolites, P. aeruginosa may identify these different carbon sources as niche location 
signals, and modulate expression of genes in the crc regulon accordingly. There is precedent for such 
signalling in the literature: the gut commensal Bacteroides thetaiotaomicron produces succinate at 
the edge of the intestinal epithelium, which acts as a signal to enterohemorrhagic Escherichia coli 
(EHEC) to increase expression of type 3 secretion, resulting in exacerbated host pathology and 
mortality [368]. While the response to succinate is consistent with our model of inter-dependent 
promoter regulation (Chapter 1.4), the unilateral decrease in promoter expression upon a shift to 
fructose suggests that conditions do exist in which both integron gene functions are deemed too 
expensive, unless what we are seeing is a wholesale down-regulation of transcription reflecting a 
global switch to a slow-growth phenotype. Our data suggest that the early response (t = 2 hr) of P. 
aeruginosa to a move to this significantly poorer carbon source consists of deprioritisation of the 
potentially protective mechanisms of integron gene expression, which may reflect general changes 
in cell physiology and a transient metabolism slowdown. This hypothesis could be tested by 
examining transcription of other metabolic genes such as those involved in carbon and nitrogen 
utilisation or amino acid synthesis using a quantitative reverse-transcription PCR approach in 
conjunction with further carbon shift assays using a wider range of carbon sources as both the initial 
growth medium and shifted media.  
 
The principle objective of the thesis was to examine the utility of a compendium approach to 
identifying novel regulators of mobile integron regulation. This objective has been achieved, given 
that evidence presented from a thorough examination of a sub-library of mutants has demonstrated 
a role for muxC (PA14_31900) via multiple routes of investigation: via an in vitro transcriptional 
reporter screen (phenotype observed in high-throughput screen, but failed to achieve significance in 
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rescreen; Chapter 6), an in vitro screen for functionally significant mutants under selective pressure 
(Chapter 7), and in vivo investigations of altered susceptibility to imipenem through alterations in Pc-
mediated blaVIM-1 expression (Chapter 8). However, while we are confident in the identification of 
PA14_31900 as a regulator of interest, further work is required to elucidate the mechanism by which 
regulatory control is imposed.  
 
This mutant displayed increased expression from Pc alongside decreased Pint transcription under 
non-stressed conditions (Table 6.2) and functionally significant increased resistance to imipenem 
both in vitro and in vivo. PA14_31900 is a 100 % identical orthologue of PA2526 (muxC) in P. 
aeruginosa PAO1 [329]. muxC encodes one of two RND components (muxB and muxC) in the RND-
type multidrug efflux pump MuxABC-OpmB [358]. MuxABC-OpmB is one of 12 identified RND-type 
efflux pumps in P. aeruginosa [369], and has been shown to increase resistance to novobiocin, 
aztreonam, macrolides, tetracycline, ampicillin and carbenicillin [358, 369] and attenuated virulence 
in Brassica pekinensis and Drosophila melanogaster infection models [369]. In strains where muxC 
(PA14_31900) is interrupted, we have found tolerance of imipenem is increased both in vitro and in 
vivo. Therefore it is reasonable to postulate that, conversely, overexpression of muxC would result in 
increased susceptibility to imipenem.  
 
Despite previous studies having demonstrated that mutation of the muxA component of P. 
aeruginosa PAO1 MuxABC-OpmB results in intrinsically increased resistance to β-lactams [369], our 
data do not support the idea that this intrinsically increased resistance extends to carbapenem 
antibiotics, since no increase in resistance was observed in our muxC mutant compared with wild 
type in the absence of functional Pc-mediated blaVIM-1 (Figure 7.2 and Appendix 7.1, control screen 
harbouring pMP220-intA). Mutants in an alternative RND efflux pump, MexGHI-OpmD, have also 
been demonstrated to exhibit increased resistance to kanamycin, spectinomycin, carbenicillin, 
rifampicin, tetracycline and chloramphenicol as a result of an absence of Pseudomonas quinolone 
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signal (PQS) in these mutants [370], however PQS levels were not found to be the cause of increased 
β-lactam resistance in the PAO1 muxA mutant [369]. Nevertheless, it may be useful to examine 
whether increased imipenem resistance in muxC mutant is governed by an absence of PQS, by 
performing experiments to compare PQS levels in the wild type and mutant, and to determine 
whether addition of exogenous PQS restores imipenem sensitivity to muxC mutant.  
 
The model we propose to explain the increased resistance to imipenem in the muxC mutant is 
summarised in Figure 9.1, and presumes a dose-dependent effect of intracellular imipenem upon 
integron gene expression. In the wild type strain, under normal growth conditions, transcription of 
gene cassettes from Pc predominates, with the transcriptional activity of Pint limited by repressors 
including LexA and Pc activity (Figure 9.1A, wild type). Upon exposure to imipenem, the drug enters 
the periplasm, and is simultaneously pumped out by a functional MuxABC-OpmB and degraded by 
BlaVIM-1, leaving a low - intermediate concentration of intracellular imipenem while the external 
stress is continued (Figure 9.1B, wild type). This concentration results in a constant flux between 
increased integrase and BlaVIM-1 expression until the stress is removed, as outlined in Figure 1.7C. 
We have demonstrated that imipenem stress results in increased transcription from Pint compared 
with non-stressed cells (Figure 5.5A), with no significant effect upon Pc induction (Figure 5.5B. 
However, since our model predicts that subsequent induction of Pc is integrase-mediated, a 
transcriptional reporter is insufficient for examination of this aspect of the model. We propose to 
utilise the cassette scavenging plasmid outlined below (Figure 9.2) to investigate subsequent 
induction of Pc. This proposed response to imipenem stress would allow cells to increase the 
frequency of cassette scavenging and recombination events while ensuring cell survival, taking 
advantage of environmental conditions which are likely to result in the death of surrounding cells 
(particularly in mixed bacterial populations), and an increase in the availability of potentially 
beneficial exogenous genetic material.  
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In contrast, in the muxC mutant under normal growth conditions, mutation of muxC simultaneously 
results in increased expression from Pc and reduced Pint activity (Table 6.2 and Appendix 6.2: average 
activity levels of 175 % and 27 % respectively, compared with wt in high-throughput transcriptional 
screen), which concurs with our model of interdependent regulation of integron promoters (Figure 
1.7). Upon imipenem exposure, imipenem is not exported by MuxABC-OpmB, leading to a high 
intracellular drug concentration (Figure 9.1B, muxC mutant). While Pint is still induced by intracellular 
imipenem, the high concentration directly results in increased Pc expression. As described in Chapter 
1.4, we hypothesise that expression from Pc simultaneously acts to repress Pint induction in order to 
focus cellular resources on the cell’s immediate survival by maximising blaVIM expression, therefore 
under conditions of imipenem exposure we expect that Pint activity will not be increased in a muxC 
mutant. 
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Figure 9.1 Proposed model of integron gene induction in wild type and muxC mutant in non-stressed (A) and imipenem-
stressed conditions (B). A: In normal growth conditions in wild type, transcription of gene cassettes (blue arrow) from Pc 
predominates, with the transcriptional activity of Pint limited by repressors including LexA (pink/green ovals) and Pc activity 
(red line). Mutation of muxC results in increased expression from Pc, causing increased repression of Pint. B: Wild type cells 
exposed to imipenem experience increased IntI1 expression (grey blob) via induction of Pint, which results in increased 
BlaVIM-1 expression (blue blobs). The drug is therefore both degraded by BlaVIM-1 (broken red stars within BlaVIM) and 
exported by MuxABC-OpmB (orange rectangle). As MuxABC-OpmB is inactive in the muxC mutant (crossed through orange 
rectangle), imipenem (red stars) is not exported, leading to high intracellular drug concentrations. This induces 
transcription of blaVIM-1 (blue arrow), allowing BlaVIM-1 to degrade the imipenem (blue blobs) while simultaneously 
repressing expression of intI1 (grey arrow). 
 
Collectively, these results demonstrate an essential function for the MuxABC-OpmB pump in 
antibiotic susceptibility both in vitro and in vivo in P. aeruginosa and provide a new route of clinically 
relevant investigations to pursue. In order to examine our hypothesis for the role of MuxABC-OpmB 
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in integron-associated resistance to imipenem in P. aeruginosa, and to begin to elucidate the 
molecular mechanism by which this regulation occurs, the following experiments might be useful:  
- Investigation of transcriptional regulation of Pint in muxC mutant under imipenem stress to 
determine if imipenem stress results in no change in Pint expression as hypothesised in our 
model. 
- Titration of the proposed dose-dependent effect on Pc induction under carbapenem stress. 
- Complementation of muxC, followed by repetition of the above described transcriptional and 
functional assays to confirm that restoration of MuxC function negates the observed increased 
resistance phenotype. 
- Overexpression of muxC, followed by repetition of the above described transcriptional and 
functional assays to examine whether increased drug sensitivity results. 
- Examine whether the increased drug resistance and virulence effect of muxC is upheld under 
the influence of alternative drugs and/or integrons containing alternative resistance gene 
cassettes. 
- Confirmation of the mutant phenotype in mice, using a targeted analysis of the mutant, 
reconstituted and wild type isolates. 
 
While there is already a significant amount of evidence for the conjugative transfer of integron 
containing plasmids between isolates [289, 364, 371], there is currently little direct evidence of 
cassette transfer. Encouraged by the frequency with which cassette mobilisation appears to occur 
amongst nosocomial bacterial isolates [364], future studies will utilise a plasmid construct designed 
to address whether bacteria can access and express a relevant resistance cassette under 
carbapenem selection, both in vitro and in vivo. This construct (Figure 9.2, currently under 
construction), placed within the pMP220 vector, will contain a naturally occurring, functional 
integron, pKOX105 integron A (Figure 9.2A, Chapter 3.3.2 and [300]); an incomplete Pseudomonas-
optimised lux bioluminescence operon from P.aeruginosa Xen41 (Kevin Francis, Xenogen, CA) under 
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the control of Plac (constitutively active in Pseudomonas spp. [372, 373]) (Figure 9.2B); and a 
scavengeable attC-bounded cassette consisting of a blaVIM-1 carbapenemase gene fused to the 
Pseudomonas-optimised luxA gene to complete the P.aeruginosa Xen41 lux operon (Figure 9.2C).  
 
Figure 9.2 Scavenging plasmid schematic. This plasmid construct contains pKOX105 integron A (A), an incomplete 
Pseudomonas-optimised lux operon under the constitutive control of Plac (B), and an artificial attC-bounded cassette 
consisting of a blaVIM-1 carbapenemase gene fused to the Pseudomonas-optimised luxA gene which completes the lux 
operon (C). Map of construct: intI1, integrase (grey arrow); Pc, cassette promoter; Pint, integrase promoter; attI, cassette 
recombination site (purple arrow); dfrA14, trimethoprim resistance gene (dark blue arrow); attC, cassette recombination 
site (red arrow); luxEBDC, Pseudomonas-optimised lux operon from P. aeruginosa Xen41 minus luxA (green arrows); Plac, 
lac promoter; attC, cassette recombination site (red arrow); blaVIM-1, carbapenem resistance gene (light blue arrow); 
luxA, Pseudomonas-optimised luxA from P. aeruginosa Xen41 (green arrow); attC, cassette recombination site (red arrow).  
 
Strains harbouring this plasmid would be resistant to trimethoprim through Pc-mediated expression 
of dfrA14, but would theoretically not be bioluminescent despite constitutive expression of luxC, 
luxD, luxB and luxE, due to the essential luxA component of the bacterial luciferase not being 
expressed. However, upon integrase-mediated scavenging of the artificial cassette (Figure 9.2C) and 
reintegration at the attI site, strains would simultaneously become carbapenem resistant and 
bioluminescent, through Pc-mediated expression of blaVIM-1 and luxA respectively. This plasmid 
would allow us to directly examine pathogen-associated integron cassette acquisition in a relevant 
model of infection, by addressing whether bacteria can access and express a relevant resistance 
cassette under carbapenem selection in vivo. 
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Appendix 2.1 - Bacterial strains 
 
Species Strain Genotype Description Reference 
E. coli TOP10 F- mcrA Δ(mrr-
hsdRMS-mcrBC) 
φ80lacZΔM15 
ΔlacX74 recA1 
araD139 Δ(ara-
leu)7697 galU galK 
rpsL (StrR) endA1 
nupG 
  
E. coli 1047  Helper strain in triparental 
matings. 
[277] 
E. coli DH5α F– Φ80lacZΔM15 
Δ(lacZYA-argF) U169 
recA1 endA1 hsdR17 
(rK–, mK+) phoA supE44 
λ– thi-1 gyrA96 relA1 
  
E. coli TG1 F'[traD36 proAB+ lacIq 
lacZΔM15] supE thi-1 
Δ(lac-proAB) Δ(mcrB-
hsdSM)5, (rK-mK-) 
Commercial strain for phage 
display library screening and 
protein expression. Donor strain 
in triparental matings. 
AF lab collection 
P. aeruginosa PA01  Sequenced wild type clinical 
isolate 
[230] 
P. aeruginosa PA14  Sequenced wild type clinical 
isolate. 
[282] 
P. aeruginosa Xen5  Derived from parental strain P. 
aeruginosa ATCC 19660, a 
mucoid clinical strain isolated 
from human septicaemia. 
Possesses a single stable copy of 
the P. luminescens luxCDABE 
operon on the bacterial 
chromosome. 
Kevin Francis 
(Xenogen, 
Alameda, CA) 
P. aeruginosa Xen 41  Derived from parental strain 
PA01. Possesses a single stable 
copy of the P. luminescens 
luxCDABE operon on the bacterial 
chromosome. 
Kevin Francis 
(Xenogen, 
Alameda, CA) 
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Appendix 2.2 - Oligonucleotides 
Bases in red represent homologous overhangs for GeneArt recombination reactions. 
 
Primer name Sequence (5' - 3')  Chapter reference 
pMP220 seq A GCCTCACCCCAAAAATGGC Chapter 3.3.3 
pMP220 seq B AAGGACCGAGAAAGGGTGAC Chapter 3.3.3 
pMP220 seq D AGTATCGGCGGAATTCCAG Chapter 3.3.3 
pMP220 seq F GAGCAACTGACTGAAATGCC Chapter 3.3.3 
pICEX vec A GACGTCCAAGCTAGCTTCGGGCTGAAATTGC Chapter 3.3.3 
pICEX vec B TCACTACCCCTGCGCATGCCTGCAGGTCGACTCTAG Chapter 3.3.3 
pICEX 1a TGCAGGCATGCGCAGGGGTAGTGAATCCGC Chapter 3.3.3 
pICEX 5c GCTAGCTTGGACGTCTGTTGGTCACGATGCTGTAC Chapter 3.3.3 
IP212L AAGCTTACGAACCCAGTGGACAT Chapter 4.3.1 
IP212U GGATCCCCACGGCGTAACG Chapter 4.3.1 
GA Pi214c A CTCTAGCTAGAAGCTTACGAACCCAGTGGACATAAGCCTG Chapter 4.3.1 
GA Pi214c B TTATTGCCCGGGGATCCCCACGGCGTAACGCGCTTGCTGC Chapter 4.3.1 
GA pICP C TCGACCTGCAGGCATGTTTTCATAGCACCATCCCTC Chapter 4.3.3 
GA pICP D TTCAGCCCGAAGCTAGATTGTCTCATGAGCGGATAC Chapter 4.3.3 
GA pICP vec A GAGACAATCTAGCTTCGGGCTGA Chapter 4.3.3 
GA pICP vec B TATGAAAACATGCCTGCAGGTCG Chapter 4.3.3 
pMP220 seq G CTCTTCGCTATTACGCCAGC Chapter 4.3.3 
Pi214c Pc AAGCTTACGAACCCAGTGGACAT Chapter 4.3.3 
MAR2xT7 (T7) TAATACGACTCACTATAGGG Chapter 8.3.2 
PA14_02660 qPCR AAGCAGCCGATGTCGATCT Chapter 8.3.2 
PA14_02750 qPCR CCTTGAACGTCGAGTGACTG Chapter 8.3.2 
PA14_03480 qPCR GCCTTCGGTTTCCTTGTAGA Chapter 8.3.2 
PA14_04160 qPCR ATGTAGATGGTGCCCTCGTC Chapter 8.3.2 
PA14_05410 qPCR GAATTTCACATGGGGTCGTC Chapter 8.3.2 
PA14_06710 qPCR AGCAGGTAGCGCAGGTGTT Chapter 8.3.2 
PA14_10120 qPCR AACAGGTGCGGTAGAACGTC Chapter 8.3.2 
PA14_10700 qPCR TCATGACGGAAACGGTAGG Chapter 8.3.2 
PA14_10770 qPCR CGAGTTCCTCGTTCTCCTTG Chapter 8.3.2 
PA14_10770 qPCR-2 CGGAGTCAGTTGCTGGATG Chapter 8.3.2 
PA14_11180 qPCR TCGACCACGTCGCAGAT Chapter 8.3.2 
PA14_11630 qPCR TTCTCCAGCAGGTTGAACAG Chapter 8.3.2 
PA14_13150 qPCR GTACTGTCGCAAGCCATCG Chapter 8.3.2 
PA14_13660 qPCR GATGAAGCTGACCACCGTCT Chapter 8.3.2 
PA14_16470 qPCR GCTCCTCGTCGTTGTCGT Chapter 8.3.2 
PA14_16550 qPCR GGTGTCGGTGATGAGATCG Chapter 8.3.2 
PA14_16790 qPCR TCGAAGAACAGCTCGGAAAG Chapter 8.3.2 
PA14_19120 qPCR GGAAATGGTGGTCTGGAGC Chapter 8.3.2 
PA14_19190 qPCR ATACCTCGTCGCTGGTATGC Chapter 8.3.2 
PA14_19800 qPCR CCGACAGCGAATTGAAGC Chapter 8.3.2 
PA14_20750 qPCR GTTGAGCGCGGTCATTTC Chapter 8.3.2 
PA14_22370 qPCR ACAACTGGTGGAAGCAACTG Chapter 8.3.2 
PA14_22470 qPCR AACCCAGACCGTGCAACAG Chapter 8.3.2 
PA14_26600 qPCR AATACCTCGCGCTGTTCCTC Chapter 8.3.2 
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PA14_27230 qPCR GTGCGGGTAATCAGACCTTC Chapter 8.3.2 
PA14_27250 qPCR GGCTATTGGCTTTCCAGGTT Chapter 8.3.2 
PA14_27400 qPCR AGGGTGATCAGCACGTCCA Chapter 8.3.2 
PA14_27550 qPCR ACTTCGCGATTGATGGATG Chapter 8.3.2 
PA14_27700 qPCR CAGGACGGATATCATTGACG Chapter 8.3.2 
PA14_27810 qPCR GGCTTCACCAGGTAATCGTC Chapter 8.3.2 
PA14_30620 qPCR AGGCGGACCAGTTCCAGAT Chapter 8.3.2 
PA14_30650 qPCR CTCTTCGCAGACGGTGACTA Chapter 8.3.2 
PA14_31620 qPCR AGTTCGTTTTCCCGTTCTCC Chapter 8.3.2 
PA14_31900 qPCR CAGTGCTTGTCGTCCTTCTC Chapter 8.3.2 
PA14_31950 qPCR ACCAGCAGGTTGCAGATCG Chapter 8.3.2 
PA14_34210 qPCR TCAGCAAGGTATGGTGGATG Chapter 8.3.2 
PA14_35380 qPCR ATGACCCTTACCGATCGC Chapter 8.3.2 
PA14_35540 qPCR AATGCAGGTCAGGGTATTGG Chapter 8.3.2 
PA14_36420 qPCR GATGTCACGGGTTACCTTGG Chapter 8.3.2 
PA14_37690 qPCR AGGCGATCGTCTGTTCCT Chapter 8.3.2 
PA14_38300 qPCR GAAGCTGGACTTGGTCTTGC Chapter 8.3.2 
PA14_41870 qPCR CTGCTTGATGCTCTCGACCT Chapter 8.3.2 
PA14_43380 qPCR ACGCCATAGATCAGCAGGTT Chapter 8.3.2 
PA14_43380 qPCR-2 ACTTGGCGATCACGTTCAG Chapter 8.3.2 
PA14_45250 qPCR CATCCTCTGCATGCCCAAC Chapter 8.3.2 
PA14_46480 qPCR CTCTGCGTAGTGGCGATTG Chapter 8.3.2 
PA14_47240 qPCR CGGTCTTGGCTTGGAAGTAG Chapter 8.3.2 
PA14_47270 qPCR CGAGTCTTGAGGAAGTCGATG Chapter 8.3.2 
PA14_48420 qPCR CATCACGCAGTCGACATAGG Chapter 8.3.2 
PA14_48830 qPCR GTGATGACCAGGATGCGTTC Chapter 8.3.2 
PA14_49170 qPCR AGCGGCGTCTTCAGACTGT Chapter 8.3.2 
PA14_49440 qPCR CACCTCGTTGATCCAGTGC Chapter 8.3.2 
PA14_60250 qPCR GGAAGAAGGTCAGGTAGAGCA Chapter 8.3.2 
PA14_65450 qPCR GTGATGACGATGCCGAGTA Chapter 8.3.2 
PA14_65950 qPCR GTGATCACCCAGAGCACCA Chapter 8.3.2 
PA14_68680 qPCR CAAACCCGTCGAGTATCAGG Chapter 8.3.2 
PA14_69980 qPCR CTTCGTGGTTGAGCATTTCC Chapter 8.3.2 
PA14_70970 qPCR CTCGGACTGTCGTCGTAGAG Chapter 8.3.2 
PA14_72690 qPCR GAGTTCGGAGAGATCGTTGG Chapter 8.3.2 
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Appendix 2.3 - Plasmids 
 
Name Resistance marker(s) Characteristics Reference 
pCB267 AmpR Narrow range dual reporter plasmid  
pCB267-intA AmpR Bi-directional (phoA and lacZ) transcriptional 
reporter vector pCB267 carrying all integron 
promoters from pKOX105 integron A 
Chapter 4.3.1 
pCB267-intB AmpR Bi-directional (phoA and lacZ) transcriptional 
reporter vector pCB267 carrying all integron 
promoters from pKOX105 integron B 
Chapter 4.3.1 
pCB267-
intSOSminus 
AmpR Bi-directional (phoA and lacZ) transcriptional 
reporter vector pCB267 carrying all integron 
promoters from Tn21 In2 
[207] and 
Chapter 4.3.1 
pCB267-Pint AmpR Bi-directional (phoA and lacZ) transcriptional 
reporter vector pCB267 carrying only Pint from 
Tn21 In2. 
[207] and 
Chapter 4.3.1 
pEVM2a TetR, IpmR pKOX105 integron B and carbapenemase cassette 
(intI1-attI-blaVIM-1-attC) in pMP220 backbone. 
Chapter 3.3.3 
pKOX105 TmpR, IpmR Plasmid from Klebsiella oxytoca clinical isolate with 
carbapenemase-containing integron. aacA4 also 
carried but expression profile unknown. 
[300] 
pMP220 TetR Wide host-range vector for promoterless lacZ 
fusions.  
[302] 
pMP220-intA TetR Vector pMP220 carrying bi-directional reporters 
(phoA and lacZ) and integron promoter region 
from Pi214c_A. 
Chapter 4.3.3 
pMP220-Pint TetR Vector pMP220 carrying bi-directional reporters 
(phoA and lacZ) and promoter region from Pi. 
Chapter 4.3.3 
pRK2013 KanR Mob(RP4). Used as helper plasmid in 
mobilisations. 
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Appendix 4.3 – pCB267-intB sequence 
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Appendix 4.4 – pCB267-Pint sequence 
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Appendix 4.6 – pMP220-Pint sequence 
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Appendix 6.2 – Transcriptional screen data 
Alkaline phosphatase output calculations 
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Β-galactosidase output calculations 
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Appendix 6.3 - Quantile normalised transcriptional screen output for mutants 
showing significant results in either activity assay 
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Appendix 6.4 – Rescreen output calculations 
Alkaline phosphatase rescreen calculations 
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Β-galactosidase rescreen calculations 
 
 
 
  
Appendix 7.1 – Functional screen data 
Screen with pEVM2a-conjugated mutants, grown in LB containing 30 µg/ml 
tetracycline and 512 µg/ml imipenem 
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Screen with pMP220-intA-conjugated mutants grown in LB containing 30 µg/ml 
tetracycline and 1 µg/ml imipenem 
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Appendix 7.2 – Venn diagram sector contents (Figure 7.4) 
 
 
 
